Hi, I am a 2nd yr BSc Cardiac Technology student wanted to prepar for my carrer as well as university exams also I wanted to do my higher studies on Msc physician assistant so I want your help for my preparation

Welcome! That's a great combination of goals - acing your BSc Cardiac Technology exams, building clinical knowledge for your career, and preparing for MSc Physician Assistant admission. Let me understand your needs better before diving in.
Asking for Preferences

What would you like to focus on first? Β· Which subjects are you currently studying or struggling with? Β· How would you prefer to learn/prepare?

Asking for Preferences

Which subject areas are you covering in your 2nd year? Β· Which MSc Physician Assistant entrance exam are you targeting?

Perfect - that gives me everything I need. Let me build you a complete roadmap now.
Searching the Web

BSc Cardiac Technology 2nd year syllabus India subjects

Searching the Web

MSc Physician Assistant entrance exam India eligibility syllabus 2025 2026

Here is your complete, structured preparation roadmap. Save this - it covers all three goals together.

πŸ«€ Your Complete Preparation Roadmap

BSc Cardiac Technology (2nd Year) + Career + MSc PA Entrance


πŸ“Œ OVERVIEW: YOUR THREE GOALS AT A GLANCE

GoalTimelineWhat It Needs
University ExamsOngoing (each semester)Subject mastery + MCQs + practicals
Career ReadinessBuild now, apply after internshipClinical skills + certifications + logs
MSc PA EntranceAfter BSc completionPre-clinical sciences + GK + hospital experience
Good news: all three goals share ~70% of the same core content. Master your BSc subjects deeply and you automatically build the foundation for the other two.

πŸ“š PART 1: SUBJECT-WISE STUDY PLAN (2nd Year)

These are your core subjects. Here is how to approach each one:

1. πŸ«€ Cardiovascular Anatomy & Physiology

What to focus on:
  • Chambers, valves, great vessels - structure AND function
  • Cardiac cycle (systole/diastole), pressure-volume loops
  • Conduction system: SA node β†’ AV node β†’ Bundle of His β†’ Purkinje fibers
  • Frank-Starling law, preload, afterload, contractility
  • Coronary circulation (LAD, LCx, RCA territories - critical for ECG)
Study method:
  • Draw the heart and label it repeatedly - anatomy sticks visually
  • Link every anatomical structure to its physiological role
  • Use Guyton & Hall (physiology) + Gray's Anatomy for Allied Health (anatomy)

2. ⚑ ECG Interpretation & Techniques

What to focus on (high-yield for exams AND career):
  • Systematic ECG reading: Rate β†’ Rhythm β†’ Axis β†’ P wave β†’ PR interval β†’ QRS β†’ ST β†’ T wave
  • Normal values: PR 120-200ms, QRS <120ms, QTc <440ms (male) / <460ms (female)
  • 12-lead electrode placement (must be perfect in practicals)
  • Key arrhythmias: AFib, VTach, VFib, Heart block (1st/2nd/3rd degree), LBBB, RBBB
  • ST changes: STEMI patterns by territory (anterior, inferior, lateral)
  • ACS: STEMI vs NSTEMI vs Unstable Angina differentiation
Resources:
  • ECG Made Easy by John Hampton (best beginner-to-intermediate book)
  • The Only EKG Book You'll Ever Need by Malcolm Thaler
  • Practice with real ECG strips daily - even 5 ECGs/day adds up massively

3. πŸ’Š Cardiac Pharmacology

High-yield drug groups for exams + clinical use:
Drug ClassKey DrugsMechanismUse
Beta blockersMetoprolol, Atenolol, CarvedilolBlock Ξ²1 receptors β†’ ↓HR, ↓BPHTN, HF, post-MI, arrhythmias
ACE inhibitorsRamipril, EnalaprilBlock ACE β†’ ↓Angiotensin IIHF, HTN, post-MI, CKD
ARBsLosartan, ValsartanBlock AT1 receptorSame as ACEi, ACEi intolerance
StatinsAtorvastatin, RosuvastatinInhibit HMG-CoA reductaseDyslipidemia, CAD prevention
AntiplateletsAspirin, ClopidogrelCOX-1 inhibition / P2Y12 blockACS, post-PCI, post-stent
AnticoagulantsHeparin, Warfarin, NOACsVarious coagulation factorsDVT, AFib, PE, post-valve
NitratesGTN, ISDNNO β†’ vasodilationAngina relief
DigoxinDigoxinNa/K ATPase inhibitionAFib rate control, HFrEF
DiureticsFurosemide, SpironolactoneLoop/K-sparingHF, HTN, edema
AntiarrhythmicsAmiodarone, LidocaineVaughan-Williams classesArrhythmias
Tip: Learn drugs by class + mechanism first, then add clinical uses. Don't memorize in isolation.

4. πŸ”Š Echocardiography

What to focus on for 2nd year:
  • Physics of ultrasound: frequency, wavelength, Doppler effect
  • 2D Echo views: Parasternal long axis (PLAX), Parasternal short axis (PSAX), Apical 4-chamber (A4C), Apical 2-chamber (A2C), Subcostal
  • M-mode measurements: LV dimensions (LVEDD, LVESD), EF calculation
  • Ejection Fraction (EF): Normal >55%; HFrEF <40%; HFmrEF 40-49%
  • Basic valvular assessment: AS (peak gradient, AVA), MR (vena contracta), MS (MVA, PHT)
  • Tissue Doppler, E/A ratio for diastolic function
Resources:
  • Echocardiography: A Practical Guide for Reporting by David Chambers
  • YouTube channels: 123Sonography, EchoFirst (free, excellent visual learning)

5. πŸ“Š Hemodynamics

Core concepts:
  • Cardiac Output = Heart Rate Γ— Stroke Volume (normal CO: 4-8 L/min)
  • Cardiac Index = CO / BSA (normal: 2.5-4.0 L/min/mΒ²)
  • Pressures to memorize (normal ranges):
    • RA: 0-5 mmHg
    • RV: 15-30 / 0-5 mmHg
    • PA: 15-30 / 5-15 mmHg (mean <25)
    • PCWP: 6-12 mmHg
    • LV: 100-140 / 3-12 mmHg
    • Aorta: 100-140 / 60-90 mmHg
  • Fick principle for CO measurement
  • Thermodilution method (Swan-Ganz catheter)
  • Pulmonary hypertension classification (WHO groups)

6. 🩺 Cardiac Pathology (CAD, MI, HF, Valvular)

CAD & MI:
  • Atherosclerosis pathogenesis: fatty streak β†’ fibrous plaque β†’ complicated plaque
  • ACS spectrum: UA β†’ NSTEMI β†’ STEMI
  • Troponin I/T kinetics (rises 3-4h, peaks 12-24h, normalizes 7-14 days)
  • Killip classification for MI severity
  • TIMI / GRACE risk scores
Heart Failure:
  • HFrEF vs HFpEF vs HFmrEF definitions
  • New York Heart Association (NYHA) Class I-IV
  • Compensatory mechanisms (Frank-Starling, neurohormonal activation, hypertrophy)
  • Treatment: GDMT = ACEi/ARB/ARNI + Beta blocker + MRA + SGLT2i (the "fantastic four")
Valvular Disease:
  • AS: Systolic murmur, Ejection click, narrow pulse pressure, Heaves - "SAD" (Syncope, Angina, Dyspnea)
  • MR: Holosystolic murmur at apex radiating to axilla
  • MS: Mid-diastolic rumble, Opening snap, Malar flush
  • AR: Early diastolic murmur, collapsing pulse, wide pulse pressure

πŸ₯ PART 2: CAREER PREPARATION

Skills to Build Right Now (During 2nd Year)

  1. ECG reading speed - Aim to read and report a 12-lead ECG in under 3 minutes
  2. Echo probe handling - Practice in lab; learn to acquire standard views confidently
  3. Cath lab familiarity - Understand radiation safety, sterile technique, contrast protocols
  4. Patient communication - Practice explaining procedures simply to patients
  5. Documentation - Write structured cardiac reports (ECG reports, echo reports)

Certifications to Target (During/After BSc)

  • BLS (Basic Life Support) - Get this in 2nd year itself; AHA or Red Cross certified
  • ACLS (Advanced Cardiac Life Support) - After BLS; critical for career advancement
  • CardioSmart / Echocardiography certification - After BSc during internship
  • Registered Cardiac Sonographer (RCS) or RDCS - Long-term international goal

Where Cardiac Technologists Work

  • Cath labs (cardiac catheterization laboratories)
  • ICUs / CCUs (Cardiac Care Units)
  • OTs (for open-heart surgeries, pacemaker implants)
  • Echocardiography labs
  • Holter monitoring / Stress testing labs
  • Electrophysiology labs

πŸŽ“ PART 3: MSc PHYSICIAN ASSISTANT PREPARATION

What MSc PA Programs Look For

  • BSc in a healthcare field (Cardiac Technology qualifies)
  • 50% or above aggregate
  • Entrance exam (varies by university - AIIMS PA, CMC Vellore, SRM, Manipal, etc.)
  • Interview + practical assessment at some institutes

MSc PA Entrance Exam - General Syllabus

The entrance is broadly based on:
1. Basic Sciences (40-50%)
  • Anatomy (general + cardiovascular + respiratory)
  • Physiology (cardiovascular, respiratory, renal, GI)
  • Biochemistry (metabolism, enzymes, lab values)
  • Pathology (inflammation, neoplasia, organ pathologies)
  • Microbiology (basic bacteriology, common infections)
2. Clinical Sciences (30-40%)
  • Medicine: Common presentations (chest pain, dyspnea, edema, palpitations)
  • Pharmacology: Mechanisms, drug interactions, ADRs
  • Diagnostics: ECG, echo interpretation, lab interpretation
3. English / GK / Reasoning (10-20%)
  • Depending on the university

MSc PA Study Strategy (Start Now - 18 Month Plan)

2nd Year (Now - Year 3): Focus on BSc subjects - this IS your PA foundation
  • Every cardiac topic you study now = MSc entrance syllabus
During Internship:
  • Rotate through multiple departments (not just cardio)
  • Keep a clinical log / case diary (shows commitment at interviews)
  • Attempt BLS/ACLS certification
Final 6 Months Before Entrance:
  • Solve previous years' papers from AIIMS, JIPMER PA exams
  • Revise anatomy + physiology intensively
  • Practice MCQ series (500+ MCQs/month)

πŸ“… WEEKLY STUDY SCHEDULE (Template)

DayFocus AreaActivity
MondayAnatomy / PhysiologyRead + make notes (1.5 hr)
TuesdayECG / ArrhythmiasTheory + practice 5 ECG strips
WednesdayPharmacologyDrug class flashcards (Anki)
ThursdayEchocardiographyConcepts + YouTube visual learning
FridayPathology / HemodynamicsMechanism-based learning
SaturdayMixed MCQs30-50 MCQs across all topics
SundayRevision + Weak areasReview errors from the week

πŸ“– KEY BOOKS (Prioritized)

BookSubjectPriority
Guyton & Hall - Medical PhysiologyPhysiology⭐⭐⭐ Must-have
ECG Made Easy - John HamptonECG⭐⭐⭐ Must-have
Robbins Basic PathologyPathology⭐⭐⭐ Must-have
Katzung Basic & Clinical PharmacologyPharmacology⭐⭐⭐ Must-have
Gray's Anatomy for StudentsAnatomy⭐⭐ Important
Echocardiography by David ChambersEcho⭐⭐ Important
Harrison's Internal Medicine (select chapters)Clinical⭐ Reference

πŸ’‘ TOP TIPS FOR YOU

  1. Connect every topic to ECG or Echo - This makes learning practical and memorable
  2. Use Anki flashcards for pharmacology drug facts - space repetition works
  3. Follow cardiology accounts on Instagram/X - @cardionerds, @ECGpedia for daily practice
  4. Keep a "clinical diary" now - write one interesting case per week from your practicals
  5. Start an MCQ habit from today - 20 MCQs/day adds 7,300 MCQs by end of the year
  6. Network with senior Cardiac Technologists - LinkedIn is great for this; they share job leads and exam tips

Whenever you want to go deeper on any specific topic - whether it's ECG arrhythmias, echo calculations, a pharmacology drug class, hemodynamic numbers, or pathology mechanisms - just ask me and I will pull from our medical library and give you detailed study notes, MCQs, or explanations. I am here throughout your entire preparation journey! πŸ«€

I don't want to prepare for MSC PA now I just gave my plan to you

Got it! You shared your full plan and just want help with the immediate priorities - your BSc Cardiac Technology university exams and career preparation. The MSc PA part is noted for the future when you're ready.
So from now on, I'll focus on:
  • βœ… University exam preparation - subject-wise notes, explanations, MCQs
  • βœ… Career skills - ECG, echo, cath lab, clinical knowledge
Just tell me what you want to study or practice today. For example:
  • "Explain the cardiac conduction system"
  • "Give me 20 MCQs on ECG"
  • "Explain heart failure mechanisms"
  • "Notes on echocardiography views"
  • "Pharmacology - anti-arrhythmic drugs"
What topic shall we start with? πŸ«€
attachment
attachment
attachment
attachment
attachment
attachment
attachment
attachment
attachment
attachment
attachment
attachment
attachment
attachment
attachment
attachment
attachment
attachment
attachment
attachment

This is the schedule I have prepared for university I A I give you the topic daily I just want you to give me a the complete notes for me from scratch with diagram, flow charts and table

Understood! I've read your full schedule clearly:
  • Phase 1 (Weeks 1-2) - Foundation: Heart Structure, Vessels, Vascular Pathology
  • Phase 2 (Weeks 3-6) - Paper I: CAD, Valvular, Heart Failure, Arrhythmias, BLS
  • Phase 3 (Weeks 7-10) - Paper II: Advanced ECG, TMT, Holter
  • Phase 4 (Weeks 11-13) - Paper III: Echocardiography
The system is simple: You tell me the topic for the day, I give you complete notes with diagrams (text-based), flowcharts, and tables - exactly matching your schedule.
Today is Monday, July 13 - so you're starting Week 1, Day 1:
Gross Anatomy of the Heart - chambers, valves, great vessels, pericardium + Sketch a 4-chamber cross-section with valves labelled

Shall I begin with today's notes right now?
Just say "Start Day 1" or tell me any day's topic from your schedule and I'll deliver the full notes immediately. πŸ«€

Start Day 1

Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Loading Image
Loading Image
I have all the content needed from Gray's Anatomy for Students and Fuster & Hurst's The Heart. Now let me compile your complete Day 1 notes.

πŸ“˜ WEEK 1 - DAY 1

Gross Anatomy of the Heart: Chambers, Valves, Great Vessels & Pericardium

Source: Gray's Anatomy for Students | Fuster & Hurst's The Heart, 15th Ed

1. OVERVIEW - THE HEART AS A DOUBLE PUMP

The heart is a hollow, muscular organ that functions as two pumps working side by side, each consisting of an atrium + ventricle separated by a valve.
Heart as two pumps - showing right pump (blue/deoxygenated) and left pump (red/oxygenated) with circulation
RIGHT PUMP                          LEFT PUMP
RA β†’ (Tricuspid) β†’ RV              LA β†’ (Mitral) β†’ LV
        ↓                                   ↓
  Pulmonary valve                      Aortic valve
        ↓                                   ↓
  Pulmonary trunk                         Aorta
        ↓                                   ↓
      LUNGS                          GENERAL BODY

2. POSITION & ORIENTATION

FeatureDetails
ShapePyramid resting on one side
ApexProjects forward, downward, LEFT - formed by inferolateral LV
Apex locationLeft 5th intercostal space, 8-9 cm from midsternal line
BaseFaces posteriorly - formed mostly by Left Atrium
AxisOblique - right to left, posterior to anterior

Surfaces of the Heart

SurfaceFacingFormed By
Anterior (sternocostal)AnteriorlyMostly RV + some RA (right) + LV (left)
Diaphragmatic (inferior)Inferiorly (rests on diaphragm)LV + small part RV
Left pulmonaryLeft lungLV + part of LA
Right pulmonaryRight lungRA
Base (posterior)PosteriorlyLA (mostly) + small part RA

Borders (important for CXR reading)

Border on CXR (PA view)Structures
Right borderSVC + RA + IVC
Left borderAortic arch + Pulmonary trunk + Left auricle + LV
Inferior borderRV + LV (at apex)

3. THE FOUR CHAMBERS

πŸ”΅ RIGHT ATRIUM (RA)

  • Forms the right border of the heart
  • Receives blood from: SVC (upper body), IVC (lower body), Coronary sinus (heart wall)
  • Key internal feature: Crista terminalis - muscular ridge dividing smooth (sinus venarum) from rough (pectinate muscles) portions
  • Fossa ovalis - remnant of foramen ovale in interatrial septum (fetal shunt)
  • Leads blood β†’ RV through the Tricuspid valve (right AV orifice)

πŸ”΅ RIGHT VENTRICLE (RV)

  • Wall thickness: 3-5 mm (thin - pumps to low-resistance pulmonary circulation)
  • Key features: Trabeculae carneae (irregular muscle bundles), Papillary muscles, Chordae tendineae, Moderator band (septomarginal trabecula - carries part of right bundle branch)
  • Outflow tract: Conus arteriosus (infundibulum) β†’ leads to Pulmonary valve β†’ Pulmonary trunk
  • Pulmonary valve: 3 semilunar cusps - Left, Right, Anterior

πŸ”΄ LEFT ATRIUM (LA)

  • Forms most of the base/posterior surface of the heart
  • Receives blood from: 4 pulmonary veins (2 right + 2 left - carry oxygenated blood)
  • Smooth posterior wall (derived from incorporated pulmonary veins)
  • Rough anterior wall with musculi pectinati + left auricle
  • Valve of foramen ovale - in interatrial septum (opposite fossa ovalis of RA)
  • Leads blood β†’ LV through Mitral valve (left AV orifice)

πŸ”΄ LEFT VENTRICLE (LV)

  • Wall thickness: 8-12 mm (thicker - pumps against high systemic resistance)
  • Forms apex of heart and left/diaphragmatic surface
  • Circular cross-section (vs. crescent-shaped RV)
  • Features: Trabeculae carneae, 2 papillary muscles (anterior + posterior), Chordae tendineae
  • Outflow: Aortic vestibule β†’ Aortic valve β†’ Ascending aorta

4. THE FOUR VALVES

ATRIOVENTRICULAR (AV) VALVES           SEMILUNAR VALVES
(prevent backflow during systole)       (prevent backflow during diastole)

  Tricuspid (Right)                        Pulmonary (Right)
  - 3 cusps: Anterior, Posterior,          - 3 semilunar cusps: Left, Right,
    Septal                                   Anterior
  - Held by chordae tendineae             - Pocket-like sinuses fill and close
    from 3 papillary muscles                valve after systole

  Mitral/Bicuspid (Left)                  Aortic (Left)
  - 2 cusps: Anterior (aortic) +          - 3 semilunar cusps: Left, Right,
    Posterior (mural)                        Posterior (non-coronary)
  - Held by chordae from 2 papillary      - Coronary arteries arise from left
    muscles (anterior + posterior)          and right aortic sinuses

Valve Summary Table

ValveTypeLocationCuspsFunction
TricuspidAVRight AV orifice3Prevents RA backflow during RV systole
PulmonarySemilunarRV outflow (infundibulum)3Prevents PA backflow during diastole
Mitral (Bicuspid)AVLeft AV orifice2Prevents LA backflow during LV systole
AorticSemilunarLV outflow (vestibule)3Prevents aortic backflow during diastole
Memory trick: "Try Pulling My Aorta" = Tricuspid, Pulmonary, Mitral, Aortic (right to left, inflow to outflow)

5. GREAT VESSELS

Base of heart showing great vessels and all four chambers

Vessels Entering the Heart (Veins)

VesselCarriesEnters
Superior Vena Cava (SVC)Deoxygenated blood from upper body (above diaphragm)Upper posterior RA
Inferior Vena Cava (IVC)Deoxygenated blood from lower body (below diaphragm)Lower posterior RA
Coronary SinusVenous drainage from heart wallLower posterior RA
4 Pulmonary Veins (2L + 2R)Oxygenated blood from lungsPosterior LA (2 on each side)

Vessels Leaving the Heart (Arteries)

VesselCarriesLeaves From
Pulmonary TrunkDeoxygenated blood to lungsRV (via pulmonary valve)
Ascending AortaOxygenated blood to bodyLV (via aortic valve)

Aorta - Divisions

Ascending Aorta
    ↓ (gives off Left + Right Coronary Arteries)
Aortic Arch
    ↓ (gives off Brachiocephalic trunk β†’ Right subclavian + Right common carotid)
    ↓ (gives off Left Common Carotid)
    ↓ (gives off Left Subclavian)
Descending Thoracic Aorta
    ↓ (passes through diaphragm at T12)
Abdominal Aorta

6. PERICARDIUM

PERICARDIUM (fibroserous sac surrounding the heart)
        |
        |-------- FIBROUS PERICARDIUM (outer layer)
        |           - Tough, inextensible
        |           - Attached to: Central tendon of diaphragm (below),
        |             Sternum (anteriorly), Great vessels (superiorly)
        |           - Function: Prevents overdistension, anchors heart
        |
        |-------- SEROUS PERICARDIUM (inner layer)
                    |
                    |---- PARIETAL LAYER - lines inner fibrous pericardium
                    |
                    |---- VISCERAL LAYER (EPICARDIUM) - covers heart surface
                    |
                    |---- PERICARDIAL CAVITY (between parietal + visceral)
                              - Contains 15-50 mL of serous fluid
                              - Acts as lubricant reducing friction

Pericardial Sinuses

SinusLocationClinical Relevance
Transverse sinusBetween great arteries (front) and great veins (behind)Surgeons pass ligature around aorta + PA during bypass surgery
Oblique sinusBehind LA, between pulmonary veinsPericardial effusion collects here (blind pouch)

Clinical Relevance: Cardiac Tamponade

When fluid accumulates excessively in the pericardial cavity (> ~200 mL acutely), it compresses the heart β†’ cardiac tamponade. The fibrous pericardium cannot expand, so pressure rises rapidly. (You will study this in detail in Week 5!)

7. DIAGRAM TO DRAW - 4-Chamber Cross-Section

Draw and label this in your notebook:
                    AORTA      PULMONARY TRUNK
                      |               |
          ============|===============|============
          |   AORTIC VALVE    PULM. VALVE         |
          |                                        |
    SVC ───   LEFT ATRIUM β”‚ RIGHT ATRIUM   β”œβ”€β”€ SVC
          |        (LA)   β”‚    (RA)         |
          |     ──────────│──────────       |
    Pulm. |   MITRAL VALVEβ”‚ TRICUSPID VALVE |
    Veins──               β”‚                β”œβ”€β”€ IVC
    (x4)  |   LEFT VENTRICLEβ”‚RIGHT VENTRICLE|
          |      (LV)       β”‚    (RV)       |
          |   THICK WALL    β”‚  THIN WALL    |
          |      (8-12mm)   β”‚   (3-5mm)     |
          |                 β”‚               |
          |       APEX (formed by LV)       |
          ==========================================

         KEY:
         LA + LV = Left heart (RED = oxygenated)
         RA + RV = Right heart (BLUE = deoxygenated)
         β”‚ = Interventricular / Interatrial septum

8. BLOOD FLOW THROUGH THE HEART - MASTER FLOWCHART

BODY (deoxygenated blood)
        ↓
SVC / IVC / Coronary Sinus
        ↓
RIGHT ATRIUM (RA)
        ↓  [Tricuspid Valve OPENS]
RIGHT VENTRICLE (RV)
        ↓  [Pulmonary Valve OPENS]
PULMONARY TRUNK β†’ Left & Right Pulmonary Arteries
        ↓
LUNGS (gas exchange: COβ‚‚ out, Oβ‚‚ in)
        ↓
4 PULMONARY VEINS (oxygenated blood)
        ↓
LEFT ATRIUM (LA)
        ↓  [Mitral Valve OPENS]
LEFT VENTRICLE (LV)
        ↓  [Aortic Valve OPENS]
AORTA β†’ Systemic Circulation
        ↓
BODY (oxygen delivered to tissues)
        ↓ (cycle repeats)

9. KEY FACTS FOR MCQs

Question TypeAnswer
Which chamber forms the base of the heart?Left Atrium
Which chamber forms the apex?Left Ventricle
Which valve has only 2 cusps?Mitral (Bicuspid) valve
Which structure is the remnant of the foramen ovale?Fossa ovalis (in RA)
Normal pericardial fluid volume?15-50 mL
Which surface of the heart faces the diaphragm?Diaphragmatic (inferior) surface
Coronary sinus drains into which chamber?Right Atrium
Pulmonary veins carry which type of blood?Oxygenated (exception: veins carrying arterial blood)
LV wall thickness vs RV?LV = 8-12 mm; RV = 3-5 mm
Which valve lies between LA and LV?Mitral valve
Apex of heart - which intercostal space?Left 5th intercostal space
Moderator band is found in which chamber?Right Ventricle

10. SELF-TEST (Do this before Day 2)

  1. Name the 4 chambers and what vessel enters/exits each
  2. Draw the 4-chamber cross-section from memory and label all valves
  3. Trace the path of one red blood cell from the IVC all the way back to the aorta
  4. What is the difference between fibrous and serous pericardium?
  5. Which 3 structures form the right border of the heart on CXR?

Day 1 done! Tomorrow (Day 2) we cover Coronary Arteries & Cardiac Conduction System with the SAβ†’AVβ†’Bundle of Hisβ†’Purkinje flowchart. Just say "Day 2" when you're ready! πŸ«€

Hii

Hi! Good morning! πŸ‘‹
Welcome back! Today is Tuesday, July 14 β€” that means it's Week 1, Day 2 on your schedule:
Coronary Arteries & Cardiac Conduction System (SA node β†’ AV node β†’ Bundle of His β†’ Purkinje fibres)
  • Flowchart of the conduction pathway
  • Clinical link: Base for CAD, MI localisation & arrhythmias
Before we dive in β€” did you complete Day 1's self-test? (Redraw the 4-chamber diagram from memory?)
Whenever you're ready, just say "Day 2" and I'll deliver the full notes! πŸ«€

Day 2

Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Loading Image
Loading Image
All the content from Gray's Anatomy for Students is loaded. Here are your complete Day 2 notes!

πŸ“˜ WEEK 1 - DAY 2

Coronary Arteries & Cardiac Conduction System

Source: Gray's Anatomy for Students | Fuster & Hurst's The Heart, 15th Ed

PART A: CORONARY ARTERIES

1. Overview

The coronary arteries are the first branches of the aorta - they arise from the aortic sinuses (pouches behind the cusps of the aortic valve) and supply the myocardium (heart wall) with oxygenated blood. They fill during diastole (when the heart is relaxed), not during systole.
There are two main coronary arteries:
  • Right Coronary Artery (RCA) - from the right aortic sinus
  • Left Coronary Artery (LCA) - from the left aortic sinus
Coronary artery anatomy - anterior view showing RCA, LAD, LCx and their branches, with actual coronary angiogram images

2. Right Coronary Artery (RCA)

Origin: Right aortic sinus of ascending aorta
Course: Passes anteriorly β†’ descends in coronary sulcus (between RA and RV) β†’ turns posteriorly onto diaphragmatic surface
Key Branches:
BranchSupplies
SA nodal branch (early atrial branch)Sinu-atrial (SA) node (in ~60% of people)
Right marginal branchAnterior surface of RV toward apex
AV nodal branchAtrioventricular (AV) node
Posterior Interventricular branch (PDA - Posterior Descending Artery)Posterior IVS, posterior LV wall
Total territory supplied by RCA:
  • Right atrium + Right ventricle
  • SA node and AV node (in most people)
  • Interatrial septum + part of LA
  • Posterior 1/3 of interventricular septum
  • Posterior part of LV

3. Left Coronary Artery (LCA)

Origin: Left aortic sinus of ascending aorta
Course: Passes between pulmonary trunk and left auricle β†’ enters coronary sulcus β†’ immediately divides into 2 terminal branches
LEFT CORONARY ARTERY (Left Main Stem)
         |
    _____|_____
    |          |
   LAD        LCx
(Anterior    (Circumflex
Interventri-  branch)
 cular)

Branch 1: LAD (Left Anterior Descending) = Anterior Interventricular Artery

  • Descends in anterior interventricular sulcus toward apex
  • Gives off diagonal branches (cross anterior LV surface)
  • Gives off septal perforators (supply anterior 2/3 of IVS)
  • Supplies: Anterior LV wall, anterior 2/3 of IVS, apex, Bundle of His, bundle branches
  • Called "Widow Maker" - most critical artery; LAD blockage = massive anterior MI

Branch 2: LCx (Circumflex branch)

  • Courses left in coronary sulcus around to posterior/diaphragmatic surface
  • Gives off Left Marginal Artery (supplies lateral LV wall)
  • Supplies: Most of LA, lateral and posterior LV wall
  • In ~15% of people (Left Dominant) = gives off PDA instead of RCA

4. Coronary Dominance - Very Exam Important!

DominanceWho gives off PDA?Frequency
Right DominantRCA~70% (most common)
Co-dominantBoth RCA + LCx~15%
Left DominantLCx~15%
Key point: Dominance is defined by which artery gives off the Posterior Descending Artery (PDA)

5. Coronary Artery β†’ ECG Territory β†’ MI Location

This table is extremely high-yield for your career and exams:
Artery BlockedWall of LV AffectedECG Leads Showing Changes
LADAnteriorV1, V2, V3, V4
LCxLateralI, aVL, V5, V6
RCAInferiorII, III, aVF
RCA (proximal)Inferior + Right VentricleII, III, aVF + V3R, V4R
LAD (proximal)Anterior + SeptalV1-V4 + LBBB possible
You will use this table every single day in the cath lab and when reading ECGs. Memorise it now!

6. Coronary Veins (Blood Returns to RA)

VeinDrainsEmpties Into
Great cardiac veinAnterior surface (alongside LAD)Coronary sinus
Middle cardiac veinPosterior surface (alongside PDA)Coronary sinus
Small cardiac veinRight sideCoronary sinus
Anterior cardiac veinsRV anterior surfaceDirectly into RA
Coronary SinusAll the aboveRight Atrium

PART B: CARDIAC CONDUCTION SYSTEM

7. Overview

The conduction system is a network of specialised cardiac muscle cells that generate and coordinate electrical impulses. It ensures the heart contracts in an orderly, sequential manner: atria first, then ventricles.
Conduction system showing SA node, AV node, AV bundle, right & left bundle branches, and Purkinje fibres

8. Components of the Conduction System

πŸ”΅ 1. Sinu-Atrial (SA) Node - "The Pacemaker"

  • Location: Superior end of crista terminalis, at junction of SVC and RA
  • Intrinsic rate: 60-100 beats/min
  • Function: Generates the primary electrical impulse β†’ spreads across both atria β†’ causes atrial contraction
  • Blood supply: SA nodal branch of RCA (60%) or LCx (40%)
  • ECG correlation: Produces the P wave

πŸ”΅ 2. Atrioventricular (AV) Node - "The Gatekeeper"

  • Location: Floor of RA, near opening of coronary sinus, close to septal cusp of tricuspid valve, within AV septum
  • Intrinsic rate: 40-60 beats/min (backup pacemaker)
  • Function: Receives impulse from SA node β†’ delays it by 0.1 sec β†’ allows atria to finish contracting before ventricles fire
  • Blood supply: AV nodal branch of RCA (80%)
  • ECG correlation: Produces the PR interval delay

πŸ”΅ 3. Bundle of His (AV Bundle) - "The Bridge"

  • Location: Lower border of membranous IVS β†’ splits into Right and Left bundle branches
  • Function: Only electrical connection between atria and ventricles (rest of AV junction is insulated by fibrous skeleton)
  • Blood supply: Dual - LAD + RCA

πŸ”΅ 4. Right Bundle Branch (RBB)

  • Course: Down right side of IVS β†’ enters septomarginal trabecula (moderator band) β†’ reaches base of anterior papillary muscle β†’ Purkinje fibres
  • Function: Conducts impulse to RV myocardium
  • Clinical: Blockage = Right Bundle Branch Block (RBBB) β†’ RSR' pattern in V1

πŸ”΅ 5. Left Bundle Branch (LBB) β†’ splits into:

  • Left Anterior Fascicle (LAF): Supplies anterosuperior LV
  • Left Posterior Fascicle (LPF): Supplies posteroinferior LV (thicker, dual blood supply - more resistant to ischemia)
  • Clinical: Blockage = Left Bundle Branch Block (LBBB) β†’ broad notched R in V6

πŸ”΅ 6. Purkinje Fibres - "The Sprinter"

  • Location: Subendocardial plexus throughout ventricular walls
  • Intrinsic rate: 20-40 beats/min (last resort pacemaker)
  • Function: Rapidly conducts impulse to all ventricular myocardium β†’ causes coordinated ventricular contraction from apex upward to outflow tracts
  • ECG correlation: Produces QRS complex

9. MASTER CONDUCTION FLOWCHART (Draw This!)

SA NODE (60-100/min) - RIGHT ATRIUM
[Junction of SVC + RA, superior crista terminalis]
        |
        | Impulse spreads across both atria
        | (via internodal pathways + Bachmann's bundle to LA)
        ↓
  ATRIAL CONTRACTION β†’ P wave on ECG
        |
        ↓
AV NODE (40-60/min) - FLOOR OF RA
[Near coronary sinus opening, AV septum]
        |
        | DELAY = 0.1 second
        | (allows atria to finish emptying into ventricles)
        ↓
  PR INTERVAL on ECG (normal 120-200ms)
        |
        ↓
BUNDLE OF HIS (AV Bundle)
[Lower border of membranous IVS]
        |
        |___________________________
        |                          |
        ↓                          ↓
RIGHT BUNDLE BRANCH          LEFT BUNDLE BRANCH
(down right IVS β†’            (splits into)
Moderator band β†’              β”œβ”€β”€ Left Anterior Fascicle
Ant. papillary muscle)        └── Left Posterior Fascicle
        |                          |
        ↓                          ↓
PURKINJE FIBRES (20-40/min) throughout both ventricular walls
        |
        | Simultaneous activation - apex to base
        ↓
VENTRICULAR CONTRACTION β†’ QRS complex on ECG (normal <120ms)
        |
        ↓
  REPOLARISATION β†’ T wave on ECG

10. Intrinsic Rates - Pacemaker Hierarchy Table

StructureIntrinsic RateTakes Over When...
SA Node60-100 /minNormal sinus rhythm
AV Node40-60 /minSA node fails (junctional escape rhythm)
Bundle of His30-40 /minAV node fails
Purkinje / Ventricle20-40 /minAll above fail (idioventricular rhythm)
Rule: The structure with the highest intrinsic rate normally controls the heart. The SA node always wins.

11. Autonomic Control of the Heart

SympatheticParasympathetic (Vagus)
NeurotransmitterNoradrenalineAcetylcholine
Effect on HR↑ (Positive chronotropy)↓ (Negative chronotropy)
Effect on conduction↑ AV node speed↓ AV node speed (longer PR)
Effect on contractility↑ (Positive inotropy)↓ (Negative inotropy)
Effect on coronary arteriesDilatesConstricts
ReceptorΞ²1 adrenoceptorsM2 muscarinic receptors
Clinical link: Beta blockers (e.g. metoprolol) block Ξ²1 β†’ slow SA node β†’ slow AV node β†’ ↓HR. Used in arrhythmias, hypertension, post-MI.

12. Blood Supply to the Conduction System

Node/StructurePrimary Blood SupplyWhy It Matters
SA NodeRCA (60%) or LCx (40%)RCA occlusion β†’ SA node ischemia β†’ Sinus bradycardia / Sick Sinus Syndrome
AV NodeRCA (80%)Inferior MI (RCA) β†’ AV block (prolonged PR, heart block)
Bundle of HisDual: LAD + RCAProtected by dual supply
Right Bundle BranchLAD (septal perforators)Anterior MI β†’ RBBB
Left Bundle BranchDual: LAD + RCALBBB = sign of significant disease

13. KEY FACTS FOR MCQs

QuestionAnswer
Normal pacemaker of the heart?SA node
Location of SA node?Junction of SVC and RA (superior crista terminalis)
Location of AV node?Floor of RA, near coronary sinus opening
Which is the only electrical connection between atria and ventricles?Bundle of His
Which structure carries RBB to anterior papillary muscle?Moderator band (septomarginal trabecula)
Intrinsic rate of SA node?60-100/min
Intrinsic rate of AV node?40-60/min
Intrinsic rate of Purkinje fibres?20-40/min
Which artery most commonly supplies AV node?RCA (80%)
Which MI commonly causes AV block?Inferior MI (RCA occlusion)
Most dangerous artery to block?LAD ("Widow Maker")
Most common coronary dominance?Right dominant (~70%)
Dominance is defined by which artery gives off?PDA (Posterior Descending Artery)
Coronary arteries fill during?Diastole

14. DIAGRAM TO DRAW

Draw this in your notebook today:
AORTA
  |
  |-------- RCA (Right aortic sinus)
  |           |-- SA nodal branch
  |           |-- Right marginal branch
  |           |-- AV nodal branch
  |           β””-- PDA (Posterior Descending Artery)
  |
  |-------- LCA (Left aortic sinus)
              |
         Left Main Stem
              |
         _____|_____
         |          |
        LAD         LCx
         |           |-- Left marginal branch
         |-- Diagonal |-- (PDA in left dominant)
         |-- Septal
             perforators

15. SELF-TEST (Do Before Day 3)

  1. Name all branches of the RCA in order
  2. What is the difference between right dominant and left dominant coronary circulation?
  3. Trace an electrical impulse from the SA node to the point where the QRS complex is generated
  4. A patient has an inferior MI (RCA blocked) - which node's blood supply is at risk and what arrhythmia might develop?
  5. Why do coronary arteries fill during diastole and not systole?

Day 2 complete! Tomorrow (Day 3) is Cardiac Cycle & Physiology - systole/diastole, heart sounds, Wiggers diagram. Just say "Day 3" when ready! πŸ«€

Day 3

Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Finding Sources
Reading File
Reading File
Loading Image
All the content from Guyton & Hall, Costanzo Physiology, and Gray's Anatomy for Students is ready. Here are your complete Day 3 notes!

πŸ“˜ WEEK 1 - DAY 3

Cardiac Cycle & Physiology: Systole/Diastole, Heart Sounds, Wiggers Diagram

Source: Guyton & Hall Medical Physiology | Costanzo Physiology 7th Ed | Gray's Anatomy for Students

1. WHAT IS THE CARDIAC CYCLE?

The cardiac cycle = all mechanical and electrical events from the beginning of one heartbeat to the beginning of the next.
  • At heart rate of 72 beats/min β†’ one cardiac cycle = 0.833 seconds
  • Systole (contraction) β‰ˆ 0.3 sec
  • Diastole (relaxation/filling) β‰ˆ 0.5 sec
Key principle: The atria act as "primer pumps" - they contract just before the ventricles, topping up the ventricle with extra blood (last 20-30% of filling). The ventricles provide the main pumping power.

2. THE 7 PHASES OF THE CARDIAC CYCLE

(Learn these in order - this IS the Wiggers diagram in text form)

PHASE A - Atrial Systole

What happensAtria contract, actively pushing remaining blood into ventricles (final 20-30% of ventricular filling)
ECG eventP wave (atrial depolarisation)
ValvesMitral + Tricuspid = OPEN; Aortic + Pulmonary = CLOSED
LV pressureSlight increase (blip from atrial kick)
LV volumeIncreases to maximum = End-Diastolic Volume (EDV) = ~120-130 mL
Heart soundS4 (not heard in normal adults; heard in LV hypertrophy - stiff ventricle)
Venous pulse'a' wave (atrial contraction reflected back)

PHASE B - Isovolumetric Ventricular Contraction (IVC)

What happensVentricles begin contracting; pressure rises rapidly BUT no blood leaves yet (all valves closed)
ECG eventQRS complex (ventricular depolarisation)
ValvesALL VALVES CLOSED (most important phase - brief but critical)
LV pressureRises sharply
LV volumeConstant - "Iso" = same volume
Heart soundS1 ("LUB") - closure of Mitral + Tricuspid valves
Why isovolumetric? Mitral just closed (LV pressure > LA pressure), but Aortic hasn't opened yet (LV pressure still < Aortic pressure). So no blood moves. Volume stays fixed while pressure builds.

PHASE C - Rapid Ventricular Ejection

What happensLV pressure exceeds aortic pressure β†’ Aortic valve OPENS β†’ Blood rapidly ejected (~70% of stroke volume)
ECG eventST segment
ValvesAortic + Pulmonary = OPEN; Mitral + Tricuspid = CLOSED
LV pressureReaches maximum (peak systolic ~120 mmHg)
LV volumeDecreases rapidly
Aortic pressureRises sharply
Heart soundNone

PHASE D - Reduced Ventricular Ejection

What happensVentricles begin to repolarise; still contracting but weaker; blood still ejected but at slower rate
ECG eventT wave (ventricular repolarisation begins)
ValvesAortic + Pulmonary still OPEN
LV pressureStarts to fall
LV volumeContinues to decrease - reaches End-Systolic Volume (ESV) = ~50-60 mL
Aortic pressureBegins to fall (blood running off into arteries faster than ejected)

PHASE E - Isovolumetric Ventricular Relaxation (IVR)

What happensVentricles relax; LV pressure drops below aortic β†’ Aortic valve CLOSES. All valves closed again
ECG eventEnd of T wave
ValvesALL VALVES CLOSED again
LV pressureFalls rapidly
LV volumeConstant (no blood entering or leaving)
Aortic pressureShows dicrotic notch (incisura) = the "blip" when aortic valve closes
Heart soundS2 ("DUB") - closure of Aortic + Pulmonary valves
Dicrotic notch = small upward deflection on the aortic pressure curve, representing elastic recoil of the aorta when the aortic valve closes. Important landmark in arterial pressure waveform!

PHASE F - Rapid Ventricular Filling

What happensLV pressure falls below LA pressure β†’ Mitral valve OPENS β†’ Blood rushes in from atrium passively
ECG eventNo ECG event (electrical silence - between T and next P)
ValvesMitral + Tricuspid = OPEN; Aortic + Pulmonary = CLOSED
LV pressureRemains low (ventricle is compliant/relaxed)
LV volumeIncreases rapidly
Heart soundS3 - normal in children; in adults = pathological (sign of volume overload / heart failure)

PHASE G - Reduced Ventricular Filling (Diastasis)

What happensPassive filling continues slowly; pressure gradients equalise between atria and ventricles
ECG eventNone (waiting for next P wave)
ValvesMitral + Tricuspid still OPEN
LV volumeSlowly increases
Heart soundNone
Ends whenNext P wave fires β†’ Atrial systole (Phase A) of the next cycle begins

3. THE WIGGERS DIAGRAM - DRAW THIS

TIME β†’  |---DIASTOLE----|--SYS--|--IVR--|-------DIASTOLE--------|

ECG:    |  P  |  PR  |  QRS  |  ST  |  T  |         |  P  |

PHASES: |--A--|--B----|---C---|--D---|--E--|---F---|-G-|--A--|
        Atrial  IVC   Rapid   Slow   IVR  Rapid  Slow  Next
        Systole        Ejec  Ejec        Fill   Fill  Cycle

LV      120 |          ___peak___
PRESSURE     |         /          \
(mmHg)   80 |___peak__/    Aortic  \___dicrotic notch
          0 |_____/LA\______________mitral opens_____

LV      130|___EDV
VOLUME       |        \stroke vol/
(mL)      50|_________\________/ESV____________________

HEART    [S4]  [S1-LUB]               [S2-DUB] [S3]
SOUNDS    A      B                      E        F

VALVES:
Mitral:  OPEN|CLOSED|CLOSED|CLOSED|CLOSED|OPEN|OPEN|OPEN
Aortic:  CL  | CL   | OPEN | OPEN | CL  | CL | CL | CL

4. KEY VOLUMES & CALCULATIONS

ParameterDefinitionNormal Value
EDV (End-Diastolic Volume)Volume in LV just before systole begins120-130 mL
ESV (End-Systolic Volume)Volume remaining in LV after systole50-60 mL
Stroke Volume (SV)EDV - ESV = volume ejected per beat70 mL
Ejection Fraction (EF)SV / EDV Γ— 100β‰₯55% (normal)
Cardiac Output (CO)SV Γ— Heart Rate4-8 L/min
Cardiac IndexCO / Body Surface Area2.5-4.0 L/min/mΒ²

Ejection Fraction Classification (exam high-yield!)

EFDiagnosis
β‰₯55%Normal
40-54%HFmrEF (mildly reduced)
<40%HFrEF (reduced EF = systolic heart failure)
>75%HFpEF may have preserved or hyperdynamic EF

5. THE FOUR HEART SOUNDS

SoundCalledCauseWhenNormal?Clinical Significance
S1"LUB"Closure of Mitral + Tricuspid (AV valves)Start of systole (Phase B)βœ… AlwaysLoud S1 = MS; Soft S1 = MR, LBBB
S2"DUB"Closure of Aortic + Pulmonary (Semilunar valves)End of systole (Phase E)βœ… AlwaysFixed split S2 = ASD; Wide split = RBBB
S3Ventricular gallopRapid ventricular filling; blood hitting wallsEarly diastole (Phase F)βœ… Children onlyIn adults = Heart failure, MR, TR
S4Atrial gallopStiff ventricle resisting atrial kickLate diastole (Phase A)❌ Never normalLV hypertrophy, HTN, HOCM, severe AS

Rhythm of Gallops

Normal:     LUB - DUB  (S1 - S2)
S3 gallop:  LUB - DUB - da  (S1 - S2 - S3) β†’ "Kentucky" rhythm
S4 gallop:  da - LUB - DUB  (S4 - S1 - S2) β†’ "Tennessee" rhythm

6. AUSCULTATION AREAS - WHERE TO LISTEN

Chest auscultation areas for all four heart valves - Aortic (right 2nd ICS), Pulmonic (left 2nd ICS), Tricuspid (left lower sternal border), Mitral (apex/5th ICS MCL)
ValveAuscultation AreaLocation
AorticRight 2nd intercostal space, sternal borderUpper right
PulmonaryLeft 2nd intercostal space, sternal borderUpper left
TricuspidLeft lower sternal border (4th-5th ICS)Lower left
MitralApex - Left 5th ICS, midclavicular lineApex / lower left
Memory trick: "All Patients Take Medicine" = Aortic, Pulmonary, Tricuspid, Mitral (from right to left, top to bottom)

7. VENOUS PULSE WAVEFORM (JVP)

The Jugular Venous Pulse (JVP) reflects pressure events in the right atrium - important in clinical examination.
JVP waveform:

  a  c  x  v  y
  /\/\  \/\/\
  |  |   |  |
  a wave = atrial contraction (Phase A)
  c wave = tricuspid valve bulging back into RA (IVC)
  x descent = atrial relaxation
  v wave = venous filling of RA (while tricuspid is closed during systole)
  y descent = tricuspid opens, RA empties into RV
JVP AbnormalityCause
Giant 'a' waveTricuspid stenosis, Complete heart block
Absent 'a' waveAtrial fibrillation (no organised atrial contraction)
Giant 'v' waveTricuspid regurgitation
Kussmaul's sign (JVP rises on inspiration)Constrictive pericarditis, RV failure

8. SPLITTING OF S2

S2 has two components:
  • A2 = Aortic valve closure (comes first, normally)
  • P2 = Pulmonary valve closure (comes second, normally)
TypeWhenCause
Physiological splittingInspiration onlyNormal - inspiration β†’ more RV filling β†’ RV takes longer to empty β†’ P2 delayed
Wide splittingBoth inspiration + expirationRBBB, pulmonary hypertension, pulmonary stenosis
Fixed splittingDoesn't change with breathingASD (equalised filling of both ventricles)
Paradoxical splittingExpiration only (reversed!)LBBB, severe AS, HCM

9. CLINICAL LINKS (Exam + Career)

Physiology ConceptClinical Relevance
S4 gallopLV hypertrophy from HTN - target organ damage
S3 gallop in adultHeart failure - important bedside finding
Fixed split S2Atrial Septal Defect (ASD)
Absent 'a' wave in JVPAtrial fibrillation
Dicrotic notch on arterial lineMarks aortic valve closure - seen in ICU monitoring
Low EF (<40%)Systolic HF β†’ needs beta blocker + ACEi + spironolactone
Tachycardia shortens diastole more than systoleHeart fills less β†’ risk of inadequate coronary perfusion

10. MASTER FLOWCHART - CARDIAC CYCLE SUMMARY

P WAVE fires (SA node)
        ↓
ATRIAL SYSTOLE
Mitral valve OPEN β†’ final filling of LV
LV volume = EDV (120-130 mL)
[S4 if heard]
        ↓
QRS fires (ventricular depolarisation)
        ↓
ISOVOLUMETRIC CONTRACTION (IVC)
ALL VALVES CLOSED
LV pressure rises rapidly
[S1 = Mitral + Tricuspid close]
        ↓
LV pressure > Aortic pressure
        ↓
AORTIC VALVE OPENS
RAPID EJECTION β†’ peak LV pressure ~120 mmHg
ST segment on ECG
        ↓
T WAVE (repolarisation begins)
        ↓
REDUCED EJECTION
LV pressure falls β†’ ESV reached (50-60 mL)
Stroke Volume = EDV - ESV = 70 mL
        ↓
LV pressure < Aortic pressure
        ↓
AORTIC VALVE CLOSES
[Dicrotic notch on Aortic pressure trace]
[S2 = Aortic + Pulmonary close]
        ↓
ISOVOLUMETRIC RELAXATION (IVR)
ALL VALVES CLOSED
LV pressure falls rapidly
        ↓
LV pressure < LA pressure
        ↓
MITRAL VALVE OPENS
RAPID FILLING β†’ LV volume rises fast
[S3 if heard]
        ↓
DIASTASIS (slow filling)
        ↓
Next P WAVE β†’ cycle repeats

11. KEY FACTS FOR MCQs

QuestionAnswer
Which phase has ALL valves closed (Γ—2)?IVC (Phase B) and IVR (Phase E)
S1 is caused by closure of which valves?Mitral + Tricuspid (AV valves)
S2 is caused by closure of which valves?Aortic + Pulmonary (Semilunar valves)
S3 in an adult is a sign of?Heart failure (volume overload)
S4 is a sign of?Stiff (hypertrophied) ventricle
Normal ejection fraction?β‰₯55%
Normal stroke volume?~70 mL
Normal cardiac output?4-8 L/min
What is EDV?Volume in LV just before systole (~120-130 mL)
What is ESV?Volume remaining after systole (~50-60 mL)
EF formula?(SV/EDV) Γ— 100 = (EDV-ESV)/EDV Γ— 100
Dicrotic notch represents?Closure of the aortic valve
Fixed split S2 is diagnostic of?Atrial Septal Defect (ASD)
Absent 'a' wave in JVP means?Atrial Fibrillation
Which phase does S1 occur in?Beginning of systole (IVC / Phase B)
Which phase does S2 occur in?End of systole (IVR / Phase E)

12. SELF-TEST (Do Before Day 4)

  1. List all 7 phases of the cardiac cycle in order with their key valve event
  2. Draw the Wiggers diagram from memory - mark S1, S2, EDV, ESV, dicrotic notch
  3. A patient has an S3 gallop at the apex. What does this indicate?
  4. Why does the aortic valve close before the pulmonary valve?
  5. Calculate Stroke Volume and EF if EDV = 150 mL and ESV = 75 mL
  6. What is "physiological splitting" of S2 and when does it occur?

Day 3 done! Tomorrow (Day 4) is Hemodynamics - preload, afterload, contractility, Frank-Starling law, and cardiac output. This is the foundation for understanding anti-failure drugs! Just say "Day 4" when ready πŸ«€

Day 4

Finding Sources
Finding Sources
Finding Sources
Reading File
Finding Sources
Reading File
Finding Sources
Reading File
Reading File
Reading File
Reading File
Loading Image
All content from Morgan & Mikhail's Clinical Anesthesiology, Harrison's Internal Medicine, and Guyton & Hall is ready. Here are your complete Day 4 notes!

πŸ“˜ WEEK 1 - DAY 4

Hemodynamics: Preload, Afterload, Contractility, Frank-Starling Law & Cardiac Output

Source: Morgan & Mikhail's Clinical Anesthesiology 7th Ed | Harrison's Principles of Internal Medicine 22E | Guyton & Hall Medical Physiology

1. THE BIG PICTURE

Stroke volume - and therefore cardiac output - is controlled by three fundamental determinants:
STROKE VOLUME
      |
      |________ 1. PRELOAD       (how full the heart is BEFORE it squeezes)
      |
      |________ 2. AFTERLOAD     (how hard the heart must squeeze AGAINST)
      |
      |________ 3. CONTRACTILITY (how powerfully the heart squeezes)
Master these three, and you understand heart failure, cardiogenic shock, hypertension, and every cardiac drug mechanism.

2. PRELOAD

Definition

Preload = the stretch on the ventricular muscle fibres JUST BEFORE contraction = End-Diastolic Volume (EDV)
  • It is the "fill" - how much blood is in the ventricle at the end of diastole
  • Clinically measured as Left Ventricular End-Diastolic Pressure (LVEDP) or PCWP (Pulmonary Capillary Wedge Pressure)

What Increases Preload?

FactorHow it raises preload
↑ Blood volume (e.g., IV fluids, transfusion)More blood returns to heart
Bradycardia (slow HR)More time to fill in diastole
VenoconstrictionSqueezes blood from veins β†’ RA
Lying flat (recumbent)More venous return from legs
Atrial contraction (S4 at end)Adds final 20-30% to EDV

What Decreases Preload?

FactorHow it lowers preload
Haemorrhage / dehydrationLess blood volume
Diuretics (Furosemide)Reduce blood volume
Nitrates (GTN)Vasodilate veins β†’ blood pools in periphery β†’ less returns
TachycardiaLess time to fill in diastole
Cardiac tamponadeExternal compression prevents filling
PEEP ventilationRaised intrathoracic pressure ↓ venous return

3. AFTERLOAD

Definition

Afterload = the resistance the ventricle must overcome to EJECT blood = the "load" it faces AFTER it starts contracting
  • For the LV: afterload β‰ˆ Systemic Vascular Resistance (SVR) = aortic pressure / peripheral resistance
  • For the RV: afterload β‰ˆ Pulmonary Vascular Resistance (PVR)
  • Clinically estimated by aortic pressure (blood pressure)

Key Rule:

↑ Afterload β†’ ↓ Stroke Volume (heart works harder but ejects less)
↓ Afterload β†’ ↑ Stroke Volume (heart ejects more easily)

What Increases Afterload?

FactorExample
HypertensionSystemic HTN β†’ LV afterload ↑
Aortic stenosisLV must generate huge pressure to open stenotic valve
Vasoconstriction (vasopressors)Noradrenaline, phenylephrine
Pulmonary hypertensionRV afterload ↑

What Decreases Afterload?

FactorDrug example
VasodilatorsACE inhibitors, ARBs, hydralazine, nitroprusside
Calcium channel blockersAmlodipine, nifedipine
IABP (Intra-Aortic Balloon Pump)Deflates before systole β†’ ↓ LV afterload
Clinical link: In heart failure, the heart is already struggling. If afterload is also high (e.g., untreated HTN), stroke volume drops further. That's why ACE inhibitors and ARBs (afterload reducers) are key drugs in heart failure!

4. CONTRACTILITY (Inotropy)

Definition

Contractility = the INTRINSIC ability of the heart muscle to generate force, INDEPENDENT of preload and afterload
  • Also called inotropic state
  • Reflects the strength of the actin-myosin cross-bridge interaction
  • At the cellular level: depends on intracellular Ca²⁺ concentration during systole

What Increases Contractility?

FactorMechanism
Sympathetic stimulation (Adrenaline, Noradrenaline)Ξ²1 receptor β†’ ↑ cAMP β†’ ↑ Ca²⁺ influx
DigoxinInhibits Na/K ATPase β†’ ↑ intracellular Ca²⁺
Dobutamine / DopamineΞ²1 agonists β†’ ↑ cAMP
MilrinonePDE inhibitor β†’ ↑ cAMP
Tachycardia (Bowditch effect)More beats β†’ more Ca²⁺ loading
Increased preload (up to a point)Frank-Starling effect

What Decreases Contractility (Negative Inotropes)?

FactorMechanism
Beta blockers (metoprolol, bisoprolol)Block Ξ²1 β†’ ↓ cAMP β†’ ↓ Ca²⁺
Calcium channel blockers (verapamil, diltiazem)Block Ca²⁺ entry
Heart failureLoss of myocytes, remodeling
Myocardial ischemia / MIDead muscle can't contract
Acidosis / HypoxiaImpairs enzyme function
Volatile anaesthetic agentsDirect myocardial depression

5. FRANK-STARLING LAW OF THE HEART

The Law (in plain English):

"The more the heart is filled (stretched), the harder it contracts and the more it ejects"
  • Within physiological limits, ↑ EDV β†’ ↑ Stroke Volume

The Cellular Mechanism:

  • Increased stretch β†’ sarcomere length increases toward optimal ~2.2 ΞΌm
  • At this length: maximum actin-myosin overlap = maximum force generation
  • Also: increased stretch β†’ increased sensitivity of troponin C for Ca²⁺
  • Beyond 2.2 ΞΌm: over-stretching β†’ filaments lose overlap β†’ force decreases
SARCOMERE STRETCH (↑ Preload)
         ↓
Optimal actin-myosin overlap at ~2.2 ΞΌm
         ↓
Maximum Ca²⁺-troponin C sensitivity
         ↓
Stronger cross-bridge formation
         ↓
↑ Force of contraction β†’ ↑ Stroke Volume

Frank-Starling Curve:

Frank-Starling curve showing cardiac output vs ventricular end-diastolic volume for normal at rest, exercise, heart failure, and cardiogenic shock states

Reading the Frank-Starling Curve:

Curve PositionStateMeaning
Upper left curveNormal during exerciseHigh contractility - same EDV produces more output
Middle curveNormal at restBaseline cardiac function
Lower curveHeart failureReduced contractility - needs higher EDV to produce same output
Lowest curveCardiogenic shockSeverely impaired - curve flattened

Key Points About the Curve:

MOVING ALONG THE CURVE (same curve, different position):
β†’ Changing Preload (EDV changes) β†’ changes position ON the curve
β†’ Example: Giving IV fluids β†’ ↑ EDV β†’ moves RIGHT on same curve β†’ ↑ CO

SHIFTING THE CURVE (entire curve moves up or down):
β†’ Changing Contractility β†’ SHIFTS the whole curve
β†’ Positive inotropy (dobutamine) β†’ curve shifts UP/LEFT
β†’ Negative inotropy (heart failure) β†’ curve shifts DOWN/RIGHT

6. CARDIAC OUTPUT

Formula & Normal Values:

CARDIAC OUTPUT (CO) = Heart Rate (HR) Γ— Stroke Volume (SV)

Normal CO = 70 beats/min Γ— 70 mL/beat = ~4,900 mL/min β‰ˆ 5 L/min
Normal range = 4-8 L/min

CARDIAC INDEX (CI) = CO Γ· Body Surface Area (BSA)
Normal CI = 2.5 - 4.0 L/min/mΒ²

Fick Principle (for measuring CO):

CO = Oβ‚‚ consumption (VOβ‚‚)
     ─────────────────────────────────────────
     Arteriovenous Oβ‚‚ difference (CaOβ‚‚ - CvOβ‚‚)

Normal VOβ‚‚ β‰ˆ 250 mL/min
Normal (CaOβ‚‚ - CvOβ‚‚) β‰ˆ 50 mL/L
So CO = 250/50 = 5 L/min βœ“

7. MASTER FLOWCHART: PRELOAD β†’ AFTERLOAD β†’ CONTRACTILITY β†’ CO

VENOUS RETURN (blood flowing back to heart)
         ↓
PRELOAD = EDV (how full the ventricle is at end-diastole)
         ↓
FRANK-STARLING (more stretch = more force)
         ↓
CONTRACTILITY (intrinsic muscle strength)
         ↓
STROKE VOLUME = EDV - ESV
         ↓
   Γ· Afterload (SVR)
   (↑ afterload resists ejection β†’ ↓ SV)
         ↓
STROKE VOLUME Γ— HEART RATE
         ↓
CARDIAC OUTPUT (L/min)
         ↓
Γ— Peripheral Vascular Resistance
         ↓
MEAN ARTERIAL PRESSURE (MAP)

8. PRESSURE-VOLUME (P-V) LOOP

The P-V loop is a graphical way to show one complete cardiac cycle. It is highly tested in exams and used in echo/cath lab.
LV        120|           C (peak systole)
PRESSURE      |          /|
(mmHg)    80 |   B------/ |
             |   |        |  D
          40 |   |        \__|
             |   |  E---F /
           0 |   A________/
              |__________________________
              50     70      130
                  LV VOLUME (mL)
                  ESV  SV    EDV

A = Mitral opens β†’ diastolic filling (bottom flat line)
B = Mitral closes β†’ IVC begins (LV pressure rises at constant volume)
C = Aortic opens β†’ ejection (pressure rises, volume falls)
D = Aortic closes β†’ IVR begins (pressure falls at constant volume)

How P-V Loop Changes:

ChangeEffect on P-V Loop
↑ Preload (↑ EDV)Loop widens to the RIGHT β†’ bigger SV
↑ Afterload (↑ SVR)Loop gets TALLER and NARROWER β†’ smaller SV
↑ ContractilityLoop shifts LEFT β†’ smaller ESV β†’ bigger SV
Heart failure ↓ contractilityLoop shifts RIGHT β†’ larger ESV β†’ smaller SV

9. PHARMACOLOGY LINK (Foundation for Anti-Failure Drugs)

DrugActs OnEffectWhy Used in HF
Furosemide (loop diuretic)↓ PreloadReduces blood volume β†’ ↓ EDV β†’ ↓ filling pressuresRelieves pulmonary congestion
Nitrates (GTN, ISDN)↓ PreloadVenodilate β†’ blood pools in veins β†’ ↓ venous returnRelieves pulmonary oedema, angina
ACE inhibitors (Ramipril)↓ AfterloadDilate arteries β†’ ↓ SVR β†’ LV ejects more easily↑ SV, ↓ LV remodelling
ARBs (Losartan)↓ AfterloadSame as ACEiACEi intolerant patients
Dobutamine↑ ContractilityΞ²1 agonist β†’ ↑ cAMP β†’ ↑ Ca²⁺ β†’ stronger contractionAcute decompensated HF
Digoxin↑ Contractility↑ Intracellular Ca²⁺Chronic HFrEF + AF rate control
Beta blockers (Carvedilol)↓ HR + remodelling↓ Sympathetic overdrive β†’ ↓ remodelling (long-term benefit)Chronic HF mortality ↓

10. KEY FORMULAS SUMMARY TABLE

FormulaNormal Value
CO = HR Γ— SV4-8 L/min
CI = CO / BSA2.5-4.0 L/min/mΒ²
SV = EDV - ESV~70 mL
EF = (SV/EDV) Γ— 100β‰₯55%
MAP = DBP + 1/3 (SBP - DBP)70-100 mmHg
SVR = (MAP - CVP) / CO Γ— 80800-1200 dynesΒ·sec/cm⁡
PVR = (MPAP - PCWP) / CO Γ— 8020-120 dynesΒ·sec/cm⁡

11. KEY FACTS FOR MCQs

QuestionAnswer
Preload is measured clinically by?LVEDP or PCWP
What is the optimal sarcomere length for max contraction?~2.2 ΞΌm
Frank-Starling law: ↑ EDV leads to?↑ Stroke volume (up to a limit)
Moving ALONG the Frank-Starling curve means?Change in preload
SHIFTING the Frank-Starling curve means?Change in contractility
Drug that reduces preload?Furosemide, Nitrates
Drug that reduces afterload?ACE inhibitors, ARBs, Hydralazine
Drug that increases contractility?Dobutamine, Digoxin, Adrenaline
Afterload for LV is clinically estimated by?Systemic Vascular Resistance (SVR)
Afterload for RV is?Pulmonary Vascular Resistance (PVR)
Normal cardiac output at rest?4-8 L/min
Normal cardiac index?2.5-4.0 L/min/mΒ²
Fick principle measures?Cardiac output
In heart failure: Frank-Starling curve shifts?Downward and to the right
Dobutamine shifts Frank-Starling curve?Upward and to the left

12. SELF-TEST (Do Before Day 5)

  1. Define preload, afterload, and contractility in ONE sentence each
  2. Draw the Frank-Starling curve. Show how it shifts in heart failure vs. with dobutamine
  3. A patient with acute MI has low BP and low cardiac output. Which part of the Frank-Starling mechanism is failing?
  4. Why does giving a diuretic help a heart failure patient breathe better? (Use the preload concept)
  5. Calculate MAP if SBP = 120 mmHg and DBP = 80 mmHg
  6. Draw a P-V loop and label: EDV, ESV, SV, IVC, IVR, ejection phase

Day 4 complete! Tomorrow (Day 5) is Blood Vessel Structure - artery wall layers (intima/media/adventitia), vascular smooth muscle, arterial and venous system. This is the foundation for understanding hypertension and vasodilator pharmacology. Just say "Day 5" when ready! πŸ«€

Day 5

Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Loading Image
Loading Image
Excellent content from the Histology textbook loaded with real microscopy diagrams. Here are your complete Day 5 notes!

πŸ“˜ WEEK 1 - DAY 5

Blood Vessel Structure: Artery Wall Layers, Vascular Smooth Muscle & the Arterial/Venous System

Source: Histology: A Text and Atlas with Correlated Cell and Molecular Biology | Katzung's Basic & Clinical Pharmacology 16th Ed

1. OVERVIEW - THE VASCULAR SYSTEM

The cardiovascular system delivers blood to every tissue. Vessels are not passive tubes - they are living, dynamic structures that actively control blood pressure, flow distribution, and vascular resistance.
HEART
   ↓
AORTA (elastic artery - large)
   ↓
MUSCULAR ARTERIES (medium - e.g. coronary, femoral, brachial)
   ↓
ARTERIOLES (resistance vessels - control BP)
   ↓
CAPILLARIES (exchange vessels - gas/nutrient transfer)
   ↓
VENULES
   ↓
SMALL VEINS β†’ MEDIUM VEINS β†’ LARGE VEINS (capacitance vessels)
   ↓
SVC / IVC β†’ HEART (RA)

2. THE THREE LAYERS OF ALL BLOOD VESSELS

Every blood vessel (except capillaries) has THREE concentric tunics (layers):
LUMEN (blood flows here)
    |
    |── TUNICA INTIMA (innermost layer)
    |
    |── [Internal Elastic Membrane] ← separates intima from media
    |
    |── TUNICA MEDIA (middle layer)
    |
    |── [External Elastic Membrane] ← separates media from adventitia
    |
    |── TUNICA ADVENTITIA (outermost layer)
    |
SURROUNDING CONNECTIVE TISSUE

3. TUNICA INTIMA (Innermost Layer)

Components:

ComponentDescriptionFunction
Endothelial cellsSingle layer of flat cells; long axis parallel to blood flow; joined by tight + gap junctionsBarrier, anti-thrombotic, vasoactive mediator production
Basal laminaThin ECM layer beneath endotheliumStructural support
Subendothelial connective tissueCollagen + elastic fibres + some smooth muscle cellsSupport
Internal Elastic Membrane (IEM)Wavy, fenestrated elastic sheet (most prominent in muscular arteries)Separates intima from media; has pores for diffusion

Endothelial Cell Functions (exam high-yield!):

FunctionMediator Released
VasodilationNitric oxide (NO), Prostacyclin (PGIβ‚‚)
VasoconstrictionEndothelin-1, Thromboxane Aβ‚‚
Anti-coagulationProstacyclin, Thrombomodulin, Heparan sulphate
Pro-coagulation (when injured)von Willebrand factor (stored in Weibel-Palade bodies), Tissue factor
InflammationP-selectin (stored in Weibel-Palade bodies), ICAM-1, VCAM-1
Growth regulationPDGF, FGF (stimulate smooth muscle proliferation)
Clinical link: Endothelial dysfunction (e.g., from smoking, HTN, diabetes) is the FIRST step in atherosclerosis. Damaged endothelium stops producing NO β†’ vasoconstriction + plaque formation begins.

4. TUNICA MEDIA (Middle Layer)

Components:

ComponentDescription
Vascular smooth muscle cells (VSMCs)Arranged in circular (spiral) layers around the vessel
Elastic lamellaeConcentric fenestrated sheets of elastin (more in elastic arteries)
Collagen fibresType I and III; provide tensile strength
Ground substanceProteoglycans; synthesized by VSMCs
Key fact: In the media, fibroblasts are ABSENT - it is the vascular smooth muscle cells (not fibroblasts) that synthesize collagen, elastin, and ECM here.

External Elastic Membrane (EEM):

  • Separates media from adventitia
  • More distinct in muscular arteries
  • Not well-defined in elastic arteries

5. TUNICA ADVENTITIA (Outermost Layer)

Components:

ComponentDescriptionFunction
Collagen fibres (Type I)Thick, dense bundlesPrevent over-distension during systole
Elastic fibresLoose network (not lamellae)Elastic recoil
Fibroblasts + MacrophagesMain cells hereECM maintenance, immune surveillance
Vasa vasorumSmall arterioles/capillaries within the adventitiaSupply Oβ‚‚/nutrients to outer wall of large vessels
Nervi vasorum (Nervi vascularis)Unmyelinated sympathetic fibresRelease noradrenaline β†’ vasoconstriction
Vasa vasorum = "vessels of the vessels". Present in arteries with lumen >0.5 mm. High density of vasa vasorum is associated with severity of atherosclerotic plaque.

6. TYPES OF ARTERIES - COMPARISON TABLE

Elastic artery cross-section diagram and photomicrograph showing all three tunics with elastic lamellae in tunica media
Muscular artery cross-section diagram and photomicrograph showing prominent IEM, EEM, and smooth muscle-dominated tunica media
FeatureElastic ArteryMuscular ArteryArteriole
Also calledConducting arteryDistributing arteryResistance vessel
ExamplesAorta, Pulmonary trunk, CarotidsCoronary, Femoral, Brachial, RadialPre-capillary vessels
Lumen sizeVery largeMediumVery small (<0.3 mm)
Tunica mediaMany elastic lamellae + smooth muscleMostly smooth muscle; prominent IEM + EEM1-2 layers smooth muscle only
Tunica adventitiaThin (< half of media)Thick connective tissueVery thin
IEMNot well definedProminent - wavy, refractilePresent
EEMNot prominentWell definedAbsent
Main functionWindkessel effect (absorb pulse pressure)Distribute blood to organsControl peripheral resistance and blood flow

The Windkessel Effect (Elastic Arteries):

During SYSTOLE:
Aorta receives blood β†’ elastic walls STRETCH β†’ absorb pulse pressure

During DIASTOLE:
Elastic walls RECOIL β†’ continue to push blood forward even when heart relaxes

Result: Continuous (not pulsatile) blood flow to organs
Loss of elasticity with age β†’ ↑ systolic BP (isolated systolic hypertension in elderly)

7. CAPILLARIES

The smallest vessels - the site of all exchange (Oβ‚‚, COβ‚‚, nutrients, waste).

Types:

TypeStructureFound InPermeability
ContinuousTight endothelium; tight junctionsMuscle, lung, brain (BBB), skinLow (only small molecules)
FenestratedEndothelium with pores/fenestraeKidney glomerulus, intestinal villi, endocrine glandsModerate (medium molecules)
Sinusoidal (Discontinuous)Large gaps between cells; incomplete BMLiver, spleen, bone marrowHigh (large molecules + cells)

8. VEINS - COMPARISON WITH ARTERIES

FeatureArteryVein
Wall thicknessThickerThinner
Tunica mediaThick (dominant in arteries)Thin
Tunica adventitiaThinDominant layer in veins
LumenSmaller, roundLarger, irregular/oval
ValvesAbsent (except semilunar valves)Present (prevent backflow, esp. in limbs)
Elastic tissueAbundantLess
Blood pressureHigh (60-120 mmHg)Low (0-10 mmHg)
Blood volume held~15% of total~65% of total (capacitance vessels)
Veins as capacitance vessels: They hold 65% of total blood volume. Venodilator drugs (e.g., nitrates, GTN) pool blood in veins β†’ ↓ preload β†’ ↓ cardiac filling β†’ ↓ pulmonary congestion in heart failure.

9. VASCULAR SMOOTH MUSCLE (VSM)

Key Features:

  • Spindle-shaped cells with elongated nucleus
  • Arranged in circular (low-pitch spiral) pattern β†’ appear circular on cross-section
  • Gap junctions between cells allow coordinated contraction
  • VSMCs synthesize their own ECM: collagen, elastin, proteoglycans
  • Can proliferate and migrate from media β†’ intima in response to PDGF, FGF (critical in atherosclerosis)

How VSM Contracts (Pharmacology foundation):

VASOCONSTRICTION pathway:
Noradrenaline (from sympathetic nerves)
        ↓
Ξ±1-adrenoceptors on VSMCs
        ↓
Gq protein β†’ ↑ IP3 β†’ Ca²⁺ release from SR
        ↓
Ca²⁺ + Calmodulin β†’ activates MLCK
        ↓
Myosin light chain phosphorylation
        ↓
Actin-Myosin cross-bridge β†’ CONTRACTION β†’ vasoconstriction

VASODILATION pathway:
NO (from endothelium) / Nitrates (drugs)
        ↓
Activates Guanylate Cyclase β†’ ↑ cGMP
        ↓
cGMP β†’ activates PKG β†’ dephosphorylates myosin
        ↓
Actin-Myosin cross-bridge releases β†’ RELAXATION β†’ vasodilation

Regulators of Vascular Tone:

Causes VasoconstrictionCauses Vasodilation
Noradrenaline (Ξ±1 agonist)Nitric Oxide (NO) from endothelium
Angiotensin IIProstacyclin (PGIβ‚‚)
Endothelin-1Adenosine (metabolic autoregulation)
Vasopressin (ADH)Bradykinin
Thromboxane Aβ‚‚Atrial Natriuretic Peptide (ANP)
↑ Ca²⁺↑ cGMP / cAMP

10. DIAGRAM TO DRAW - ARTERY WALL LAYERS

         LUMEN
    ________________
   |                |
   |   ENDOTHELIUM  |  ← flat cells, long axis = blood flow
   |________________|
   |                |
   |  subendothelial|  ← connective tissue, collagen
   |   CT layer     |
   |________________|
   | INTERNAL ELASTIC|  ← wavy, fenestrated (prominent in muscular A)
   |   MEMBRANE     |
   |________________|
   |  TUNICA MEDIA  |  ← smooth muscle (circular) + elastic lamellae
   |  smooth muscle |
   |  elastic fibre |
   |________________|
   | EXTERNAL ELASTIC|  ← distinct in muscular arteries
   |   MEMBRANE     |
   |________________|
   | TUNICA ADVENTITIA| ← collagen, fibroblasts, vasa vasorum, nervi vasorum
   |________________|
   SURROUNDING TISSUE

11. PHARMACOLOGY LINK - Vasodilator Drugs & Their Targets

DrugLayer/Structure TargetedMechanismClinical Use
GTN / NitratesVSM (via cGMP)↑ NO β†’ ↑ cGMP β†’ smooth muscle relaxationAngina, acute HF, acute pulmonary oedema
ACE inhibitorsEndothelium + VSMBlock AngII β†’ less vasoconstriction + ↓ aldosteroneHTN, HF, post-MI
Calcium channel blockers (Amlodipine)VSMBlock L-type Ca²⁺ channels β†’ ↓ Ca²⁺ β†’ relaxationHTN, angina
Alpha blockers (Prazosin)VSM (Ξ±1 receptors)Block noradrenaline β†’ prevent vasoconstrictionHTN, BPH
HydralazineArteriolar VSMUnknown - may ↑ cGMP + ↓ Ca²⁺HTN in pregnancy, severe HF
Sodium NitroprussideVSM (arterial + venous)Releases NO directly β†’ ↓↓ SVRHypertensive emergency

12. KEY FACTS FOR MCQs

QuestionAnswer
Which layer is the innermost layer of an artery?Tunica intima
Which layer contains vascular smooth muscle?Tunica media
Which layer contains vasa vasorum and nervi vasorum?Tunica adventitia
Which elastic structure separates intima from media?Internal Elastic Membrane (IEM)
Which layer is dominant in veins?Tunica adventitia
What % of blood volume do veins hold?~65%
Fibroblasts are absent from which layer?Tunica media
What organelle in endothelium stores vWF and P-selectin?Weibel-Palade bodies
What does endothelium release to cause vasodilation?Nitric oxide (NO)
What does endothelium release to cause vasoconstriction?Endothelin-1
Elastic arteries dampen pulsatile flow by?Windkessel effect
Which type of artery best controls peripheral resistance?Arterioles
Nitrates work by increasing which second messenger?cGMP
Noradrenaline causes vasoconstriction via which receptor?Ξ±1 adrenoceptors
Which capillary type has the highest permeability?Sinusoidal (discontinuous)
Where are sinusoidal capillaries found?Liver, spleen, bone marrow

13. SELF-TEST (Do Before Day 6 Revision)

  1. Draw an artery wall cross-section from memory and label all three tunics
  2. What is the difference between elastic and muscular arteries in terms of tunica media composition?
  3. Why are arterioles called "resistance vessels"?
  4. A patient with endothelial damage (e.g., from diabetes) has less NO production. What happens to their blood pressure and why?
  5. Explain the Windkessel effect and why elderly patients develop isolated systolic hypertension
  6. Name TWO vasodilators and their specific mechanisms at the smooth muscle cell level

Day 5 complete! Tomorrow (Day 6) is your Weekly Revision + Self-Quiz - you'll redraw both the conduction pathway flowchart and the Wiggers diagram from memory, and test yourself across Week 1 topics. Just say "Day 6" when ready, and I'll give you the full revision quiz! πŸ«€

Day 6

No tools needed for Day 6 - this is your revision and self-quiz day! Everything comes from the notes you've already studied this week.

πŸ“˜ WEEK 1 - DAY 6

Weekly Revision + Self-Quiz

🎯 Today's Goal:

  • Redraw both flowcharts from memory (no peeking!)
  • Answer all MCQs
  • Identify your weak spots before Week 2 begins

PART A: DRAW FROM MEMORY (Do These First - Before Reading Any Notes)

✏️ Task 1 - Redraw the Conduction Pathway Flowchart

On a blank paper, draw the full conduction system from SA node to Purkinje fibres. Include:
  • Location of each structure
  • Intrinsic rate of each
  • What ECG wave each produces
  • Blood supply of SA node and AV node

✏️ Task 2 - Redraw the Wiggers Diagram

On a blank paper, draw the Wiggers diagram showing:
  • All 7 phases (A through G)
  • LV pressure curve with dicrotic notch
  • LV volume curve (EDV β†’ ESV)
  • S1, S2, S3, S4 positions
  • Valve opening/closing points

✏️ Task 3 - Redraw the Artery Wall

Draw a cross-section of a muscular artery and label:
  • All 3 tunics
  • IEM and EEM
  • Key cell types in each layer
  • Vasa vasorum and nervi vasorum location

PART B: 50 MCQ SELF-QUIZ (Week 1 - All 5 Days)

Answer on paper first, then check answers at the bottom.

πŸ«€ SECTION 1: Heart Anatomy (Day 1) - 10 Questions

1. Which chamber forms the BASE (posterior surface) of the heart?
  • a) Left ventricle
  • b) Right atrium
  • c) Left atrium βœ…
  • d) Right ventricle
2. The apex of the heart is located at which intercostal space?
  • a) 3rd left ICS
  • b) 4th left ICS
  • c) 5th left ICS βœ…
  • d) 6th left ICS
3. Which structure is the remnant of the fetal foramen ovale?
  • a) Crista terminalis
  • b) Fossa ovalis βœ…
  • c) Moderator band
  • d) Coronary sinus
4. Normal LV wall thickness is?
  • a) 3-5 mm
  • b) 5-8 mm
  • c) 8-12 mm βœ…
  • d) 12-15 mm
5. Which valve has only 2 cusps?
  • a) Tricuspid
  • b) Pulmonary
  • c) Aortic
  • d) Mitral βœ…
6. The right border of the heart on a PA chest X-ray is formed by?
  • a) RV + RA + SVC
  • b) SVC + RA + IVC βœ…
  • c) Aortic arch + RA + IVC
  • d) SVC + RV + IVC
7. Which layer of pericardium is also called the epicardium?
  • a) Fibrous pericardium
  • b) Parietal layer of serous pericardium
  • c) Visceral layer of serous pericardium βœ…
  • d) Endocardium
8. The coronary sinus drains into the?
  • a) Left atrium
  • b) Right ventricle
  • c) Right atrium βœ…
  • d) Left ventricle
9. Which chamber is most anterior (faces the sternum)?
  • a) Left ventricle
  • b) Right atrium
  • c) Left atrium
  • d) Right ventricle βœ…
10. Pulmonary veins carry which type of blood?
  • a) Deoxygenated
  • b) Oxygenated βœ…
  • c) Mixed
  • d) Depends on age

❀️ SECTION 2: Coronary Arteries & Conduction (Day 2) - 10 Questions

11. Which artery is called the "Widow Maker"?
  • a) RCA
  • b) LCx
  • c) LAD βœ…
  • d) PDA
12. An inferior MI on ECG (changes in II, III, aVF) is due to occlusion of which artery?
  • a) LAD
  • b) LCx
  • c) RCA βœ…
  • d) Left main stem
13. Coronary dominance is defined by which artery gives off the?
  • a) LAD
  • b) LCx
  • c) Right marginal branch
  • d) Posterior Descending Artery (PDA) βœ…
14. The SA node is located at the?
  • a) Floor of RA near coronary sinus
  • b) Junction of SVC and RA βœ…
  • c) Membranous interventricular septum
  • d) Apex of right ventricle
15. What is the intrinsic rate of the AV node?
  • a) 60-100/min
  • b) 40-60/min βœ…
  • c) 20-40/min
  • d) 100-120/min
16. The only electrical connection between atria and ventricles is the?
  • a) AV node
  • b) SA node
  • c) Bundle of His βœ…
  • d) Purkinje fibres
17. Which structure carries the right bundle branch to the anterior papillary muscle of the RV?
  • a) Crista terminalis
  • b) Pectinate muscles
  • c) Septomarginal trabecula (Moderator band) βœ…
  • d) Fossa ovalis
18. AV nodal blood supply comes predominantly from?
  • a) LAD (80%)
  • b) LCx (80%)
  • c) RCA (80%) βœ…
  • d) Left main stem
19. Coronary arteries fill during?
  • a) Systole
  • b) Isovolumetric contraction
  • c) Diastole βœ…
  • d) Isovolumetric relaxation
20. Lateral wall MI (changes in I, aVL, V5, V6) is due to occlusion of?
  • a) RCA
  • b) LAD
  • c) LCx βœ…
  • d) PDA

πŸ”„ SECTION 3: Cardiac Cycle & Heart Sounds (Day 3) - 10 Questions

21. S1 is caused by closure of which valves?
  • a) Aortic + Pulmonary
  • b) Mitral + Tricuspid βœ…
  • c) All four valves
  • d) Only mitral valve
22. The dicrotic notch on the aortic pressure trace represents?
  • a) Mitral valve opening
  • b) Aortic valve opening
  • c) Aortic valve closure βœ…
  • d) End of rapid ejection
23. During which phase are ALL valves closed for the SECOND time?
  • a) Isovolumetric contraction
  • b) Rapid ejection
  • c) Isovolumetric relaxation βœ…
  • d) Rapid filling
24. S3 in a 45-year-old patient most likely indicates?
  • a) Normal finding
  • b) LV hypertrophy
  • c) Heart failure / volume overload βœ…
  • d) Atrial fibrillation
25. Normal ejection fraction is?
  • a) β‰₯40%
  • b) β‰₯50%
  • c) β‰₯55% βœ…
  • d) β‰₯65%
26. EDV = 140 mL, ESV = 70 mL. What is the ejection fraction?
  • a) 40%
  • b) 50% βœ…
  • c) 60%
  • d) 70%
(EF = (140-70)/140 Γ— 100 = 50%)
27. The 'a' wave of the JVP represents?
  • a) Tricuspid valve closure
  • b) Venous filling of RA
  • c) Atrial contraction βœ…
  • d) RV systole
28. Fixed splitting of S2 is diagnostic of?
  • a) RBBB
  • b) ASD βœ…
  • c) LBBB
  • d) Pulmonary stenosis
29. The aortic valve opens when?
  • a) LV pressure > LA pressure
  • b) LV pressure > Aortic pressure βœ…
  • c) LA pressure > LV pressure
  • d) Aortic pressure > LV pressure
30. Which ECG event corresponds to the start of isovolumetric ventricular contraction?
  • a) P wave
  • b) QRS complex βœ…
  • c) ST segment
  • d) T wave

πŸ’ͺ SECTION 4: Hemodynamics (Day 4) - 10 Questions

31. Preload is best defined as?
  • a) Resistance to blood flow in arteries
  • b) Intrinsic strength of myocardium
  • c) End-diastolic volume / ventricular filling βœ…
  • d) Aortic valve resistance
32. Which drug REDUCES preload?
  • a) Dobutamine
  • b) Noradrenaline
  • c) Furosemide βœ…
  • d) Digoxin
33. Afterload for the LV is clinically estimated by?
  • a) PCWP
  • b) Central venous pressure
  • c) Systemic vascular resistance βœ…
  • d) Heart rate
34. Frank-Starling law states that within limits, increasing preload (EDV) causes?
  • a) Decreased stroke volume
  • b) No change in stroke volume
  • c) Increased stroke volume βœ…
  • d) Decreased heart rate
35. Shifting the Frank-Starling curve UPWARD AND LEFT represents?
  • a) Increased preload
  • b) Increased contractility βœ…
  • c) Increased afterload
  • d) Decreased heart rate
36. Optimal sarcomere length for maximum force generation is?
  • a) 1.5 ΞΌm
  • b) 1.8 ΞΌm
  • c) 2.2 ΞΌm βœ…
  • d) 2.8 ΞΌm
37. Normal cardiac output at rest is?
  • a) 2-3 L/min
  • b) 4-8 L/min βœ…
  • c) 8-12 L/min
  • d) 1-2 L/min
38. In heart failure, the Frank-Starling curve shifts?
  • a) Upward and left
  • b) Downward and right βœ…
  • c) No shift - only moves along the curve
  • d) Upward and right
39. ACE inhibitors improve heart failure primarily by?
  • a) Increasing contractility
  • b) Decreasing heart rate
  • c) Reducing afterload βœ…
  • d) Increasing preload
40. A patient has CO = 6 L/min and BSA = 2 mΒ². What is the cardiac index?
  • a) 2.0 L/min/mΒ²
  • b) 3.0 L/min/mΒ² βœ…
  • c) 4.0 L/min/mΒ²
  • d) 12 L/min/mΒ²
(CI = 6/2 = 3.0 L/min/mΒ²)

🩸 SECTION 5: Blood Vessel Structure (Day 5) - 10 Questions

41. Which layer of the artery contains vascular smooth muscle cells arranged circularly?
  • a) Tunica intima
  • b) Tunica media βœ…
  • c) Tunica adventitia
  • d) Subendothelial layer
42. The Internal Elastic Membrane (IEM) separates which two layers?
  • a) Media from adventitia
  • b) Intima from media βœ…
  • c) Endothelium from subendothelial tissue
  • d) Adventitia from surrounding tissue
43. Vasa vasorum and nervi vasorum are found in?
  • a) Tunica intima
  • b) Tunica media
  • c) Tunica adventitia βœ…
  • d) Endothelium
44. Which organelle in endothelial cells stores von Willebrand factor?
  • a) Lysosomes
  • b) Golgi apparatus
  • c) Weibel-Palade bodies βœ…
  • d) Mitochondria
45. The dominant tunic in veins is?
  • a) Tunica intima
  • b) Tunica media
  • c) Tunica adventitia βœ…
  • d) Same as arteries
46. Approximately what percentage of total blood volume is held in veins?
  • a) 15%
  • b) 30%
  • c) 50%
  • d) 65% βœ…
47. Arterioles are called "resistance vessels" because?
  • a) They have the thickest walls
  • b) They have valves
  • c) They control peripheral resistance and distribute blood flow βœ…
  • d) They have the most elastic tissue
48. Nitric oxide causes vasodilation by?
  • a) Blocking Ξ±1 receptors
  • b) Activating guanylate cyclase β†’ ↑ cGMP β†’ smooth muscle relaxation βœ…
  • c) Blocking calcium channels
  • d) Inhibiting ACE
49. The Windkessel effect is a function of?
  • a) Arterioles
  • b) Capillaries
  • c) Elastic arteries βœ…
  • d) Veins
50. Which cell type is absent from the tunica media?
  • a) Smooth muscle cells
  • b) Endothelial cells (not present here anyway)
  • c) Fibroblasts βœ…
  • d) Macrophages

PART C: SCORE YOUR RESULTS

ScoreWhat It MeansWhat To Do
45-50Excellent - Week 1 mastered!Move confidently to Week 2
38-44Good - minor gapsRe-read weak sections tonight
30-37Average - some concepts unclearRevisit 2-3 days' notes today
Below 30Needs revisionSpend today going through all 5 days again

PART D: TOPIC WEAKNESS TRACKER

After checking your answers, fill this in:
DayTopicMy Score (out of 10)Weak Points
Day 1Heart Anatomy/10
Day 2Coronary + Conduction/10
Day 3Cardiac Cycle + Heart Sounds/10
Day 4Hemodynamics/10
Day 5Blood Vessels/10

PART E: MASTER MIND MAP (Draw This Tonight)

Connect all of Week 1 into one diagram:
HEART ANATOMY (Day 1)
        ↓
    4 Chambers + 4 Valves
        ↓
CORONARY ARTERIES (Day 2)          CONDUCTION SYSTEM (Day 2)
RCA β†’ inferior wall               SA node β†’ AV node β†’ Bundle of His
LAD β†’ anterior wall               β†’ Bundle branches β†’ Purkinje
LCx β†’ lateral wall                β†’ ECG: P β†’ PR β†’ QRS β†’ T
        ↓                                   ↓
CARDIAC CYCLE (Day 3)             HEMODYNAMICS (Day 4)
7 phases β†’ S1/S2/S3/S4            Preload / Afterload / Contractility
EDV β†’ SV β†’ ESV β†’ EF              Frank-Starling curve
Wiggers diagram                   CO = HR Γ— SV
        ↓
BLOOD VESSELS (Day 5)
Intima (endothelium β†’ NO, vWF)
Media (smooth muscle β†’ VSR)
Adventitia (vasa vasorum, nervi vasorum)
Elastic vs Muscular β†’ Arterioles β†’ Capillaries β†’ Veins
        ↓
CLINICAL LINKS
HTN = ↑ afterload β†’ LV hypertrophy
HF = ↓ contractility β†’ Frank-Starling shifts down
Diuretics β†’ ↓ preload
ACEi/ARBs β†’ ↓ afterload
Endothelial damage β†’ atherosclerosis starts

πŸ—“οΈ LOOKING AHEAD - WEEK 2 PREVIEW

Week 2 - Vascular Pathology Basics:
DayTopic
Day 7Hypertension & Hypotension - etiology, pathophysiology, classification
Day 8Atherosclerosis - mechanism, risk factors, complications
Day 9Raynaud's disease - pathophysiology, clinical features
Day 10Aneurysms - types, etiopathogenesis
Day 11Peripheral vascular disorders - clinical approach
Day 12Revision + Master mind-map

Week 1 is done! You've covered all the foundations that every disease topic in your course builds on. Come back tomorrow and say "Day 7" to start Week 2! πŸ«€

Day 7

Finding Sources
Finding Sources
Your credits are exhausted. You can purchase a top-up or subscribe to a plan to continue using Orris. If you're already subscribed, your daily credits will reset tomorrow.

Day 7

Finding Sources
Finding Sources
Reading File
Finding Sources
Reading File
Finding Sources
Reading File
Finding Sources
Reading File
Searching Images

renin angiotensin aldosterone system RAAS hypertension flowchart

A complex pathophysiology diagram and pharmacological flowchart titled 'Neurohumoral Imbalance in Heart Failure'. It illustrates the interaction between the Renin-Angiotensin-Aldosterone System (RAAS), the Sympathetic Nervous System (SNS), and the Natriuretic Peptide (NP) system in the context of heart failure. The left side of the diagram outlines the RAAS cascade: Renin production leads to Angiotensin I, which is converted to Angiotensin II by ACE, ultimately binding to the AT1 receptor to cause deleterious effects like vasoconstriction, myocardial fibrosis, and water retention. The right side shows the NP system (ANP, BNP, CNP) which promotes diuresis and vasodilation. Centrally, the diagram depicts the pharmacological intervention of the ARNI class: Valsartan (an ARB) inhibiting the AT1 receptor, and Sacubitril (a neprilysin inhibitor) preventing the breakdown of natriuretic peptides. A comparison list at the bottom contrasts the pathological effects of uncontrolled RAAS/SNS activation against the beneficial physiological outcomes of ARNI therapy, including reduced ventricular hypertrophy, increased insulin sensitivity, and improved cardiac output. The diagram uses standard medical icons for the heart, kidneys, and liver to indicate anatomical sites of hormone production and action.

A complex pathophysiology diagram and pharmacological flowchart titled 'Neurohumoral Imbalance in Heart Failure'. It illustrates the interaction between the Renin-Angiotensin-Aldosterone System (RAAS), the Sympathetic Nervous System (SNS), and the Natriuretic Peptide (NP) system in the context of heart failure. The left side of the diagram outlines the RAAS cascade: Renin production leads to Angiotensin I, which is converted to Angiotensin II by ACE, ultimately binding to the AT1 receptor to cause deleterious effects like vasoconstriction, myocardial fibrosis, and water retention. The right side shows the NP system (ANP, BNP, CNP) which promotes diuresis and vasodilation. Centrally, the diagram depicts the pharmacological intervention of the ARNI class: Valsartan (an ARB) inhibiting the AT1 receptor, and Sacubitril (a neprilysin inhibitor) preventing the breakdown of natriuretic peptides. A comparison list at the bottom contrasts the pathological effects of uncontrolled RAAS/SNS activation against the beneficial physiological outcomes of ARNI therapy, including reduced ventricular hypertrophy, increased insulin sensitivity, and improved cardiac output. The diagram uses standard medical icons for the heart, kidneys, and liver to indicate anatomical sites of hormone production and action.

This pathophysiology diagram illustrates the Renin-Angiotensin-Aldosterone System (RAAS) pathway and its role in obesity-related kidney injury, highlighting pharmaceutical intervention points. The central pathway shows the enzymatic conversion of Angiotensinogen to Angiotensin I by Renin, and Angiotensin I to Angiotensin II via Angiotensin-Converting Enzyme (ACE). Angiotensin II acts on receptors AT1AR and AT2AR, facilitating kidney reabsorption of ions and water. The diagram specifically notes that adipose tissue contributes to increased Angiotensin II levels. Further down the cascade, Angiotensin II stimulates Aldosterone, which activates the Mineralocorticoid Receptor (supported by Rac1). This activation leads to the production of Nitric Oxide (NO), contributing to glomerular hyperfunction and renal vasodilation. Two major drug classes are highlighted: ACE Inhibitors (ACEI), which block the ACE enzyme to reduce hypertension, proteinuria, and inflammation; and Angiotensin Receptor Blockers (ARB), which inhibit AT1AR/AT2AR receptors and are associated with decreased fat mass and leptin levels.

This pathophysiology diagram illustrates the Renin-Angiotensin-Aldosterone System (RAAS) pathway and its role in obesity-related kidney injury, highlighting pharmaceutical intervention points. The central pathway shows the enzymatic conversion of Angiotensinogen to Angiotensin I by Renin, and Angiotensin I to Angiotensin II via Angiotensin-Converting Enzyme (ACE). Angiotensin II acts on receptors AT1AR and AT2AR, facilitating kidney reabsorption of ions and water. The diagram specifically notes that adipose tissue contributes to increased Angiotensin II levels. Further down the cascade, Angiotensin II stimulates Aldosterone, which activates the Mineralocorticoid Receptor (supported by Rac1). This activation leads to the production of Nitric Oxide (NO), contributing to glomerular hyperfunction and renal vasodilation. Two major drug classes are highlighted: ACE Inhibitors (ACEI), which block the ACE enzyme to reduce hypertension, proteinuria, and inflammation; and Angiotensin Receptor Blockers (ARB), which inhibit AT1AR/AT2AR receptors and are associated with decreased fat mass and leptin levels.

All content from Fuster & Hurst's The Heart and Harrison's Principles of Internal Medicine 22E loaded. Here are your complete Day 7 notes!

πŸ“˜ WEEK 2 - DAY 7

Hypertension & Hypotension: Etiology, Pathophysiology, Classification

Source: Fuster & Hurst's The Heart, 15th Ed | Harrison's Principles of Internal Medicine 22E | Brenner & Rector's The Kidney

1. WHAT IS BLOOD PRESSURE?

BP = Cardiac Output (CO) Γ— Total Peripheral Resistance (TPR)

MAP = Diastolic BP + 1/3 (Systolic BP - Diastolic BP)
    = DBP + 1/3 Pulse Pressure

Normal MAP = 70-100 mmHg
Normal BP = <120/80 mmHg
Three major systems regulate BP long-term:
  1. RAAS (Renin-Angiotensin-Aldosterone System) - sodium retention + vasoconstriction
  2. Sympathetic Nervous System (SNS) - vasoconstriction + ↑ HR + ↑ contractility
  3. Kidney - controls blood volume via sodium/water excretion (pressure-natriuresis)

2. CLASSIFICATION OF HYPERTENSION

By JNC / ACC/AHA Guidelines (2017):

CategorySystolic (mmHg)Diastolic (mmHg)
Normal<120AND <80
Elevated (Prehypertension)120-129AND <80
Stage 1 HTN130-139OR 80-89
Stage 2 HTNβ‰₯140OR β‰₯90
Hypertensive Crisis>180AND/OR >120

Hypertensive Crisis - Two Types:

Hypertensive UrgencyHypertensive Emergency
BP>180/120 mmHg>180/120 mmHg
Organ damageNo target organ damageYes - acute organ damage
ExamplesAsymptomatic severe HTNHypertensive encephalopathy, Aortic dissection, Acute MI, Acute pulmonary oedema
ManagementOral antihypertensives; lower BP over 24-48 hrsIV drugs (nitroprusside/labetalol); lower BP by 25% in first hour

By Aetiology - Most Important Classification:

HYPERTENSION
      |
      |──── PRIMARY (Essential) HTN β†’ >90-95% of cases
      |         - No identifiable single cause
      |         - Multifactorial
      |
      └──── SECONDARY HTN β†’ <5-10% of cases
                - Identifiable, potentially treatable cause

3. PRIMARY (ESSENTIAL) HYPERTENSION

Definition:

High BP with no identifiable single secondary cause - it is multifactorial.

Risk Factors / Contributing Causes:

CategoryFactors
Non-modifiableAge, Family history/genetics, Race (higher in Africans), Male sex (before menopause)
Modifiable - majorObesity/overweight (accounts for 65-75% of primary HTN risk!), Physical inactivity, High dietary sodium, Alcohol excess, Low potassium intake
Modifiable - otherSmoking, Dyslipidaemia, Diabetes, Stress

Pathophysiology - How Primary HTN Develops (Multifactorial):

MULTIPLE CONTRIBUTING MECHANISMS:

1. INCREASED SYMPATHETIC ACTIVITY
   Stress/obesity β†’ ↑ SNS tone
        ↓
   ↑ Heart rate + ↑ contractility β†’ ↑ CO
   ↑ Vasoconstriction β†’ ↑ TPR
   ↑ Renal sodium reabsorption β†’ ↑ volume

2. RAAS ACTIVATION
   ↑ Angiotensin II β†’ ↑ TPR + ↑ aldosterone
   ↑ Aldosterone β†’ ↑ Na⁺/Hβ‚‚O retention β†’ ↑ CO

3. RENAL SODIUM RETENTION
   Impaired pressure-natriuresis
   ↑ Na⁺ retention β†’ volume expansion β†’ ↑ CO
   (autoregulation then ↑ TPR to normalise flow)

4. VASCULAR REMODELLING (long-term)
   Chronic ↑ BP β†’ vessel wall thickening
   Arteriolar hyalinosis β†’ ↑ TPR becomes structural/irreversible

5. ENDOTHELIAL DYSFUNCTION
   ↓ Nitric oxide production β†’ ↓ vasodilation
   ↑ Endothelin-1 β†’ ↑ vasoconstriction

6. OBESITY-SPECIFIC PATHWAY
   Excess fat β†’ ↑ Leptin β†’ hypothalamic MC4R activation
        ↓
   ↑ Renal sympathetic nerve activity β†’ Na⁺ retention + ↑ CO
   ↑ RAAS activation (adipose tissue produces angiotensinogen)
   ↑ Aldosterone β†’ Na⁺ retention

4. SECONDARY HYPERTENSION

Definition:

HTN caused by an identifiable and often correctable underlying condition.

Causes and Key Features:

CauseMechanismClue / Hallmark
Renovascular disease (Renal artery stenosis)↓ renal perfusion β†’ ↑ Renin β†’ ↑ Ang II β†’ ↑ BPAbdominal bruit, young woman, refractory HTN, ↑ creatinine on ACEi
Primary Aldosteronism (Conn's syndrome)↑ Aldosterone β†’ Na⁺ retention + K⁺ lossHypokalaemia + HTN, adrenal adenoma
PhaeochromocytomaCatecholamine-secreting adrenal tumour β†’ ↑ SVREpisodic HTN + headache + sweating + palpitations ("Rule of 10s")
Cushing's syndromeExcess cortisol β†’ Na⁺ retention + ↑ SVRCentral obesity, moon face, striae, buffalo hump
Chronic kidney disease (CKD)↓ GFR β†’ Na⁺/Hβ‚‚O retention + ↑ RAAS↑ Creatinine, proteinuria
Hypothyroidism↓ HR + ↑ TPR (diastolic HTN)Cold intolerance, fatigue, ↑ TSH
Hyperthyroidism↑ CO + ↓ TPR (systolic HTN)Weight loss, palpitations, ↓ TSH
Coarctation of AortaMechanical obstruction β†’ ↑ BP in armsHTN in arms + low BP in legs, rib notching on CXR
Obstructive Sleep ApnoeaIntermittent hypoxia β†’ ↑ SNS + ↑ RAASSnoring, obese, refractory morning HTN
Pre-eclampsiaPregnancy-induced HTN + proteinuriaAfter 20 weeks gestation, ↑ BP + proteinuria
When to suspect Secondary HTN: Age <40, no family history, resistant to 3+ drugs, hypokalaemia, episodic symptoms, acute onset, renal impairment

5. THE RAAS PATHWAY - MASTER FLOWCHART (Diagram to Draw)

↓ Renal perfusion pressure
↓ Na⁺ delivery to macula densa
↑ Sympathetic stimulation (Ξ²1 receptors)
        ↓
JUXTAGLOMERULAR CELLS of kidney
        ↓ secrete
      RENIN
        ↓ acts on
ANGIOTENSINOGEN (from liver)
        ↓ cleaves to
   ANGIOTENSIN I  (inactive decapeptide)
        ↓ ACE (from lung endothelium)
   ANGIOTENSIN II (active octapeptide)
        ↓
   β”Œβ”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”¬β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”¬β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”
   ↓            ↓               ↓               ↓
ADRENAL       BLOOD            KIDNEY           BRAIN
CORTEX        VESSELS          TUBULES
   ↓             ↓               ↓               ↓
↑Aldosterone  Vasoconstriction  ↑Na⁺/Hβ‚‚O      ↑Thirst
   ↓             ↓               reabsorption     ↑ADH
↑Na⁺/Hβ‚‚O    ↑ TPR             ↑ Blood volume     ↑
retention      ↑ BP              ↑ CO β†’ ↑ BP    ↑ BP
        ↓
  NET RESULT: ↑ Blood Pressure
RAAS pathway diagram showing renin-angiotensin-aldosterone cascade with ACE inhibitor and ARB drug intervention points

Drugs That Block RAAS:

Drug ClassWhere it ActsEffect
ACE Inhibitors (Ramipril, Enalapril)Block ACE β†’ ↓ Ang II↓ Vasoconstriction + ↓ Aldosterone + ↑ Bradykinin (β†’ cough as SE)
ARBs (Losartan, Valsartan)Block AT1 receptor↓ All Ang II effects; no bradykinin β†’ no cough
Renin inhibitors (Aliskiren)Block Renin directly↓ Ang I + II + Aldosterone
Aldosterone antagonists (Spironolactone)Block mineralocorticoid receptor↓ Na⁺ retention + ↑ K⁺; used in resistant HTN + HF
Beta blockers (Atenolol, Bisoprolol)Block Ξ²1 on JG cells β†’ ↓ Renin release↓ RAAS activation + ↓ HR + ↓ CO

6. BP REGULATION FLOWCHART (Diagram to Draw)

↑ Blood Pressure detected by
        ↓
BARORECEPTORS (carotid sinus + aortic arch)
        ↓
MEDULLARY CARDIOVASCULAR CENTRE (NTS)
        ↓
Sends signals:
        β”Œβ”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”
        ↓                              ↓
↓ Sympathetic outflow          ↑ Parasympathetic (Vagal)
        ↓                              ↓
↓ HR, ↓ contractility, ↓ CO   ↓ HR (SA node slowed)
↓ Vasoconstriction β†’ ↓ TPR
        ↓
↓ MAP (pressure normalises)
        ↓
KIDNEY also responds:
↑ GFR + ↓ Na⁺ reabsorption β†’ pressure natriuresis
β†’ ↓ blood volume β†’ ↓ CO β†’ ↓ BP

7. TARGET ORGAN DAMAGE FROM HYPERTENSION

Chronic untreated HTN damages these organs ("CHESS"):
OrganDamageClinical Sign
CardiacLV hypertrophy β†’ HF; Coronary artery disease; Aortic dissectionS4 gallop, dyspnea, angina
Head (Brain)Hypertensive encephalopathy; Haemorrhagic/ischaemic stroke; Lacunar infarctsHeadache, confusion, focal deficits
EyesHypertensive retinopathy (AV nipping, flame haemorrhages, papilloedema)Blurred vision, visual field loss
Small vessels (Kidney)Nephrosclerosis β†’ CKD; Proteinuria↑ Creatinine, ↓ GFR
Systemic vesselsAccelerated atherosclerosis; Aortic aneurysm; PADClaudication, absent pulses

Keith-Wagener Classification of Hypertensive Retinopathy:

GradeFinding
Grade ISilver/copper wiring of arterioles
Grade IIAV nipping (AV crossing changes)
Grade IIIFlame haemorrhages + Cotton-wool spots
Grade IVPapilloedema ← Malignant HTN

8. HYPOTENSION

Definition: Systolic BP <90 mmHg or MAP <65 mmHg

Types and Causes:

TypeDefinitionCommon Causes
Absolute hypotensionBP consistently lowHypovolaemia, Addison's disease, hypothyroidism, sepsis
Orthostatic (Postural) hypotensionSBP drops β‰₯20 mmHg or DBP β‰₯10 mmHg within 3 min of standingDehydration, autonomic neuropathy (diabetes, Parkinson's), medications (alpha blockers, diuretics)
Neurally mediated (Vasovagal)Sudden ↑ vagal tone β†’ ↓ HR + ↓ BP β†’ syncopeEmotional stress, pain, prolonged standing, Valsalva
Cardiogenic hypotensionHeart fails to pump adequate COMassive MI, severe HF, cardiac tamponade

Physiological Response to Hypotension:

↓ BP β†’ baroreceptors detect ↓ stretch
        ↓
↑ Sympathetic outflow (rapid, seconds)
        ↓
↑ HR + ↑ contractility + ↑ vasoconstriction
        ↓
Short-term BP restoration

+

↑ RAAS activation (hours to days)
↑ ADH (vasopressin) release
↑ Na⁺/Hβ‚‚O retention β†’ ↑ volume β†’ ↑ CO
        ↓
Long-term BP restoration

9. ANTI-HYPERTENSIVE PHARMACOLOGY PREVIEW

Your schedule links this to anti-hypertensive drugs - here is the overview (detail in Week 2):
Drug ClassPrimary MechanismBP Target
Diuretics (Thiazides: HCTZ)↓ Na⁺/Hβ‚‚O β†’ ↓ volume β†’ ↓ CO; long-term: ↓ TPR1st line, esp. elderly
ACE inhibitors↓ Ang II β†’ ↓ TPR + ↓ Aldosterone1st line, esp. DM/CKD/HF
ARBs↓ AT1 receptor β†’ ↓ TPR + ↓ AldosteroneACEi intolerant
Calcium channel blockers (DHP: Amlodipine)Block L-type Ca²⁺ in VSM β†’ ↓ TPRHTN + angina; elderly
Beta blockers (Metoprolol)↓ HR + ↓ CO + ↓ ReninHTN + post-MI/HF/arrhythmia
Alpha blockers (Doxazosin)Block Ξ±1 β†’ ↓ vasoconstrictionHTN + BPH
Aldosterone antagonists (Spironolactone)↓ Na⁺ retentionResistant HTN + HF
Vasodilators (Hydralazine)Direct arteriolar dilationHTN in pregnancy

10. KEY FACTS FOR MCQs

QuestionAnswer
Most common type of hypertension?Primary / Essential (>90-95%)
Biggest single contributing factor to primary HTN?Obesity (65-75% of risk)
HTN + hypokalaemia β†’ suspect?Primary Aldosteronism (Conn's syndrome)
Episodic HTN + headache + sweating β†’ suspect?Phaeochromocytoma
HTN in arms + low BP in legs β†’ suspect?Coarctation of Aorta
BP formula?BP = CO Γ— TPR
RAAS: what does ACE convert?Ang I β†’ Ang II
ACE inhibitor side effect (why)?↑ Bradykinin β†’ dry cough
Grade IV hypertensive retinopathy = ?Papilloedema = Malignant HTN
Orthostatic hypotension definition?SBP drop β‰₯20 mmHg or DBP drop β‰₯10 mmHg on standing
Stage 2 HTN BP value?β‰₯140/90 mmHg
Hypertensive emergency: how fast to lower BP?By 25% in first hour (NOT all at once - risks cerebral ischaemia)
Long-term HTN β†’ what cardiac change?LV hypertrophy (↑ afterload β†’ concentric hypertrophy)
Drug for HTN in pregnancy?Methyldopa, Labetalol, Nifedipine (ACEi/ARBs CONTRAINDICATED)
Pressure natriuresis = ?↑ BP β†’ ↑ Na⁺ excretion by kidney β†’ ↓ volume β†’ ↓ BP (negative feedback)

11. SELF-TEST (Do Before Day 8)

  1. Draw the RAAS flowchart from memory - from ↓ renal perfusion to ↑ BP, marking where each drug class acts
  2. A 28-year-old woman has severe HTN with hypokalaemia. What is the likely diagnosis and what test confirms it?
  3. A patient develops a dry cough after starting Ramipril. Why? What do you switch to?
  4. Explain the difference between hypertensive urgency and emergency
  5. What are the 5 target organs damaged by chronic hypertension? (CHESS)
  6. Why does obesity cause hypertension? Name at least 3 mechanisms

Day 7 complete! Tomorrow (Day 8) is Atherosclerosis - mechanism, risk factors, stages of plaque formation, complications, and the diagram of atherosclerotic plaque stages. Just say "Day 8" when ready! πŸ«€

Day 8

Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Searching Images

atherosclerosis plaque formation stages fatty streak fibrous plaque diagram

This composite educational graphic illustrates the progression of atherosclerosis in the human aorta through macroscopic photography and histopathology. The content is organized into three rows: Healthy Aorta, Fatty Streak, and Fibroatheroma. Macroscopic clinical photographs show the transition from a smooth luminal interface to subendothelial yellow deposits (black arrowheads) in the fatty streak, and finally a complex fibroatheroma characterized by yellow lipid deposits encased in a white fibrous capsule. Light microscopy columns utilize Masson’s trichrome staining and Iron redox activity staining (Perls reaction followed by DiAminoBenzidin polymerization). In the healthy aorta, minimal iron staining is present. The fatty streak shows intimal thickening with focal DAB-positive iron deposits associated with granular foam cells. The fibroatheroma displays a prominent lipid core and advanced plaque architecture, with intense brown DAB staining indicating significant accumulation of redox-active iron within the lesion. This comparison highlights the role of iron-dependent oxidative stress and foam cell formation in early-stage atheroma development.

This composite educational graphic illustrates the progression of atherosclerosis in the human aorta through macroscopic photography and histopathology. The content is organized into three rows: Healthy Aorta, Fatty Streak, and Fibroatheroma. Macroscopic clinical photographs show the transition from a smooth luminal interface to subendothelial yellow deposits (black arrowheads) in the fatty streak, and finally a complex fibroatheroma characterized by yellow lipid deposits encased in a white fibrous capsule. Light microscopy columns utilize Masson’s trichrome staining and Iron redox activity staining (Perls reaction followed by DiAminoBenzidin polymerization). In the healthy aorta, minimal iron staining is present. The fatty streak shows intimal thickening with focal DAB-positive iron deposits associated with granular foam cells. The fibroatheroma displays a prominent lipid core and advanced plaque architecture, with intense brown DAB staining indicating significant accumulation of redox-active iron within the lesion. This comparison highlights the role of iron-dependent oxidative stress and foam cell formation in early-stage atheroma development.

This medical pathophysiology diagram illustrates the progression of atherosclerosis across three stagesβ€”prelesional, early, and advancedβ€”focusing on the regulatory role of X-box binding protein 1 (XBP1). Section A presents cross-sections of an artery showing luminal narrowing and plaque accumulation. Section B provides a high-resolution view of the vessel wall layers, including endothelial cells (ECs), the intima, and smooth muscle cells (SMCs). In the prelesional stage, XBP1 isoforms modulate EC proliferation and detachment. The early stage is characterized by immune cell infiltration (macrophages, dendritic cells, T/B cells) and SMC transformation, where XBP1s influences contractility, dedifferentiation, and proteoglycan synthesis. The advanced stage depicts significant pathology, including SMC migration, the formation of foam-cell-like SMCs, a necrotic core, and neointimal formation. Molecular pathways highlight XBP1s interacting with HIF1 and miR-153 to regulate angiogenesis (VEGFA) and fibrous cap destabilization via senescence and apoptosis. This infographic serves as a cardiovascular research and educational tool for understanding the cellular and molecular mechanisms of atherogenesis.

This medical pathophysiology diagram illustrates the progression of atherosclerosis across three stagesβ€”prelesional, early, and advancedβ€”focusing on the regulatory role of X-box binding protein 1 (XBP1). Section A presents cross-sections of an artery showing luminal narrowing and plaque accumulation. Section B provides a high-resolution view of the vessel wall layers, including endothelial cells (ECs), the intima, and smooth muscle cells (SMCs). In the prelesional stage, XBP1 isoforms modulate EC proliferation and detachment. The early stage is characterized by immune cell infiltration (macrophages, dendritic cells, T/B cells) and SMC transformation, where XBP1s influences contractility, dedifferentiation, and proteoglycan synthesis. The advanced stage depicts significant pathology, including SMC migration, the formation of foam-cell-like SMCs, a necrotic core, and neointimal formation. Molecular pathways highlight XBP1s interacting with HIF1 and miR-153 to regulate angiogenesis (VEGFA) and fibrous cap destabilization via senescence and apoptosis. This infographic serves as a cardiovascular research and educational tool for understanding the cellular and molecular mechanisms of atherogenesis.

Loading Image
Reading File
Excellent - all content from Robbins & Kumar Basic Pathology and Basic Medical Biochemistry loaded. Here are your complete Day 8 notes!

πŸ“˜ WEEK 2 - DAY 8

Atherosclerosis: Mechanism, Risk Factors, Stages of Plaque Formation & Complications

Source: Robbins & Kumar Basic Pathology | Robbins, Cotran & Kumar Pathologic Basis of Disease | Basic Medical Biochemistry 6th Ed

1. WHAT IS ATHEROSCLEROSIS?

Atherosclerosis = a chronic inflammatory disease of medium and large arteries characterised by the formation of atheromas (plaques) within the intima of vessel walls, causing stenosis, thrombosis, and end-organ ischaemia.
  • It is the leading cause of death in Western countries (responsible for ~half of all deaths)
  • Underlies: Coronary artery disease (CAD), Stroke, Peripheral artery disease (PAD), Aortic aneurysm

Key Concept: "Response to Endothelial Injury" Theory

Atherosclerosis is best viewed as the vascular response to endothelial injury. Every step in atherogenesis is triggered by, and amplified by, endothelial dysfunction.

2. RISK FACTORS

Non-Modifiable (Constitutional):

FactorExplanation
Genetics / Family historyMost important independent risk factor; includes familial hypercholesterolaemia (defective LDL receptors)
AgeClinically silent until middle age; MI risk ↑ 5-fold from age 40-60
Male sexPre-menopausal women protected by oestrogen; after menopause, risk equalises or exceeds men
RaceHigher rates in certain populations

Modifiable Risk Factors:

FactorMechanism
Hyperlipidaemia (LDL↑, HDL↓)Most important modifiable RF; LDL accumulates in intima β†’ oxidised β†’ foam cells
HypertensionMechanical endothelial injury + ↑ Ang II β†’ endothelial dysfunction + SMC proliferation
Cigarette smokingOxidative damage to endothelium + ↑ CO β†’ hypoxia + ↑ LDL oxidation
Diabetes mellitusAdvanced glycation end-products (AGEs) damage endothelium; dyslipidaemia; ↑ oxidative stress
Obesity↑ LDL, ↑ BP, ↑ insulin resistance, ↑ systemic inflammation
Physical inactivity↓ HDL, ↑ LDL, ↑ BP, ↑ obesity
Inflammation / elevated CRPChronic inflammation drives macrophage recruitment and plaque progression
High-yield exam fact: Three risk factors together (hyperlipidaemia + hypertension + smoking) multiply risk by a factor of 7! Risk factors are roughly multiplicative, not additive.

3. PATHOGENESIS - STEP BY STEP MECHANISM

The Central Concept:

RISK FACTORS
(LDL↑, HTN, Smoking, DM, etc.)
        ↓
ENDOTHELIAL INJURY / DYSFUNCTION
        ↓
LDL accumulation in intima + Monocyte recruitment
        ↓
LDL oxidised β†’ Foam cells formed β†’ Fatty streak
        ↓
Smooth muscle migration + Fibrosis β†’ Fibrous plaque
        ↓
Necrosis + Calcification + Inflammation β†’ Advanced/Complicated plaque

Step-by-Step Detail:

STEP 1: Endothelial Injury & Dysfunction

  • Risk factors injure or activate the endothelium
  • Injured endothelium:
    • ↓ Nitric oxide (NO) production β†’ less vasodilation
    • ↑ Expression of adhesion molecules (VCAM-1, ICAM-1, P-selectin, E-selectin)
    • ↑ Permeability β†’ LDL leaks into intima
    • ↑ Procoagulant state (thrombin, PAI-1)

STEP 2: Lipoprotein Accumulation in the Intima

  • LDL particles enter the subendothelial space through the damaged endothelium
  • LDL is oxidised by oxygen free radicals (generated by macrophages and ECs) β†’ oxidised LDL (ox-LDL)
  • ox-LDL is toxic to endothelium and SMCs
  • ox-LDL stimulates local release of growth factors, cytokines, and chemokines β†’ amplifies inflammation

STEP 3: Monocyte Recruitment & Foam Cell Formation

  • Endothelial adhesion molecules capture circulating monocytes from blood
  • Monocytes migrate into the intima (diapedesis) β†’ differentiate into macrophages
  • Macrophages ingest ox-LDL via scavenger receptors (not the normal LDL receptor!)
  • Unlike normal LDL uptake, scavenger receptors are NOT downregulated β†’ macrophages keep eating LDL
  • Macrophages become engorged with lipid β†’ FOAM CELLS
  • Accumulation of foam cells β†’ FATTY STREAK (earliest visible lesion)

STEP 4: Smooth Muscle Cell (SMC) Migration & Proliferation

  • Growth factors (PDGF, FGF, EGF) released by macrophages, endothelium, and platelets
  • SMCs migrate from media β†’ intima
  • SMCs undergo phenotypic change - from contractile β†’ synthetic phenotype
  • Synthetic SMCs produce collagen, elastin, proteoglycans β†’ building the fibrous cap

STEP 5: Plaque Growth - Fatty Streak β†’ Fibrous Plaque β†’ Advanced Plaque

  • Continued lipid accumulation + SMC proliferation + ECM synthesis
  • Dead foam cells release lipid β†’ forms the necrotic lipid core
  • Fibrous cap of SMCs + collagen forms over the lipid core
  • Calcification, neovascularisation, and T-cell infiltration occur in advanced plaques

4. STAGES OF ATHEROSCLEROTIC PLAQUE FORMATION

Fatty streak - aortic gross specimen showing yellowish lipid deposits; microscopy showing foam cells (arrows) in subintimal space

Diagram to Draw:

STAGE 1: NORMAL ARTERY
β”Œβ”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”
β”‚ LUMEN                                    β”‚
│──────── Endothelium (intact)─────────────│
β”‚         Intima (thin, normal)            β”‚
│──────── IEM ─────────────────────────────│
β”‚         Media (smooth muscle)            β”‚
β””β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”˜

STAGE 2: FATTY STREAK (earliest lesion - reversible)
β”Œβ”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”
β”‚ LUMEN (not yet narrowed)                 β”‚
│── Endothelium (dysfunctional) ───────────│
β”‚   Intima: FOAM CELLS (lipid-laden        β”‚
β”‚   macrophages) accumulate                β”‚
β”‚   Yellow streaks visible on gross exam   β”‚
β””β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”˜
Seen in aorta from age 10 onwards even in healthy children!

STAGE 3: FIBROUS PLAQUE (intermediate)
β”Œβ”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”
β”‚ LUMEN (starting to narrow)               β”‚
│── Fibrous cap (SMCs + collagen) ─────────│
β”‚   Intima: foam cells + SMCs + ECM        β”‚
β”‚   Necrotic lipid core forming            β”‚
β”‚   Macrophages, T cells at "shoulder"     β”‚
β””β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”˜

STAGE 4: ADVANCED / COMPLICATED PLAQUE
β”Œβ”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”
β”‚ LUMEN (significantly narrowed)           β”‚
│── Fibrous cap ───────────────────────────│
β”‚   Lipid/necrotic core (cholesterol       β”‚
β”‚   crystals, debris, foam cells)          β”‚
β”‚   Calcification                          β”‚
β”‚   Neovascularisation (new vessels)       β”‚
β”‚   Thinned media below plaque             β”‚
β””β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”˜

Plaque Components Summary:

ComponentWhat it Contains
Fibrous capSMCs + dense collagen (Type I) + ECM
Necrotic coreCholesterol crystals, cholesterol esters, foam cells, necrotic debris, fibrin
Shoulder regionMost inflammatory - macrophages, T cells, SMCs (vulnerable to rupture here!)
NeovascularisationNew small blood vessels growing into the plaque
CalcificationDystrophic calcification (dead cell calcium deposition)

5. PLAQUE VULNERABILITY - STABLE vs. VULNERABLE PLAQUE

FeatureStable PlaqueVulnerable (Unstable) Plaque
Fibrous capThick, strongThin, weak
Lipid coreSmallLarge (>40% of plaque)
InflammationLowHigh - many macrophages at shoulder
SMC contentHighLow (macrophages digest collagen)
CalcificationOften heavily calcifiedLess calcification
RiskCauses stable anginaRupture β†’ ACS (UA/NSTEMI/STEMI)
Lumen narrowingOften severe (70-90%)Often moderate (50-70%) - paradox!
Critical exam concept: A vulnerable plaque may only cause 50-60% stenosis on angiogram, but is more dangerous than a stable plaque causing 80% stenosis - because it can suddenly rupture and cause complete occlusion (100%) by triggering thrombosis!

6. COMPLICATIONS OF ATHEROSCLEROSIS - MASTER TABLE

ComplicationMechanismClinical Result
Stenosis (ischaemia)Plaque enlarges β†’ narrows lumen β†’ ↓ blood flowStable angina, Claudication, TIA
Plaque rupture / fissureThin cap tears β†’ exposes thrombogenic lipid core + collagenACS (Unstable Angina, NSTEMI, STEMI)
ThrombosisPlaque rupture β†’ platelet aggregation + coagulation cascadeSudden occlusion β†’ Myocardial infarction, Stroke
EmbolismThrombus fragments break offDistal embolisation β†’ limb/organ ischaemia
Aneurysm formationIschaemia of media (vasa vasorum occluded) β†’ media weakens β†’ wall bulgesAortic aneurysm (especially abdominal)
CalcificationDystrophic calcification of plaque"Eggshell" coronaries on CT; reduced arterial compliance

7. VESSELS MOST COMMONLY AFFECTED

Most commonly affected (in order):
1. Abdominal aorta (especially near renal arteries)
2. Coronary arteries (especially proximal LAD)
3. Popliteal arteries
4. Descending thoracic aorta
5. Internal carotid arteries (near bifurcation)
6. Circle of Willis

Arteries usually SPARED:
- Upper limb vessels
- Mesenteric arteries (except at ostia)
- Renal arteries (except at ostia)

8. PHARMACOLOGY LINK - Statins and Antiplatelets

Statins (e.g. Atorvastatin, Rosuvastatin):

HMG-CoA + Acetyl-CoA β†’ Mevalonate β†’ ... β†’ Cholesterol

Statins BLOCK HMG-CoA Reductase
        ↓
↓ Intracellular cholesterol synthesis
        ↓
↑ LDL receptors on hepatocytes (upregulated)
        ↓
↑ LDL uptake from blood β†’ ↓ Blood LDL
        ↓
Less LDL in intima β†’ less ox-LDL β†’ less foam cell formation
β†’ Slows plaque progression + may cause regression
Statins also have pleiotropic effects: ↓ Inflammation, ↑ Endothelial NO, ↓ Platelet aggregation, stabilise plaque

Antiplatelets (e.g. Aspirin, Clopidogrel):

DrugMechanismUse
AspirinIrreversibly blocks COX-1 β†’ ↓ Thromboxane Aβ‚‚ β†’ ↓ platelet aggregationAll patients with CAD/ACS; 75-100mg/day
ClopidogrelBlocks P2Y12 (ADP receptor) on platelets β†’ ↓ platelet aggregationACS, post-PCI stent (dual antiplatelet with aspirin = DAPT)
TicagrelorReversible P2Y12 blocker (faster onset than clopidogrel)ACS (preferred over clopidogrel in NSTEMI/STEMI)

9. ATHEROSCLEROSIS PROGRESSION FLOWCHART (Draw This!)

RISK FACTORS (LDL↑, HTN, Smoking, DM, Obesity)
        ↓
ENDOTHELIAL INJURY / DYSFUNCTION
↓ NO production | ↑ Adhesion molecules (VCAM-1, ICAM-1)
↑ Permeability β†’ LDL enters intima
        ↓
LDL OXIDATION (by macrophage/EC free radicals)
Oxidised LDL β†’ TOXIC + INFLAMMATORY
        ↓
MONOCYTE ADHESION & RECRUITMENT
(via VCAM-1, MCP-1 chemoattractant)
        ↓
MONOCYTE β†’ MACROPHAGE differentiation in intima
        ↓
MACROPHAGE ingests ox-LDL via SCAVENGER RECEPTORS
(NOT downregulated β†’ unrestricted lipid uptake)
        ↓
FOAM CELLS β†’ accumulate β†’ FATTY STREAK
(visible from age 10, even in healthy children!)
        ↓
↑ PDGF, FGF, IL-1, TNF released
        ↓
SMC MIGRATION: Media β†’ Intima
SMC PROLIFERATION + ECM synthesis (collagen, elastin)
        ↓
FIBROUS PLAQUE (Fibrous cap over growing lipid core)
        ↓
NECROSIS + CALCIFICATION + Neovascularisation
        ↓
ADVANCED / COMPLICATED PLAQUE
        ↓
         β”Œβ”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”
         ↓                                     ↓
   STABLE PLAQUE                    VULNERABLE PLAQUE
   (thick cap, small core)          (thin cap, large core)
         ↓                                     ↓
  Chronic ischaemia               PLAQUE RUPTURE
  (Stable angina, PAD)                    ↓
                                  Thrombus formation
                                          ↓
                               ACS (UA / NSTEMI / STEMI)
                               Stroke / Limb ischaemia

10. KEY FACTS FOR MCQs

QuestionAnswer
Atherosclerosis = response to?Endothelial injury
Earliest visible lesion of atherosclerosis?Fatty streak
Foam cells are derived from?Lipid-laden macrophages (monocyte origin)
Which receptor do macrophages use to ingest ox-LDL?Scavenger receptor (NOT LDL receptor)
Most dangerous area of a plaque anatomically?Shoulder region (most macrophages, thinnest cap)
What makes a plaque "vulnerable"?Thin fibrous cap + large lipid core + high inflammation
Three risk factors that multiply risk Γ— 7?Hyperlipidaemia + Hypertension + Smoking
Most common site of atherosclerosis?Abdominal aorta
Statins work by blocking which enzyme?HMG-CoA reductase
Aspirin mechanism in atherosclerosis?Blocks COX-1 β†’ ↓ TXAβ‚‚ β†’ ↓ platelet aggregation
Clopidogrel blocks which receptor?P2Y12 (ADP receptor) on platelets
Cholesterol clefts in plaque are seen where?Necrotic core (cholesterol crystals washed out in processing)
Fatty streaks seen in which age group?From age 10 onwards - even in normal children!
Complication of atherosclerosis in abdominal aorta?Aortic aneurysm
What is DAPT?Dual antiplatelet therapy = Aspirin + Clopidogrel/Ticagrelor

11. SELF-TEST (Do Before Day 9)

  1. Draw the atherosclerosis progression flowchart from memory - from risk factor β†’ fatty streak β†’ ACS
  2. What is the difference between a stable plaque and a vulnerable plaque? Which is more dangerous and why?
  3. A patient with familial hypercholesterolaemia has an MI at age 22. Which genetic defect is responsible?
  4. Why do macrophages keep ingesting LDL even when they are already full of lipid?
  5. Name the 3 principal components of an advanced atheromatous plaque
  6. Why does Aspirin help in ACS? What is its specific biochemical mechanism?

Day 8 complete! Tomorrow (Day 9) is Raynaud's Disease - pathophysiology, clinical features, primary vs. secondary, and vasodilator therapy. Just say "Day 9" when ready! πŸ«€

Day 9

Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Searching Images

Raynaud phenomenon triphasic color change fingers white blue red

Clinical photograph of a patient's hands demonstrating the characteristic triphasic color changes associated with Raynaud’s phenomenon. The left image shows significant pallor (white phase) in the index finger, representing digital vasospasm and ischemia, contrasted against the erythema (red phase) of the adjacent middle finger, suggesting reperfusion. The right image shows more diffuse, patchy pallor across several digits including the index and ring fingers. These visual findings are hallmark clinical signs of Raynaud’s phenomenon, which may occur as a primary condition or secondary to autoimmune connective tissue diseases. In this clinical context, the findings are associated with a patient positive for anti-centromere antibodies and diagnosed with an autoimmune hepatitis (AIH) and primary biliary cholangitis (PBC) overlap syndrome. The image serves as an educational example of episodic vasospastic disorders and their physical manifestations in the distal extremities.

Clinical photograph of a patient's hands demonstrating the characteristic triphasic color changes associated with Raynaud’s phenomenon. The left image shows significant pallor (white phase) in the index finger, representing digital vasospasm and ischemia, contrasted against the erythema (red phase) of the adjacent middle finger, suggesting reperfusion. The right image shows more diffuse, patchy pallor across several digits including the index and ring fingers. These visual findings are hallmark clinical signs of Raynaud’s phenomenon, which may occur as a primary condition or secondary to autoimmune connective tissue diseases. In this clinical context, the findings are associated with a patient positive for anti-centromere antibodies and diagnosed with an autoimmune hepatitis (AIH) and primary biliary cholangitis (PBC) overlap syndrome. The image serves as an educational example of episodic vasospastic disorders and their physical manifestations in the distal extremities.

Clinical photograph showing two views of a patient's hands (palmar aspect) exhibiting the classic triphasic color changes associated with Raynaud's phenomenon. The image demonstrates a mottled appearance characterized by distinct zones of pallor (ischemic white), cyanosis (deoxygenated blue/purple), and reactive hyperemia (erythematous red). These vascular changes are most prominent across the digits and distal palmar surfaces. The skin texture appears intact without visible digital ulcers, gangrene, or sclerodactyly. In the clinical context of lung adenocarcinoma, these findings are representative of paraneoplastic Raynaud's phenomenon, a secondary form of the condition. This visual serves as an educational example of peripheral vasospastic disorders and their manifestations in systemic malignancy. The image highlights the importance of assessing hand coloration as a diagnostic indicator of underlying microvascular dysfunction.

Clinical photograph showing two views of a patient's hands (palmar aspect) exhibiting the classic triphasic color changes associated with Raynaud's phenomenon. The image demonstrates a mottled appearance characterized by distinct zones of pallor (ischemic white), cyanosis (deoxygenated blue/purple), and reactive hyperemia (erythematous red). These vascular changes are most prominent across the digits and distal palmar surfaces. The skin texture appears intact without visible digital ulcers, gangrene, or sclerodactyly. In the clinical context of lung adenocarcinoma, these findings are representative of paraneoplastic Raynaud's phenomenon, a secondary form of the condition. This visual serves as an educational example of peripheral vasospastic disorders and their manifestations in systemic malignancy. The image highlights the importance of assessing hand coloration as a diagnostic indicator of underlying microvascular dysfunction.

Your credits are exhausted. You can purchase a top-up or subscribe to a plan to continue using Orris. If you're already subscribed, your daily credits will reset tomorrow.

Day 9

I already have all the content needed from the earlier session! Let me compile your complete Day 9 notes now.
Searching Images

Raynaud phenomenon triphasic color change fingers white blue red vasospasm

Clinical photograph of a patient's hands demonstrating the characteristic triphasic color changes associated with Raynaud’s phenomenon. The left image shows significant pallor (white phase) in the index finger, representing digital vasospasm and ischemia, contrasted against the erythema (red phase) of the adjacent middle finger, suggesting reperfusion. The right image shows more diffuse, patchy pallor across several digits including the index and ring fingers. These visual findings are hallmark clinical signs of Raynaud’s phenomenon, which may occur as a primary condition or secondary to autoimmune connective tissue diseases. In this clinical context, the findings are associated with a patient positive for anti-centromere antibodies and diagnosed with an autoimmune hepatitis (AIH) and primary biliary cholangitis (PBC) overlap syndrome. The image serves as an educational example of episodic vasospastic disorders and their physical manifestations in the distal extremities.

Clinical photograph of a patient's hands demonstrating the characteristic triphasic color changes associated with Raynaud’s phenomenon. The left image shows significant pallor (white phase) in the index finger, representing digital vasospasm and ischemia, contrasted against the erythema (red phase) of the adjacent middle finger, suggesting reperfusion. The right image shows more diffuse, patchy pallor across several digits including the index and ring fingers. These visual findings are hallmark clinical signs of Raynaud’s phenomenon, which may occur as a primary condition or secondary to autoimmune connective tissue diseases. In this clinical context, the findings are associated with a patient positive for anti-centromere antibodies and diagnosed with an autoimmune hepatitis (AIH) and primary biliary cholangitis (PBC) overlap syndrome. The image serves as an educational example of episodic vasospastic disorders and their physical manifestations in the distal extremities.

This clinical photograph displays a patient's protruding tongue, highlighting a rare intraoral manifestation of Raynaud's phenomenon. The image captures a sharp demarcation of color change: the distal one-third (the tip and lateral margins) exhibits a pale, blanching white appearance indicative of vasospastic ischemia. In contrast, the proximal portion of the tongue shows a dusky, purplish-blue cyanotic hue. The surface morphology is relatively smooth with a prominent midline longitudinal fissure visible within the ischemic zone. This visual demonstrates the classic triphasic or biphasic color changes associated with vasospasmβ€”pallor followed by cyanosisβ€”applied here to the lingual vasculature. This educational resource is highly relevant for rheumatology and internal medicine, illustrating that Raynaud's phenomenon can occur in atypical anatomical locations beyond the digits, often triggered by cold exposure or emotional stress.

This clinical photograph displays a patient's protruding tongue, highlighting a rare intraoral manifestation of Raynaud's phenomenon. The image captures a sharp demarcation of color change: the distal one-third (the tip and lateral margins) exhibits a pale, blanching white appearance indicative of vasospastic ischemia. In contrast, the proximal portion of the tongue shows a dusky, purplish-blue cyanotic hue. The surface morphology is relatively smooth with a prominent midline longitudinal fissure visible within the ischemic zone. This visual demonstrates the classic triphasic or biphasic color changes associated with vasospasmβ€”pallor followed by cyanosisβ€”applied here to the lingual vasculature. This educational resource is highly relevant for rheumatology and internal medicine, illustrating that Raynaud's phenomenon can occur in atypical anatomical locations beyond the digits, often triggered by cold exposure or emotional stress.

Finding Sources
Reading File
Reading File
Reading File
Loading Image
All content loaded. Here are your complete Day 9 notes!

πŸ“˜ WEEK 2 - DAY 9

Raynaud's Disease & Phenomenon: Pathophysiology, Primary vs. Secondary, Clinical Features & Management

Sources: Robbins & Kumar Basic Pathology | Goldman-Cecil Medicine | Andrews' Diseases of the Skin | Fitzpatrick's Dermatology | Miller's Review of Orthopaedics

1. OVERVIEW & DEFINITIONS

Raynaud's Phenomenon (RP) is an exaggerated vasoconstrictive response of small digital arteries and arterioles to cold temperature and/or emotional stress, causing episodic ischaemia of the digits with characteristic triphasic colour changes.
Think of it as: the blood vessels in your fingers "overreact" to cold and clamp shut completely, instead of just narrowing a little.

Two Types - Key Distinction:

Primary (Raynaud's Disease)Secondary (Raynaud's Phenomenon)
Underlying causeNone - idiopathic vasospasmCaused by another disease
Also calledRaynaud's DiseaseRaynaud's Phenomenon
SeverityBenign, reversibleMore severe, progressive
Tissue damageRare (gangrene <1%)Ulcers, necrosis, gangrene common
Common inYoung women <40 yrsAny age, any sex (but still female predominant)

2. CLINICAL PHOTOGRAPH - Raynaud's Phenomenon

Clinical photograph showing characteristic pallor (white ischaemic phase) in index finger contrasted against erythema (red reperfusion phase) in adjacent finger - classic Raynaud's phenomenon
This photo shows the white (ischaemic) phase in the index finger alongside the red (reperfusion) phase in the adjacent finger - the hallmark of Raynaud's phenomenon.

3. TRIPHASIC COLOUR CHANGE (Draw This!)

                    TRIGGER: Cold exposure / Emotional stress
                                    ↓
β”Œβ”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”
β”‚  PHASE 1: WHITE (Pallor)                                        β”‚
β”‚  Vasospasm β†’ complete arterial constriction                     β”‚
β”‚  Blood flow = near zero β†’ digits turn WHITE                     β”‚
β”‚  Ischaemia β†’ cold, numb, "dead" fingers                         β”‚
β”‚  Mechanism: ↑ Sympathetic tone β†’ Ξ±β‚‚-adrenoceptor activation    β”‚
β”‚             β†’ smooth muscle contraction                         β”‚
β”œβ”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€
β”‚  PHASE 2: BLUE (Cyanosis)                                       β”‚
β”‚  Arterial vasospasm persists + postcapillary venular           β”‚
β”‚  constriction β†’ stagnant blood β†’ deoxygenation                  β”‚
β”‚  Digits turn BLUE/PURPLE                                        β”‚
β”‚  Pain and paraesthesias develop                                 β”‚
β”œβ”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€
β”‚  PHASE 3: RED (Rubor/Reactive Hyperaemia)                       β”‚
β”‚  Vasospasm releases (on rewarming)                              β”‚
β”‚  Sudden rush of oxygenated blood β†’ vasodilation                 β”‚
β”‚  Digits turn RED (hyperaemic)                                   β”‚
β”‚  Throbbing pain, tingling, burning sensation                    β”‚
β””β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”˜
Exam note: All 3 phases are NOT always seen - pallor (white) alone may be the only finding. The thumb is often SPARED.

4. PATHOPHYSIOLOGY

The exact mechanism is multifactorial. Three main abnormalities contribute:

A. Vascular Wall Abnormality

  • Small digital arteries have structural abnormalities in secondary RP (intimal thickening, fibrosis)
  • Imbalance between vasoconstrictors and vasodilators:
    • ↑ Endothelin-1 (ET-1) - potent vasoconstrictor (elevated especially in scleroderma-associated RP)
    • ↓ Nitric oxide (NO) - vasodilator
    • ↑ Thromboxane Aβ‚‚ - vasoconstrictor + platelet aggregator
    • ↓ Prostacyclin (PGIβ‚‚) - vasodilator

B. Neural Control Abnormality

  • Exaggerated sympathetic response to cold (central + peripheral)
  • Overactivation of Ξ±β‚‚-adrenoceptors on vascular smooth muscle β†’ intense vasoconstriction
  • Cold directly upregulates Ξ±β‚‚C-adrenoceptors (moved to cell surface by cold)
  • Emotional stress activates sympathetic nervous system β†’ triggers attacks even without cold

C. Intravascular Factors

  • Platelet activation β†’ release of TXAβ‚‚, serotonin β†’ further vasoconstriction
  • Oxidative stress β†’ ↓ NO bioavailability
  • Elevated homocysteine (detected in both primary and secondary RP)

Simplified Mechanism:

TRIGGER (Cold / Stress)
        ↓
↑ Sympathetic nervous system activity
        ↓
Ξ±β‚‚-adrenoceptor activation on digital artery smooth muscle
        ↓
↑ [Ca²⁺] inside vascular smooth muscle cells
        ↓
Smooth muscle CONTRACTION β†’ Digital artery VASOSPASM
        ↓
↓ Blood flow β†’ Ischaemia
        ↓
WHITE β†’ BLUE β†’ RED (on rewarming)

5. PRIMARY RAYNAUD'S DISEASE - Detailed Features

FeatureDetail
Prevalence3-5% general population; up to 5-15% in young women
Typical patientYoung woman <40 years
DistributionBilateral and symmetric
Digits most affectedMiddle and ring fingers; thumb usually spared
Gangrene/ulcersRare (<1%)
CapillaroscopyNormal nailfold capillaries
Autoantibodies (ANA)Negative or very low titre (≀1:40)
PrognosisBenign; stable over years
Family history30-50% have first-degree relative with same condition
DiagnosisExclusion - no associated disease found

Diagnostic Criteria for Primary Raynaud's Disease:

  1. Episodic vasospasm with triphasic colour change
  2. Bilateral involvement
  3. Normal nailfold capillaroscopy
  4. Negative/low-titre ANA
  5. No features of connective tissue disease (no sclerodactyly, no calcinosis, no ulcers)
  6. No underlying cause identified

6. SECONDARY RAYNAUD'S PHENOMENON - Causes

Causes (By Category):

SECONDARY RAYNAUD'S PHENOMENON
β”œβ”€β”€ RHEUMATOLOGIC (most common cause overall)
β”‚   β”œβ”€β”€ Systemic Sclerosis/Scleroderma ← MOST COMMON (>50% of cases)
β”‚   β”œβ”€β”€ Systemic Lupus Erythematosus (SLE)
β”‚   β”œβ”€β”€ Rheumatoid Arthritis
β”‚   β”œβ”€β”€ SjΓΆgren's Syndrome
β”‚   └── Mixed Connective Tissue Disease (MCTD)
β”‚
β”œβ”€β”€ OBSTRUCTIVE ARTERIAL DISEASE
β”‚   β”œβ”€β”€ Atherosclerosis
β”‚   β”œβ”€β”€ Thromboangiitis Obliterans (Buerger's disease)
β”‚   └── Arterial embolism
β”‚
β”œβ”€β”€ OCCUPATIONAL / ENVIRONMENTAL
β”‚   β”œβ”€β”€ Hand-arm vibration syndrome (jackhammer workers, miners)
β”‚   β”œβ”€β”€ Hypothenar hammer syndrome
β”‚   └── Frostbite (previous cold injury)
β”‚
β”œβ”€β”€ DRUGS
β”‚   β”œβ”€β”€ Ξ²-blockers ← common culprit in cardiac patients!
β”‚   β”œβ”€β”€ Ergotamines
β”‚   β”œβ”€β”€ Cocaine, Amphetamines
β”‚   β”œβ”€β”€ Clonidine
β”‚   └── Oral contraceptives
β”‚
β”œβ”€β”€ ENDOCRINE
β”‚   └── Hypothyroidism
β”‚
└── HAEMATOLOGIC
    β”œβ”€β”€ Polycythaemia vera
    β”œβ”€β”€ Cryoglobulinaemia
    └── Cold agglutinins
Exam high-yield: Ξ²-blockers (used in hypertension, heart failure, and post-MI) can cause or worsen Raynaud's phenomenon. A cardiac tech must know this!

7. PRIMARY vs. SECONDARY - COMPARISON TABLE

Clinical FeaturePrimary (Disease)Secondary (Phenomenon)
SexFemale predominantFemale or male
Age of onset<40 yearsβ‰₯40 years (or any age)
Sides affectedBilateralUnilateral or bilateral
Ischaemic ulcers/gangreneAbsent (rare)Present - common
Underlying diseaseNonePresent
Systemic symptomsAbsentOften present
CapillaroscopyNormalAbnormal (dilated, tortuous capillaries; "skip" areas)
ANANegativeOften positive
Blood chemistryNormalOften abnormal
ProgressionStableProgressive
Allen testNormalMay be abnormal

8. DIAGNOSIS

Key Investigations:

TestPurpose
Nailfold capillaroscopyGold standard to distinguish primary vs. secondary; abnormal in scleroderma (giant capillaries, avascular areas)
ANA (antinuclear antibody)If positive β†’ suggests underlying CTD
Anti-centromere antibodyAssociated with limited scleroderma (CREST syndrome)
Anti-Scl-70 (anti-topoisomerase-1)Associated with diffuse scleroderma
FBC, ESR, CRPBaseline; elevated in secondary causes
TFTs (thyroid function tests)Rule out hypothyroidism
Serum protein electrophoresisRule out myeloma, cryoglobulinaemia
Doppler ultrasound / Laser DopplerAssess digital blood flow
Digital thermographySkin temperature measurement; aids early diagnosis

9. MANAGEMENT

Non-Pharmacological (First Step for All Patients):

LIFESTYLE MODIFICATIONS (applies to BOTH Primary and Secondary RP)

1. AVOID COLD EXPOSURE
   - Wear warm gloves, socks, layers
   - Avoid cold drinks/foods
   - Keep core body temperature warm (vasospasm can be triggered
     by OVERALL body cooling, not just local cold!)

2. STOP SMOKING (absolutely contraindicated)
   - Nicotine is a powerful vasoconstrictor

3. AVOID EMOTIONAL STRESS
   - Relaxation techniques, biofeedback

4. AVOID TRIGGERING DRUGS
   - Stop Ξ²-blockers if possible; switch to CCBs or ARBs
   - Avoid ergotamines, cocaine

5. TRAUMA AVOIDANCE
   - Protect fingertips

6. "WINDMILL" MANOEUVRE
   - Swing arm in a wide circle from shoulder during an attack
   - Centrifugal force drives blood into the fingers

Pharmacological Treatment (Step Ladder):

StepDrugMechanismNotes
1st LineNifedipine (CCB) - extended releaseBlocks L-type Ca²⁺ channels in VSM β†’ ↓ [Ca²⁺] β†’ vasodilation~2/3 of patients respond; reduces attacks by ~1.7/week vs. placebo
1st LineAmlodipine (CCB) - prolonged releaseSame as nifedipine; longer half-lifeOften preferred for once-daily dosing
2nd LineSildenafil / Tadalafil (PDE-5 inhibitors)Block PDE-5 β†’ ↑ cGMP β†’ smooth muscle relaxation β†’ vasodilationReduces attack frequency and severity; aids digital ulcer healing
2nd LineLosartan (ARB)Blocks AT₁ receptor β†’ ↓ vasoconstrictionShown to be MORE effective than nifedipine in one RCT
3rd LineBosentan (endothelin receptor antagonist)Blocks ET-1 (ETA + ETB receptors) β†’ prevents ET-1-driven vasoconstrictionEspecially for scleroderma-associated RP; reduces new digital ulcers
3rd LineIloprost (IV prostacyclin analogue)Mimics PGIβ‚‚ β†’ potent vasodilation + ↓ platelet aggregationFor severe scleroderma-associated RP; only slightly better than nifedipine but more expensive
AdjunctSSRIs (Fluoxetine)Reduce sympathetic overactivation; some antiplatelet effectsFor refractory cases
NOT recommendedACE inhibitorsFailed to show benefit in RCTsDo not use
NOT recommendedStandard topical nitroglycerineMinimal efficacy, systemic side effectsTopical MQX-503 form shows some promise in RCTs
Cardiac tech exam link: Know why CCBs work here - the same mechanism (Ca²⁺ channel blockade on smooth muscle) used in hypertension and angina also relieves vasospasm in Raynaud's!

Surgical Options (Refractory Cases):

ProcedureIndicationNotes
Botulinum toxin injection (digital sympathectomy equivalent)Severe refractory RP with digital ulcersInject around neurovascular bundle in palm; 75-100% improvement; lasts months-years
Local digital sympathectomyChronic ulcerated digitsAvoids amputation; effective
Cervical / thoracic sympathectomySevere, generalised RPInitial good relief, but symptoms often recur after 12-18 months; digital ulcers still greatly reduced; compensatory hyperhidrosis is a common side effect
Fat graftingPilot data; severe RPFat transferred to hand; limited evidence

10. RAYNAUD'S + SCLERODERMA (Special Connection)

Raynaud's phenomenon is the most common first symptom of scleroderma (systemic sclerosis) - occurring in >90% of SSc patients!
SCLERODERMA + RAYNAUD'S
        ↓
↑ Endothelin-1 β†’ sustained vasospasm + vessel wall fibrosis
        ↓
Structural damage: intimal thickening, fibrosis of digital vessels
        ↓
Persistent ischaemia (not just episodic)
        ↓
Digital ulcers β†’ pitted scars β†’ gangrene
        ↓
"Sclerodactyly" = tight, shiny, thinned skin of fingers

Nail capillaroscopy: Giant dilated loops + avascular "skip" areas

11. PATHOPHYSIOLOGY SUMMARY FLOWCHART (Exam Drawing)

          COLD / EMOTIONAL STRESS
                    ↓
       ↑ Sympathetic nervous system
                    ↓
         Ξ±β‚‚-adrenoceptor activation
         ↑ Endothelin-1  ↑ Thromboxane Aβ‚‚
         ↓ Nitric Oxide  ↓ Prostacyclin
                    ↓
       DIGITAL ARTERY VASOSPASM
                    ↓
    β”Œβ”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”
    β”‚  PRIMARY RP                  β”‚   β”‚  SECONDARY RP                β”‚
    β”‚  - Young woman               β”‚   β”‚  - Older / any sex           β”‚
    β”‚  - Functional vasospasm      β”‚   β”‚  - Structural vessel damage  β”‚
    β”‚  - Reversible, benign        β”‚   β”‚  - Progressive, ulcers       β”‚
    β”‚  - Normal capillaroscopy     β”‚   β”‚  - Abnormal capillaroscopy   β”‚
    β””β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”˜   β””β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”˜
                    ↓
         TRIPHASIC COLOUR CHANGE
         White β†’ Blue β†’ Red
                    ↓
           MANAGEMENT LADDER:
    Lifestyle β†’ CCBs β†’ PDE-5i / ARBs β†’ Bosentan / Iloprost β†’ Surgery

12. KEY FACTS FOR MCQs

QuestionAnswer
Raynaud's phenomenon = response to?Cold exposure and/or emotional stress
Triphasic colour change sequence?White β†’ Blue β†’ Red (Pallor β†’ Cyanosis β†’ Rubor)
Which phase is due to vasospasm?White (pallor) phase
Which phase is due to deoxygenation of stagnant blood?Blue (cyanosis) phase
Which phase is reactive hyperaemia?Red (rubor) phase
Which finger is often SPARED?The thumb
Most common cause of secondary RP?Scleroderma (systemic sclerosis)
RP is the presenting feature of which disease in >90% of cases?Systemic sclerosis (scleroderma)
First-line drug treatment?Calcium channel blockers (Nifedipine / Amlodipine)
Mechanism of CCBs in Raynaud's?Block Ca²⁺ channels β†’ ↓ VSM contraction β†’ vasodilation
Second-line drug?Sildenafil (PDE-5 inhibitor) or Losartan (ARB)
Drug to AVOID in Raynaud's?Ξ²-blockers (cause/worsen vasospasm)
ACE inhibitors in Raynaud's?NOT recommended (failed in RCTs)
Drug used for scleroderma-RP to reduce new digital ulcers?Bosentan (endothelin receptor antagonist)
Gold standard test to distinguish primary from secondary RP?Nailfold capillaroscopy
"Windmill manoeuvre" is?Swinging arm in circle from shoulder to drive blood into fingers during an attack
Complication of thoracic sympathectomy?Compensatory hyperhidrosis

13. SELF-TEST (Do Before Day 10)

  1. Draw the triphasic colour change flowchart with the mechanism at each phase
  2. A 25-year-old woman presents with bilateral cold-triggered white-then-blue-then-red finger discolouration. ANA is negative, capillaroscopy is normal. What is your diagnosis and first treatment choice?
  3. A 52-year-old woman with scleroderma develops severe Raynaud's with digital ulcers not responding to nifedipine. What two second-line agents would you consider?
  4. A cardiac patient on metoprolol complains of new onset cold-triggered finger colour changes. What is the likely cause and what drug change would you suggest?
  5. What is the structural difference between primary and secondary Raynaud's at the level of the blood vessel?
  6. Name five secondary causes of Raynaud's phenomenon

Day 9 complete! Tomorrow is Day 10 - Aneurysms: types (true/false/dissecting), aortic vs. peripheral, pathogenesis, clinical features, and management. Just say "Day 10" when ready! πŸ«€

Day 10

Finding Sources
Finding Sources
Finding Sources
Reading File
Finding Sources
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Searching Images

aortic dissection Stanford DeBakey classification type A type B diagram

Educational medical composite illustrating the classification and diagnostic imaging of aortic dissections. Panel (a) presents a pathophysiology diagram showing an intimal tear and the formation of true and false lumens, alongside the DeBakey and Stanford classification systems. DeBakey Type I involves the ascending aorta, arch, and descending aorta; Type II is confined to the ascending aorta (both Stanford Type A). Type IIIa is limited to the descending thoracic aorta above the diaphragm, while Type IIIb extends below the diaphragm (both Stanford Type B). Panel (b) features an anatomical diagram of the aortic arch divided into surgical zones 0-4, identifying the brachiocephalic, left common carotid, and left subclavian arteries. Included diagnostic images show a 3D magnetic resonance angiography (MRA) reconstruction of a Type B aortic dissection and a corresponding lateral chest X-ray illustrating endovascular repair with a stent graft. This resource is designed for cardiovascular medical education, specifically for teaching the anatomical extent and management triage of acute aortic syndromes.

Educational medical composite illustrating the classification and diagnostic imaging of aortic dissections. Panel (a) presents a pathophysiology diagram showing an intimal tear and the formation of true and false lumens, alongside the DeBakey and Stanford classification systems. DeBakey Type I involves the ascending aorta, arch, and descending aorta; Type II is confined to the ascending aorta (both Stanford Type A). Type IIIa is limited to the descending thoracic aorta above the diaphragm, while Type IIIb extends below the diaphragm (both Stanford Type B). Panel (b) features an anatomical diagram of the aortic arch divided into surgical zones 0-4, identifying the brachiocephalic, left common carotid, and left subclavian arteries. Included diagnostic images show a 3D magnetic resonance angiography (MRA) reconstruction of a Type B aortic dissection and a corresponding lateral chest X-ray illustrating endovascular repair with a stent graft. This resource is designed for cardiovascular medical education, specifically for teaching the anatomical extent and management triage of acute aortic syndromes.

Summary : This illustration compares the DeBakey and Stanford classification systems for aortic dissection, showing the anatomical extent of each type using schematic diagrams of the aorta.

illustration:
# DeBakey Classification :
  β€’ Type I: Dissection originates in the ascending aorta and extends beyond the aortic arch, often into the descending aorta.
  β€’ Type II: Dissection is confined to the ascending aorta only.
  β€’ Type IIIA: Dissection originates in the descending aorta and is limited to the thoracic aorta above the diaphragm.
  β€’ Type IIIB: Dissection originates in the descending aorta and extends below the diaphragm.

# Stanford Classification :
  β€’ Type A: Involves the ascending aorta, regardless of the site of origin; includes DeBakey Types I and II.
  β€’ Type B: Involves only the descending aorta, without involvement of the ascending aorta; includes DeBakey Type III.

# Visual Encodings :
  β€’ Red shading highlights the affected segments of the aorta for each classification type.
  β€’ Black arrows indicate the origin or extent of the dissection in each schematic.
  β€’ The aorta is depicted as a simplified white tube with major branches at the top.

# Layout :
  β€’ DeBakey types (I, II, IIIA, IIIB) are shown in sequence from left to right, followed by Stanford types (A, B) on the right.
  β€’ Each type is labeled above its corresponding schematic.

# Analysis :
  β€’ The DeBakey system subdivides dissections based on both origin and extent, while the Stanford system groups them by involvement of the ascending aorta.
  β€’ Stanford Type A encompasses more anatomical territory (all cases with ascending aorta involvement), while Type B is restricted to the descending aorta.
  β€’ The visual comparison clarifies how DeBakey Types I and II map to Stanford Type A, and DeBakey Type III maps to Stanford Type B.

Summary : This illustration compares the DeBakey and Stanford classification systems for aortic dissection, showing the anatomical extent of each type using schematic diagrams of the aorta. illustration: # DeBakey Classification : β€’ Type I: Dissection originates in the ascending aorta and extends beyond the aortic arch, often into the descending aorta. β€’ Type II: Dissection is confined to the ascending aorta only. β€’ Type IIIA: Dissection originates in the descending aorta and is limited to the thoracic aorta above the diaphragm. β€’ Type IIIB: Dissection originates in the descending aorta and extends below the diaphragm. # Stanford Classification : β€’ Type A: Involves the ascending aorta, regardless of the site of origin; includes DeBakey Types I and II. β€’ Type B: Involves only the descending aorta, without involvement of the ascending aorta; includes DeBakey Type III. # Visual Encodings : β€’ Red shading highlights the affected segments of the aorta for each classification type. β€’ Black arrows indicate the origin or extent of the dissection in each schematic. β€’ The aorta is depicted as a simplified white tube with major branches at the top. # Layout : β€’ DeBakey types (I, II, IIIA, IIIB) are shown in sequence from left to right, followed by Stanford types (A, B) on the right. β€’ Each type is labeled above its corresponding schematic. # Analysis : β€’ The DeBakey system subdivides dissections based on both origin and extent, while the Stanford system groups them by involvement of the ascending aorta. β€’ Stanford Type A encompasses more anatomical territory (all cases with ascending aorta involvement), while Type B is restricted to the descending aorta. β€’ The visual comparison clarifies how DeBakey Types I and II map to Stanford Type A, and DeBakey Type III maps to Stanford Type B.

Loading Image
Reading File
Reading File
Loading Image
Reading File
Reading File
Reading File
All content loaded from Robbins, Goldman-Cecil, and S Das Surgery. Here are your complete Day 10 notes!

πŸ“˜ WEEK 2 - DAY 10

Aneurysms: Types, Pathogenesis, Clinical Features & Management

Sources: Robbins & Kumar Basic Pathology | Goldman-Cecil Medicine | S Das Manual of Clinical Surgery 13th Ed | Robbins, Cotran & Kumar Pathologic Basis of Disease

1. DEFINITION

Aneurysm = A localised, abnormal permanent dilation of a blood vessel (or the heart) caused by weakening of the vessel wall.
  • From Greek: aneurysma = "a widening"
  • Key concept: the wall is structurally weakened - the vessel cannot withstand normal blood pressure

2. CLASSIFICATION OF ANEURYSMS

By Wall Structure - The Most Important Distinction:

Diagram comparing saccular and fusiform true aneurysms alongside a false aneurysm, with cross-section showing intima, media, adventitia layers and measurement diameters relative to the vertebra
ALL ANEURYSMS
β”‚
β”œβ”€β”€ TRUE ANEURYSM
β”‚   Definition: ALL three vessel wall layers (intima + media + adventitia)
β”‚   are intact but DILATED / attenuated
β”‚   β”œβ”€β”€ Fusiform
β”‚   β”œβ”€β”€ Saccular
β”‚   └── Dissecting (special type - see below)
β”‚
└── FALSE ANEURYSM (Pseudoaneurysm)
    Definition: DEFECT in vessel wall β†’ blood leaks out
    β†’ contained by ONLY a single layer of fibrous/connective tissue
    (NOT the vessel wall itself)
    Examples: post-catheterisation femoral pseudoaneurysm,
    ventricular rupture contained by pericardium

By Shape:

TypeDescriptionLocationCause
FusiformCircumferential, symmetric dilation of the entire vessel circumferenceAortic arch, abdominal aorta, iliac arteriesAtherosclerosis, hypertension
SaccularDiscrete outpouching of PART of the circumference, like a berryCerebral arteries (Circle of Willis), aortaCongenital weakness (Berry), trauma, infection
DissectingBlood forces through intimal tear β†’ tracks within media layers, creating a false channelThoracic aorta, ascending aortaHypertension, Marfan syndrome, cystic medial degeneration

3. PATHOGENESIS - WHY DO ANEURYSMS FORM?

Core Concept:

Aneurysms form when the structural integrity of the aortic media is compromised - specifically, when there is an imbalance between synthesis and degradation of extracellular matrix (ECM).

Three Key Mechanisms:

MECHANISM 1: ↑ ECM DEGRADATION (MMP overactivity)
─────────────────────────────────────────────────
Atherosclerosis + Inflammation in vessel wall
        ↓
↑ Matrix metalloproteinases (MMP-1, 3, 9, 13) from macrophages
        ↓
Degrade elastin and collagen (structural proteins of media)
        ↓
↓ Tensile strength of aortic wall
        ↓
ANEURYSM

MECHANISM 2: ↓ ECM SYNTHESIS (Connective tissue defects)
─────────────────────────────────────────────────────────
Genetic disorders: Marfan syndrome β†’ defective FIBRILLIN-1
β†’ ↑ TGF-Ξ² bioavailability in aortic wall
β†’ Progressive loss of elastin/collagen
β†’ Cystic medial degeneration
β†’ ANEURYSM

Ehlers-Danlos syndrome β†’ defective COLLAGEN (Type III)
β†’ Vessel wall fragile
β†’ ANEURYSM

MECHANISM 3: SMC LOSS (Media ischaemia)
────────────────────────────────────────
Atherosclerosis/HTN β†’ ischaemia of vasa vasorum
        ↓
↓ Blood supply to outer 2/3 of media
        ↓
SMC apoptosis/dropout β†’ replaced by amorphous proteoglycans
= CYSTIC MEDIAL DEGENERATION (histological term)
        ↓
↓ Elastic tissue β†’ ↓ wall strength β†’ ANEURYSM

4. RISK FACTORS FOR ANEURYSMS

Risk FactorRelevance
AtherosclerosisDominant cause of AAA; intimal thickening causes media ischaemia + MMPs
HypertensionCauses vasa vasorum narrowing β†’ media ischaemia; also ↑ mechanical wall stress; dominant in ascending aortic aneurysm
Cigarette smoking↑ AAA risk by 2.7x overall; large AAAs by 5.6x; still elevated 2.5x higher in current vs. former smokers
Family history3-5x increased risk with first-degree relative with AAA; polygenic
Male sexAAA prevalence significantly higher in men
Age >60Prevalence 6% at 55-64 yrs β†’ 18.5% at 75-84 yrs
Marfan syndromeFibrillin-1 mutation β†’ cystic medial degeneration β†’ ascending thoracic aneurysm
Ehlers-Danlos syndrome (Type IV)Collagen III defect β†’ arterial fragility
Tertiary syphilisObliterative endarteritis of vasa vasorum β†’ aortic arch aneurysm
Bicuspid aortic valveAssociated with thoracic aortic aneurysm
TraumaFalse aneurysm (pseudoaneurysm)
InfectionMycotic aneurysm (from infective endocarditis emboli)

5. ABDOMINAL AORTIC ANEURYSM (AAA) - IN DEPTH

Definition and Location:

  • Dilation of the abdominal aorta >3 cm (normal = ~2 cm)
  • Almost always located between the renal arteries and the aortic bifurcation
  • Most common and most clinically important aneurysm type

Pathology:

  • Extensive atherosclerosis of the aortic wall with thinning of the media
  • Lumen contains laminated, layered mural thrombus (poorly organised)
  • Often accompanied by iliac artery aneurysms
  • Can be saccular or fusiform; up to 15 cm diameter, 25 cm length

Clinical Features:

ASYMPTOMATIC (most common) ← found incidentally on USS / CT / exam
        ↓
SYMPTOMATIC (as enlarges):
  - Pulsatile mass in the periumbilical area
  - Dull aching abdominal / lower back / flank pain
  - Sciatica (pressure on nerves)
  - Compression of ureters (hydronephrosis) / bowel (constipation)
        ↓
LEAKING/RUPTURE (EMERGENCY):
  - Sudden severe back/flank/abdominal pain
  - Hypotension β†’ haemorrhagic shock
  - Pulsatile abdominal mass (often palpable)
  - TRIAD: Abdominal/back pain + Hypotension + Pulsatile mass
    β†’ RUPTURED AAA until proven otherwise!

Size and Management Thresholds:

DiameterRisk of RuptureAction
<4 cmVery low - almost never rupturesSurveillance USS every 2-3 years
4.0-5.4 cmModerateSurveillance USS every 6-12 months + risk factor control
β‰₯5.5 cmHigh riskElective surgical repair (EVAR or open)
Any size, symptomatic/rupturingCatastrophicEmergency repair
Elective vs Emergency mortality: Elective repair mortality ~2-5%; Emergency (ruptured) AAA mortality ~50-80%! This is why surveillance matters.

Screening:

  • One-time USS screening recommended for men aged 65-75 who are current or ever-smokers

6. THORACIC AORTIC ANEURYSM (TAA)

FeatureDetail
Prevalence~2.7% of general population
CausesHypertension, Marfan syndrome, bicuspid aortic valve, Loeys-Dietz syndrome, giant cell arteritis, Takayasu arteritis, tertiary syphilis (aortic arch)
LocationAscending aorta (most common), aortic arch, descending thoracic
SymptomsOften silent until very large or dissection occurs
Specific symptomsHoarseness (recurrent laryngeal nerve compression), cough, dysphagia (oesophageal compression), chest/back pain, aortic regurgitation
Repair thresholdMarfan / heritable syndromes: β‰₯5.0 cm; Others: β‰₯5.5-6.0 cm

7. AORTIC DISSECTION - Separate but Related Entity

Definition:

Aortic dissection = The laminar planes of the aortic media split apart, and blood under systemic pressure creates a false channel (false lumen) within the aortic wall.
  • NOT the same as an aneurysm, but often coexists or results from one
  • Most serious acute vascular emergency

Pathogenesis:

PREDISPOSING CONDITION (HTN, Marfan, cystic medial degeneration)
        ↓
Weakening of aortic media
        ↓
INTIMAL TEAR (usually within 10 cm of aortic valve)
        ↓
Blood at systemic pressure enters media through tear
        ↓
Dissects along media (between middle and outer third)
        ↓
FALSE LUMEN created alongside TRUE LUMEN
(= "double-barreled aorta")
        ↓
Propagates DISTALLY (even to iliac/femoral arteries)
    OR PROXIMALLY (toward aortic valve / coronary ostia)
        ↓
Rupture through adventitia β†’ haemopericardium
β†’ CARDIAC TAMPONADE or massive haemorrhage β†’ DEATH

Who Gets It:

  1. Men aged 40-60 with hypertension (>90% of cases)
  2. Younger patients with connective tissue disorders (Marfan, Ehlers-Danlos Type IV)
  3. Iatrogenic (cardiac catheterisation, aortic cannulation during bypass surgery)
  4. Pregnancy (rare - ~10-20 per million births; usually 3rd trimester)
  5. Cocaine (abrupt BP surge)

Classification Systems - Stanford and DeBakey:

DeBakey and Stanford classification systems for aortic dissection side-by-side diagram showing Type I, II, IIIA, IIIB (DeBakey) and Type A, B (Stanford) with red shading indicating affected aortic segments
ClassificationTypeAnatomyTreatment
Stanford A (= DeBakey I + II)Involves the ASCENDING aorta (with or without descending)Intimal tear near aortic valve, propagates anywhereURGENT SURGICAL REPAIR (life-threatening)
Stanford B (= DeBakey III)Involves DESCENDING aorta ONLY (starts beyond left subclavian)Does not involve ascending aortaMedical management (BP control) first; TEVAR if complications
STANFORD CLASSIFICATION (Simple 2-type):

TYPE A = Ascending aorta involved
         β†’ SURGICAL EMERGENCY
         β†’ Risk of: tamponade, aortic regurgitation, MI (coronary ostia)

TYPE B = Descending only (beyond L. subclavian)
         β†’ Medical management: IV beta-blockers to ↓ HR + BP
         β†’ Surgery only if rupture, limb ischaemia, end-organ ischaemia

Clinical Features of Aortic Dissection:

CLASSIC PRESENTATION:
"Tearing" or "ripping" pain - sudden onset, maximal at start
Pain begins in ANTERIOR CHEST β†’ radiates to BACK between scapulae
Pain MIGRATES DOWNWARD as dissection propagates
        ↓
Differences in BP between arms (>20 mmHg = significant)
Pulse deficits (one arm/leg weaker pulse)
Aortic regurgitation murmur (Type A)
Neurological deficits (carotid involvement β†’ stroke)
Syncope / Tamponade (Type A β†’ pericardial effusion)
Exam difference from MI: Dissection pain is maximal FROM ONSET (unlike MI where pain crescendos). Dissection pain MIGRATES; MI pain RADIATES to arm/jaw but doesn't migrate.

Treatment of Aortic Dissection:

Stanford TypeManagement
Type AEmergency surgery (repair/replacement of ascending aorta) - within hours
Type B (uncomplicated)Medical: IV beta-blocker (esmolol/labetalol) to target HR <60, SBP 100-120 mmHg; then oral antihypertensives
Type B (complicated)Thoracic Endovascular Aortic Repair (TEVAR = stenting)

8. COMPLICATIONS OF ANEURYSMS - MASTER TABLE

ComplicationMechanismConsequence
RuptureWall can no longer withstand pressureMassive internal haemorrhage β†’ death (AAA mortality ~50-80% if ruptured)
ThrombosisTurbulent/stagnant blood in the sac β†’ platelet aggregationOcclusion of vessel β†’ limb ischaemia
EmbolismMural thrombus fragments break offDistal occlusion β†’ "trash foot" (blue toe syndrome), mesenteric ischaemia
Compression of adjacent structuresExpanding sac presses on neighboursUreteric compression β†’ hydronephrosis; vertebral erosion β†’ back pain; oesophageal β†’ dysphagia; nerve compression β†’ sciatica
Infection (Mycotic)Bacteraemia seeds aneurysm wallRapid expansion and rupture
Fistula formationRupture into adjacent vein or bowelAortocaval fistula (loud bruit + venous hypertension); aortoenteric fistula (GI haemorrhage)
Aortic dissectionIntimal tear in context of diseased aortaFalse lumen, tamponade, death

9. SPECIFIC ANEURYSMS - SUMMARY TABLE

AneurysmLocationKey CauseKey Feature
AAABetween renal arteries & bifurcationAtherosclerosis + smokingMost common; repair at β‰₯5.5 cm
Thoracic aorticAscending > arch > descendingHTN, Marfan, bicuspid AVHoarseness, aortic regurgitation
Berry aneurysmCircle of Willis (cerebral)Congenital elastic lamina defectRupture β†’ subarachnoid haemorrhage; associated with ADPKD
Popliteal aneurysmPopliteal arteryAtherosclerosisMost common peripheral aneurysm; presents with claudication/thrombosis
Mycotic aneurysmAny arteryInfective endocarditis embolusRapid expansion; septic; must treat infection
Syphilitic aneurysmAscending aorta / archTreponema pallidum (vasa vasorum obliteration)Classic: "tree-bark" appearance; aortic regurgitation
Ventricular aneurysmLeft ventricle (post-MI)Transmural MI (full thickness)Paradoxical systolic wall motion; arrhythmia; thrombus

10. INVESTIGATIONS FOR ANEURYSMS

TestUse
Abdominal USSFirst line screening/surveillance for AAA; safe, cheap, bedside
CT Angiography (CTA)Gold standard pre-op; shows exact size, extent, branch involvement; planning for EVAR/surgery
MRI/MRABetter for thoracic aneurysm; no radiation; takes longer
Chest X-rayMay show widened mediastinum in thoracic aneurysm or dissection
Echocardiography (TOE)Best for acute aortic dissection; can see intimal flap, true vs. false lumen, aortic regurgitation
AortographyInvasive; historically gold standard for dissection but largely replaced by CTA/TOE
Cardiac Tech point: Transoesophageal Echocardiography (TOE) is particularly important for diagnosing Type A aortic dissection at the bedside in the ICU/emergency setting - a skill directly relevant to your career!

11. COMPARISON FLOWCHART (Draw This for Exams)

VESSEL WALL WEAKENING
(MMPs ↑, SMC loss, Connective tissue defect, Atherosclerosis, HTN)
        ↓
β”Œβ”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”
β”‚           ANEURYSM FORMATION                             β”‚
β”‚                                                          β”‚
β”‚  TRUE ANEURYSM                FALSE ANEURYSM             β”‚
β”‚  (all 3 layers)               (fibrous sac only)         β”‚
β”‚  β”œβ”€ FUSIFORM                  Examples:                  β”‚
β”‚  β”‚  (AAA, Thoracic)           - Post-cath pseudoaneurysm β”‚
β”‚  β”œβ”€ SACCULAR                  - Ventricular rupture      β”‚
β”‚  β”‚  (Berry, Aorta)                                       β”‚
β”‚  └─ DISSECTING                                           β”‚
β”‚     (Aortic dissection)                                  β”‚
β””β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”˜
        ↓                              ↓
COMPLICATIONS:                   DISSECTION TYPE:
- Rupture (catastrophic)         - TYPE A β†’ SURGERY
- Thrombosis/Embolism            - TYPE B β†’ MEDICAL
- Pressure on structures           (BP control)
- Infection

12. KEY FACTS FOR MCQs

QuestionAnswer
Definition of a true aneurysm?Involves ALL three layers (intima, media, adventitia)
Definition of a false aneurysm?Defect in vessel wall β†’ hematoma contained by fibrous tissue only; NOT all three layers
Fusiform aneurysm = ?Circumferential dilation of the entire vessel diameter
Saccular aneurysm = ?Outpouching of PART of vessel circumference
Most common cause of AAA?Atherosclerosis + smoking
AAA: most common location?Infrarenal (below renal arteries, above bifurcation)
Repair threshold for AAA?β‰₯5.5 cm diameter
Strongest risk factor for AAA rupture?Size (>5.5 cm)
Classic triad of ruptured AAA?Abdominal/back pain + Hypotension + Pulsatile abdominal mass
Histological change in aorta predisposing to dissection?Cystic medial degeneration (SMC loss + elastin fragmentation)
Aortic dissection: most common risk factor?Hypertension (>90% of cases)
Pain character in aortic dissection?Sudden, "tearing/ripping", maximal at onset, migrates to back
Stanford Type A = ?Ascending aorta involved β†’ URGENT SURGERY
Stanford Type B = ?Descending aorta only (beyond L. subclavian) β†’ Medical management
DeBakey Type I + II = which Stanford?Stanford Type A
DeBakey Type III = which Stanford?Stanford Type B
Berry aneurysm location?Circle of Willis (cerebral arteries)
Berry aneurysm rupture causes?Subarachnoid haemorrhage
Berry aneurysm associated condition?ADPKD (autosomal dominant polycystic kidney disease)
Syphilitic aneurysm location?Ascending aorta / arch (obliterative endarteritis of vasa vasorum)
Most common peripheral aneurysm?Popliteal artery aneurysm
Marfan syndrome causes aneurysm by?Defective fibrillin-1 β†’ ↑ TGF-Ξ² β†’ cystic medial degeneration
Screening for AAA?One-time USS for men 65-75 who are/were smokers
Best bedside test for Type A dissection in ICU?Transoesophageal echocardiography (TOE)

13. SELF-TEST (Do Before Day 11)

  1. Draw the aneurysm classification tree from memory (true/false β†’ fusiform/saccular/dissecting)
  2. A 68-year-old male smoker presents with sudden-onset severe back pain and is found to have a 6 cm pulsatile abdominal mass with low BP. What is your diagnosis and immediate management?
  3. Explain the difference in management between Stanford Type A and Type B aortic dissection, and why Type A is a surgical emergency
  4. A 35-year-old man with Marfan syndrome has a 4.8 cm thoracic aortic aneurysm. Would you repair it? Why/why not?
  5. What is cystic medial degeneration? Which conditions cause it?
  6. Name THREE complications of an untreated abdominal aortic aneurysm other than rupture

Day 10 complete! Tomorrow is Day 11 - Peripheral Vascular Disorders (PAD, DVT, varicose veins, thromboangiitis obliterans/Buerger's disease). Just say "Day 11" when ready! πŸ«€

Day 11

Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Your credits are exhausted. You can purchase a top-up or subscribe to a plan to continue using Orris. If you're already subscribed, your daily credits will reset tomorrow.

Day 11

I already have a solid foundation from the earlier session. Let me pull the remaining content - PAD from Braunwald's and varicose veins - and deliver the complete notes.
Reading File
Reading File
Finding Sources
Searching Images

peripheral arterial disease claudication ischemic limb ankle brachial index

A clinical photograph illustrating the FlowOxβ„’ therapeutic device, a specialized medical system used for managing peripheral arterial disease (PAD) and critical limb ischemia. The image displays a patient's lower leg and foot, wearing a white sock, positioned inside a transparent, conical 'boot' chamber. The boot features a blue base and a blue adjustable top band, connected to a translucent upper sleeve that creates an airtight seal around the lower leg. The foot rests on a blue, dome-shaped internal platform designed to prevent pressure points. A clear pneumatic tube connects the boot's base to a white, cylindrical control unit that generates pulsed intermittent negative pressure (typically -40 mmHg). This therapy is designed to enhance blood flow and microcirculation in the lower extremities for patients with reduced ankle-brachial pressure index (ABPI) or claudication. The device is shown in a clinical or home-use setting, emphasizing its role as a non-invasive vascular intervention for limb salvage and wound care.

A clinical photograph illustrating the FlowOxβ„’ therapeutic device, a specialized medical system used for managing peripheral arterial disease (PAD) and critical limb ischemia. The image displays a patient's lower leg and foot, wearing a white sock, positioned inside a transparent, conical 'boot' chamber. The boot features a blue base and a blue adjustable top band, connected to a translucent upper sleeve that creates an airtight seal around the lower leg. The foot rests on a blue, dome-shaped internal platform designed to prevent pressure points. A clear pneumatic tube connects the boot's base to a white, cylindrical control unit that generates pulsed intermittent negative pressure (typically -40 mmHg). This therapy is designed to enhance blood flow and microcirculation in the lower extremities for patients with reduced ankle-brachial pressure index (ABPI) or claudication. The device is shown in a clinical or home-use setting, emphasizing its role as a non-invasive vascular intervention for limb salvage and wound care.

This composite educational image illustrates Peripheral Artery Disease (PAD) through clinical and diagnostic correlations. The left panel is a clinical photograph of a patient's lower limb, showing a medium-toned leg with a white adhesive medical dressing applied near the medial aspect of the distal third of the leg/ankle area, typically used to cover and protect skin ulcers. The right panel displays a Doppler ultrasound spectral waveform of the lower limb arteries. The waveform exhibits signs of suprapopliteal arterial stenosis, characterized by an increased systolic rise time (delayed acceleration) and a loss of normal triphasic pulsatility, resulting in a more monophasic appearance. This combination of visual evidence demonstrates the physical manifestation of arterial insufficiency (ulceration requiring dressing) and the underlying hemodynamic abnormality (impaired arterial flow) essential for diagnosing vascular disease. The image is intended for medical students and clinicians to recognize the relationship between clinical findings of ischemic ulcers and diagnostic vascular echography in PAD cases.

This composite educational image illustrates Peripheral Artery Disease (PAD) through clinical and diagnostic correlations. The left panel is a clinical photograph of a patient's lower limb, showing a medium-toned leg with a white adhesive medical dressing applied near the medial aspect of the distal third of the leg/ankle area, typically used to cover and protect skin ulcers. The right panel displays a Doppler ultrasound spectral waveform of the lower limb arteries. The waveform exhibits signs of suprapopliteal arterial stenosis, characterized by an increased systolic rise time (delayed acceleration) and a loss of normal triphasic pulsatility, resulting in a more monophasic appearance. This combination of visual evidence demonstrates the physical manifestation of arterial insufficiency (ulceration requiring dressing) and the underlying hemodynamic abnormality (impaired arterial flow) essential for diagnosing vascular disease. The image is intended for medical students and clinicians to recognize the relationship between clinical findings of ischemic ulcers and diagnostic vascular echography in PAD cases.

Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Loading Image
Reading File
All content loaded. Here are your complete Day 11 notes!

πŸ“˜ WEEK 2 - DAY 11

Peripheral Vascular Disorders: PAD, DVT, Varicose Veins, Buerger's Disease

Sources: Robbins & Kumar Basic Pathology | Bailey & Love's Surgery 28th Ed | Schwartz's Principles of Surgery 11th Ed | Gray's Anatomy for Students | Robbins, Cotran & Kumar Pathologic Basis of Disease

OVERVIEW - The Four Major Peripheral Vascular Disorders

PERIPHERAL VASCULAR DISORDERS
β”‚
β”œβ”€β”€ ARTERIAL (ischaemia β†’ not enough blood getting to tissue)
β”‚   β”œβ”€β”€ 1. Peripheral Arterial Disease (PAD) - chronic arterial occlusion
β”‚   └── 2. Thromboangiitis Obliterans (Buerger's Disease) - inflammatory
β”‚
└── VENOUS (congestion β†’ blood not draining properly)
    β”œβ”€β”€ 3. Deep Vein Thrombosis (DVT) - clot in deep veins
    └── 4. Varicose Veins - dilated, incompetent superficial veins

SECTION 1: PERIPHERAL ARTERIAL DISEASE (PAD)

Definition:

PAD = Atherosclerotic stenosis or occlusion of arteries supplying the lower extremities (ABI <0.9), causing chronic limb ischaemia.
  • Underlying cause in >90% of cases: Atherosclerosis
  • Affects ~200 million people worldwide
  • Strong marker of systemic atherosclerosis: 60-90% of PAD patients also have significant coronary artery disease

Risk Factors (Same as Atherosclerosis):

Risk FactorRelative Importance
Cigarette smokingMost powerful modifiable RF; ↑ risk 2-4x
Diabetes mellitus↑ risk of PAD and poor wound healing; accelerates progression
Hypertension
Hyperlipidaemia
Age >50Risk rises sharply
Male sexMore common in men
Family history

Pathogenesis:

Atherosclerotic plaque β†’ ↓ arterial lumen
        ↓
At REST: adequate perfusion (compensated by collaterals)
        ↓
With EXERCISE: demand exceeds supply
        ↓
INTERMITTENT CLAUDICATION (muscle ischaemia on exertion)
        ↓
Plaque progression β†’ critical stenosis/occlusion
        ↓
REST PAIN (ischaemia even at rest - severe disease)
        ↓
TISSUE NECROSIS β†’ ULCERS β†’ GANGRENE

Classification - Fontaine Stages (Learn These!):

StageSymptomsABISignificance
IAsymptomatic0.7-0.9Disease present but compensated
IIaMild claudication (walks >200m)0.5-0.7
IIbModerate-severe claudication (walks <200m)0.5-0.7
IIIRest pain (especially at night, relieved by hanging leg down)0.3-0.5Critical limb ischaemia
IVUlceration and/or gangrene<0.3Critical limb ischaemia - risk of amputation
Exam tip: Stage III-IV = "Critical Limb Ischaemia (CLI)" - threat to limb viability. These patients need urgent vascular intervention.

Ankle-Brachial Index (ABI) - Key Investigation:

ABI = Ankle systolic BP (higher of dorsalis pedis or posterior tibial)
      ──────────────────────────────────────────────────────────────
      Brachial systolic BP (higher of both arms)

Normal ABI: β‰₯1.0
Borderline: 0.91-0.99
PAD (mild-moderate): 0.5-0.9
Severe PAD/CLI: <0.5
Falsely elevated (calcified vessels in DM): >1.3

Clinical Features - The 6 P's of Acute Limb Ischaemia:

6 P's (acute ischaemia):
1. Pain (sudden, severe)
2. Pallor (white/pale limb)
3. Pulselessness (absent distal pulses)
4. Paraesthesia (numbness, tingling)
5. Paralysis (motor weakness - late, ominous sign)
6. Perishing cold (cold to touch)

Chronic PAD - Clinical Features:

FeatureDescription
Intermittent claudicationCramping calf (or thigh/buttock) pain on walking β†’ relieved by rest within 2-5 min
Rest painBurning pain in foot at night; worse lying flat; relieved by hanging leg down (gravity helps perfusion)
Trophic changesHairless, shiny, atrophic skin; thickened nails; muscle wasting
Ischaemic ulcersPunched-out, painful, on pressure points (toes, heel); arterial ulcer
GangreneDry gangrene initially; wet (infected) gangrene if secondary infection

Investigations:

TestPurpose
ABI (Ankle-Brachial Index)First-line, non-invasive, diagnostic
Duplex Doppler USSVisualises stenosis, blood flow, plaque
CT Angiography (CTA)Pre-operative planning; gold standard imaging
MR AngiographyNo radiation; good alternative
Conventional AngiographyInvasive; reserved for intervention planning

Management:

CONSERVATIVE (all patients):
β”œβ”€β”€ Smoking cessation (most important!)
β”œβ”€β”€ Exercise rehabilitation programme (walking)
β”œβ”€β”€ Weight loss, BP control, diabetes control
β”œβ”€β”€ Statin therapy (↓ LDL, pleiotropic benefits)
└── Antiplatelet therapy: Aspirin 75mg/day or Clopidogrel

PHARMACOLOGICAL:
β”œβ”€β”€ Cilostazol (PDE-3 inhibitor β†’ vasodilation + ↓ platelet aggregation)
β”‚   β†’ Improves walking distance in claudication
└── Pentoxifylline (↓ blood viscosity) - less effective than cilostazol

INTERVENTIONAL (for CLI or severe claudication):
β”œβ”€β”€ Percutaneous Transluminal Angioplasty (PTA) Β± Stenting
β”‚   β†’ Balloon dilates the stenotic segment
└── Surgical bypass (autogenous vein graft or synthetic graft)
    β†’ Bypasses occluded segment using grafted conduit

AMPUTATION:
└── Last resort for non-viable limb (unsalvageable ischaemia/infection)

SECTION 2: DEEP VEIN THROMBOSIS (DVT)

Definition:

DVT = Formation of a blood clot (thrombus) within a deep vein, most commonly in the lower limb (iliac, femoral, popliteal, tibial veins).
  • Accounts for >90% of cases of venous thrombosis
  • Key danger: Pulmonary Embolism (PE) - thrombus detaches and travels to pulmonary circulation

Virchow's Triad - The Pathogenesis of ALL Thrombosis:

Virchow's Triad diagram showing the three interconnected factors - Endothelial Injury (top), Abnormal Blood Flow (bottom left), and Hypercoagulability (bottom right) - all leading to Thrombosis in the centre
VIRCHOW'S TRIAD (1856)

1. ENDOTHELIAL INJURY
   - Trauma, surgery, IV cannula
   - Inflammation (vasculitis)
   - Atherosclerosis
   β†’ Exposes collagen + tissue factor β†’ platelet activation + coagulation cascade

2. ABNORMAL BLOOD FLOW (Stasis or Turbulence)
   - Immobility (post-op, long flights, paralysis)
   - Pregnancy (uterus compresses IVC)
   - Cardiac failure (↓ CO β†’ ↓ venous return)
   - Varicose veins
   β†’ Stasis: ↑ contact of activated clotting factors with vessel wall
   β†’ Turbulence: endothelial activation

3. HYPERCOAGULABILITY (blood clots too easily)
   Primary (genetic):
   β”œβ”€β”€ Factor V Leiden mutation (most common hereditary)
   β”‚   β†’ Factor V resistant to protein C inactivation
   β”‚   β†’ Heterozygotes: 3-4x risk; Homozygotes: 25-50x risk
   β”œβ”€β”€ Prothrombin G20210A mutation
   └── Protein C / Protein S / Antithrombin III deficiency

   Secondary (acquired):
   β”œβ”€β”€ Malignancy (cancer releases procoagulants)
   β”œβ”€β”€ OCP/HRT (oestrogen β†’ ↑ clotting factors)
   β”œβ”€β”€ Pregnancy
   β”œβ”€β”€ Antiphospholipid syndrome
   β”œβ”€β”€ Nephrotic syndrome (loss of antithrombin III)
   └── Heparin-Induced Thrombocytopenia (HIT)

Risk Factors for DVT:

CategoryExamples
SurgeryPelvic, orthopaedic (THR, TKR = highest risk), abdominal
ImmobilityLong-haul flights, bed rest >3 days, paralysis, plaster cast
MalignancyTrousseau syndrome (migratory thrombophlebitis in cancer)
Pregnancy / puerperiumIVC compression + hypercoagulable state
OCP / HRTOestrogen β†’ ↑ coagulation factors
ThrombophiliaFactor V Leiden, antiphospholipid syndrome
Previous DVT/PEStrongest predictor of recurrence
Age >60
Obesity
Dehydration

Clinical Features of DVT:

SYMPTOMS:
- Unilateral leg swelling ← most common
- Calf pain / tenderness
- Warmth of the affected limb
- Erythema / discolouration
- Engorged superficial veins

SIGNS:
- Homans' sign: calf pain on dorsiflexion of foot
  (NOTE: neither sensitive NOR specific - not reliable alone!)
- Calf tenderness on palpation
- Pitting oedema

MOST DVTs are ASYMPTOMATIC until PE occurs!

Wells Score for DVT (Clinical Probability Tool):

Clinical FeatureScore
Active cancer+1
Paralysis, paresis, or immobilised lower limb+1
Bedridden β‰₯3 days or major surgery within 12 weeks+1
Localised tenderness along deep venous system+1
Entire leg swollen+1
Calf swelling >3 cm compared to other leg+1
Pitting oedema in symptomatic leg only+1
Collateral superficial veins (non-varicose)+1
Previous DVT+1
Alternative diagnosis as likely or more likely-2
Score β‰₯2 = DVT likely β†’ proceed to Doppler USS Score <2 = DVT unlikely β†’ D-dimer test first; USS only if D-dimer positive

Investigations:

TestSignificance
D-DimerHighly sensitive, NOT specific; elevated in DVT/PE but also in infection, malignancy, post-op. A negative D-dimer rules out DVT in low-probability patients
Duplex Doppler USSFirst-line imaging; confirms diagnosis; non-compressible vein = DVT
VenographyGold standard but invasive; rarely used now
CT/MR VenographyFor pelvic/IVC thrombosis

Management of DVT:

AgentMechanismUse
LMWH (e.g. Enoxaparin)↑ Antithrombin III β†’ inhibits Xa and IIaAcute treatment; rapid anticoagulation
UFH (Unfractionated Heparin)Same; reversible with protamineRenal failure patients (renally cleared LMWH unsafe)
Rivaroxaban / Apixaban (DOACs)Direct Factor Xa inhibitorsOral; first-line maintenance for β‰₯3 months
DabigatranDirect thrombin inhibitorAlternative DOAC
WarfarinVitamin K antagonist β†’ ↓ II, VII, IX, XOlder agent; requires INR monitoring (target 2-3)
FondaparinuxIndirect Factor Xa inhibitorFor HIT patients (heparin-allergic)
IVC FilterMechanical trapWhen anticoagulation is contraindicated; prevents PE
Thrombolysis / CDTDissolves clotExtensive iliofemoral DVT; reduces post-thrombotic syndrome
Duration of anticoagulation:
  • Provoked DVT (reversible cause like surgery): 3 months
  • Unprovoked DVT / recurrent: 6-12 months or indefinite
  • DVT with active cancer: Indefinite (LMWH or DOAC)

DVT Complication - Pulmonary Embolism (PE):

Deep vein thrombus (usually iliofemoral)
        ↓
Thrombus detaches β†’ embolus
        ↓
Travels: femoral v β†’ iliac v β†’ IVC β†’ right heart β†’ pulmonary artery
        ↓
Pulmonary artery occlusion
        ↓
Small PE: pleuritic chest pain, haemoptysis, breathlessness
Large/Massive PE: acute cor pulmonale, obstructive shock, DEATH
        ↓
Treatment: anticoagulation; thrombolysis (tPA) for massive PE
Classical triad of PE: Haemoptysis + Pleuritic chest pain + Dyspnoea - but only seen in minority of cases!

SECTION 3: VARICOSE VEINS

Definition:

Varicose veins = Abnormally dilated, tortuous superficial veins caused by chronic ↑ intraluminal pressure + weakened vessel wall support, with incompetent venous valves.

Epidemiology:

  • Up to 1/5 of men and 1/3 of women develop lower limb varicose veins
  • Affects great saphenous vein (medial leg/thigh) most commonly

Pathogenesis:

RISK FACTORS:
Prolonged standing, Pregnancy, Obesity, Family history, Age

        ↓
↑ Intraluminal venous pressure
        ↓
Vein wall weakens β†’ dilates
        ↓
Venous VALVE BECOMES INCOMPETENT
(valves can no longer close properly when dilated)
        ↓
Blood refluxes backwards (from deep β†’ superficial system)
        ↓
Further venous hypertension + dilation
        ↓
TORTUOUS, DILATED SUPERFICIAL VEINS

Clinical Features:

FeatureDescription
Visible tortuous veinsMost common presenting complaint; along saphenous distribution
Aching / heavinessWorse at end of day, after prolonged standing
OedemaAnkle/lower leg swelling (venous stasis)
ItchingFrom venous congestion
Skin changes (chronic)Stasis dermatitis (eczema), hyperpigmentation (haemosiderin), lipodermatosclerosis (skin induration)
Varicose ulcersAround medial malleolus; painless; shallow; irregular edges; surrounded by pigmented skin

Varicose vs. Arterial Ulcer - Must-Know Comparison:

FeatureVaricose (Venous) UlcerArterial (Ischaemic) Ulcer
LocationMedial malleolus ("gaiter area")Pressure points (toes, heel, lateral malleolus)
PainUsually painlessVery painful
EdgesIrregular, slopingPunched-out, well-defined
BaseGranulation tissue, moistPale, necrotic, dry
Surrounding skinPigmented, eczematousHairless, shiny, atrophic
PulsesPresentAbsent/reduced
ABINormal (>1.0)Low (<0.9)
CauseVenous hypertension + valve incompetenceArterial ischaemia (atherosclerosis)
TreatmentCompression bandagingRevascularisation (angioplasty/bypass)

Management of Varicose Veins:

CONSERVATIVE:
- Compression stockings (class II: 23-32 mmHg)
- Leg elevation
- Weight loss, exercise

INTERVENTIONAL (for symptomatic/complicated disease):
- EVLT (Endovenous Laser Treatment) - laser ablates the vein
- RFA (Radiofrequency Ablation) - similar to EVLT
- Foam Sclerotherapy - chemical injection obliterates vein
- Surgical stripping (ligation + avulsion) - older technique

CONTRAINDICATION to compression stockings:
- Peripheral arterial disease (PAD/ABI <0.8) - would worsen ischaemia!
Critical exam point: NEVER apply compression stockings in a patient with suspected PAD - they will worsen arterial ischaemia!

SECTION 4: THROMBOANGIITIS OBLITERANS (BUERGER'S DISEASE)

Definition:

Thromboangiitis obliterans = A non-atherosclerotic, segmental, inflammatory occlusive disease of small and medium-sized arteries AND veins of the extremities, almost exclusively caused by tobacco.
  • Described by Leo Buerger in 1908
  • Age of onset: typically 20-50 years (young!)
  • Male predominance (though female incidence rising with increased smoking)

Key Distinguishing Features from PAD (Atherosclerosis):

FeatureBuerger's DiseasePAD (Atherosclerosis)
Age20-50 yrs (young)>50 yrs
CauseTobacco (essential)Atherosclerosis RF
Cholesterol/DMNormalOften elevated
Vessel typeSmall/medium arteries + veins + nervesLarge/medium arteries
DistributionDistal (infrapopliteal, radial/ulnar)Proximal (aortoiliac, femoropopliteal)
Upper limb involvementYes (arms + hands)Rare
Venous involvementYes (migratory superficial phlebitis)No
Nerves involvedYes (severe rest pain)Less

Pathology:

ACTIVE/ACUTE PHASE:
- Segmental thrombosis of small/medium vessels
- Dense polymorphonuclear (PMN) infiltrate = classic
- Microabscesses within thrombus
- Multinucleated giant cells (granulomatous inflammation)
- Inflammation spreads to adjacent vein and nerve ("skip lesions")

CHRONIC PHASE:
- ↓ Cellularity
- Recanalization of thrombus
- Eventual fibrosis encasing artery, vein, nerve together

KEY HISTOLOGICAL FEATURE: Intact internal elastic lamina
(distinguishes it from atherosclerosis where IEL is disrupted)

Clinical Features:

ONSET: Young male smoker <40 years
        ↓
EARLY:
- Foot/hand claudication (instep claudication = pathognomonic!)
- Raynaud's phenomenon (cold-triggered colour changes)
- Migratory superficial phlebitis (red, tender nodules along veins)
        ↓
PROGRESSION:
- Rest pain (severe, burning)
- Digital ulceration (toes/fingers)
        ↓
ADVANCED:
- Gangrene β†’ Amputation

Angiographic Feature (Pathognomonic):

"Corkscrew collaterals" on angiogram - extensive collateral vessels forming a corkscrew pattern around segmentally occluded distal vessels. Disease is confined to infrapopliteal arteries and distal to the brachial artery.

Management:

InterventionRole
Smoking cessationTHE ONLY EFFECTIVE TREATMENT - disease remission is dramatic with cessation; progression halted
Wound careFor ulcers
VasodilatorsSymptomatic relief only
Prostanoids (Iloprost IV)For severe ischaemia/ulcers
Surgical bypassLimited - often no suitable distal target vessel available
AmputationLimb loss in ~31% over 15 years; 67% in those who continue smoking vs 35% in those who stop
Critical exam fact: Smoking cessation is THE ONLY treatment that reliably prevents progression of Buerger's disease. No amount of surgical skill can substitute for stopping tobacco!

MASTER COMPARISON TABLE - All Four Disorders

FeaturePADDVTVaricose VeinsBuerger's Disease
Vessel typeArteryVein (deep)Vein (superficial)Artery + vein + nerve
AetiologyAtherosclerosisVirchow's triadValve incompetence + ↑ pressureTobacco
Age>50AnyAny20-50
SymptomClaudication, rest painLeg swelling, painAching, visible veinsInstep claudication, rest pain
Key sign↓ Pulses, ABI <0.9Non-compressible vein on USSTortuous dilated veinsCorkscrew collaterals on angiogram
RiskMI, stroke, gangrenePEVenous ulcerAmputation
Key treatmentStatin + antiplatelet + revascularisationAnticoagulation (DOAC/LMWH)Compression/ablationSmoking cessation

KEY FACTS FOR MCQs

QuestionAnswer
Most common cause of PAD?Atherosclerosis
ABI value diagnostic of PAD?<0.9
ABI <0.3 means?Critical limb ischaemia
Fontaine Stage III = ?Rest pain
First-line drug for claudication?Cilostazol (PDE-3 inhibitor)
Virchow's Triad components?Endothelial injury + Stasis/Turbulence + Hypercoagulability
Most common hereditary thrombophilia?Factor V Leiden mutation
First-line test for DVT?Duplex Doppler ultrasound
A negative D-dimer rules out DVT in which patients?Low pre-test probability patients
Homans' sign = ?Calf pain on dorsiflexion - NOT sensitive or specific
Standard duration of anticoagulation for provoked DVT?3 months
PE: most common source?DVT of iliofemoral veins
Venous ulcer location?Medial malleolus
Arterial ulcer location?Pressure points (toes, heel)
Venous ulcer appearance?Irregular edges, moist granulation base, painless
Arterial ulcer appearance?Punched-out, pale/necrotic base, very painful
Contraindication to compression stockings?Peripheral arterial disease (PAD)
Buerger's disease: age group?Young (20-50), male smokers
What is pathognomonic of Buerger's on angiogram?Corkscrew collaterals
Instep claudication is characteristic of?Buerger's disease
Only effective treatment for Buerger's disease?Smoking cessation
Migratory superficial phlebitis is associated with?Buerger's disease and malignancy (Trousseau syndrome)

SELF-TEST (Do Before Day 12)

  1. A 65-year-old male smoker presents with right calf pain on walking 100m, relieved by rest. ABI is 0.6. What is the diagnosis, Fontaine stage, and management plan?
  2. A 35-year-old female develops sudden left leg swelling and breathlessness after a 14-hour flight. What do you suspect? What is your first investigation?
  3. What is Virchow's triad? Give one clinical example of each component
  4. Distinguish between a venous ulcer and an arterial ulcer on five features
  5. A 28-year-old heavy smoker presents with Raynaud's phenomenon, instep claudication, and migratory phlebitis. What is the diagnosis and the SINGLE most important treatment?
  6. Draw the Wells DVT scoring system from memory and explain its clinical use

Day 11 complete! That wraps up the main content of Week 2! Tomorrow is Day 12 - Week 2 Revision + Master Mind-Map covering all Week 2 topics (Hypertension, Atherosclerosis, Raynaud's, Aneurysms, Peripheral Vascular Disorders) with a comprehensive revision quiz. Just say "Day 12" when ready! πŸ«€

Day 13

Before diving in, let me quickly check where Day 13 falls in your schedule!
Looking at your schedule:
  • Day 12 = Week 2 Revision + Master Mind-Map
  • Day 13 = Start of Phase 2 (Week 3) = Paper I begins β†’ Coronary Artery Disease (CAD)
Asking for Preferences

Day 12 (Week 2 Revision) was skipped - shall I include a quick revision summary at the start of today's notes, or go straight into Day 13 content?

Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Finding Sources
Reading File
Searching Images

coronary artery disease myocardial infarction zones subendocardial transmural diagram

A cross-sectional anatomical diagram illustrating the quantification of myocardial viability and remodeling following chronic infarction. The image depicts a transverse slice of the heart with specialized labeling of myocardial layers. Segment A represents the area of late gadolinium enhancement (LGE) or fibrosis, appearing as a light grey/white subendocardial layer. Segment B shows the full transmural thickness of the remodeled, thinned myocardium. Segment C highlights the remaining non-enhancing, viable myocardium in the infarcted zone. Segment D serves as a control, representing the full thickness of adjacent healthy, non-remodeled myocardium. The diagram contrasts two methodologies for surgical candidacy: the traditional approach (C/B ratio) versus the authors' proposed approach (C/D ratio) for assessing transmurality. The use of different grey scales and blue calipers demonstrates the morphological changes associated with chronic myocardial thinning, providing a visual guide for risk stratification and determining viability prior to coronary artery bypass grafting (CABG).

A cross-sectional anatomical diagram illustrating the quantification of myocardial viability and remodeling following chronic infarction. The image depicts a transverse slice of the heart with specialized labeling of myocardial layers. Segment A represents the area of late gadolinium enhancement (LGE) or fibrosis, appearing as a light grey/white subendocardial layer. Segment B shows the full transmural thickness of the remodeled, thinned myocardium. Segment C highlights the remaining non-enhancing, viable myocardium in the infarcted zone. Segment D serves as a control, representing the full thickness of adjacent healthy, non-remodeled myocardium. The diagram contrasts two methodologies for surgical candidacy: the traditional approach (C/B ratio) versus the authors' proposed approach (C/D ratio) for assessing transmurality. The use of different grey scales and blue calipers demonstrates the morphological changes associated with chronic myocardial thinning, providing a visual guide for risk stratification and determining viability prior to coronary artery bypass grafting (CABG).

This diagnostic image displays two cardiac magnetic resonance imaging (MRI) views obtained using Late Gadolinium Enhancement (LGE) technique to assess myocardial viability. Panel (a) is a four-chamber view showing subendocardial delayed enhancement in the anterolateral segment, involving less than 50% of the myocardial thickness, indicative of non-transmural infarction. Panel (b) is a short-axis view demonstrating transmural delayed enhancement of the midcavitary septal segment, where high signal intensity extends across the entire wall thickness. The imaging findings are consistent with myocardial infarction in the left anterior descending (LAD) artery territory. These views are essential for distinguishing between viable and non-viable myocardium in the setting of coronary artery disease or vasospasm-induced ischemia, as seen in this clinical case involving khat-induced vasospasm.

This diagnostic image displays two cardiac magnetic resonance imaging (MRI) views obtained using Late Gadolinium Enhancement (LGE) technique to assess myocardial viability. Panel (a) is a four-chamber view showing subendocardial delayed enhancement in the anterolateral segment, involving less than 50% of the myocardial thickness, indicative of non-transmural infarction. Panel (b) is a short-axis view demonstrating transmural delayed enhancement of the midcavitary septal segment, where high signal intensity extends across the entire wall thickness. The imaging findings are consistent with myocardial infarction in the left anterior descending (LAD) artery territory. These views are essential for distinguishing between viable and non-viable myocardium in the setting of coronary artery disease or vasospasm-induced ischemia, as seen in this clinical case involving khat-induced vasospasm.

Reading File
Searching Images

acute coronary syndrome STEMI NSTEMI ECG changes ST elevation troponin

Summary : This figure presents the types and classification of Acute Coronary Syndromes, contrasting NSTEMI (Non-ST-Elevation Myocardial Infarction) and STEMI (ST-Elevation Myocardial Infarction) based on angiographic findings, electrocardiographic changes, and cardiac biomarker changes.

flowchart:
# Main Categories :
  β€’ Acute Coronary Syndromes (central node)
    – Branches into: NSTEMI (left), STEMI (right)

# NSTEMI :
  ## Angiographic Findings :
    β€’ Illustration of a coronary artery with a partially occlusive thrombus.
    β€’ Label: "Partially occlusive thrombus"
  ## Electrocardiographic Changes :
    β€’ ST-segment depression (example ECG tracing)
    β€’ T-wave inversion (example ECG tracing)
    β€’ Note: "Nonspecific or no electrocardiographic changes may instead be seen"
  ## Biomarker Change (cardiac troponin) :
    β€’ Unstable angina: negative (–)
    β€’ NSTEMI: positive (+)

# STEMI :
  ## Angiographic Findings :
    β€’ Illustration of a coronary artery with a completely occlusive thrombus.
    β€’ Label: "Completely occlusive thrombus"
  ## Electrocardiographic Changes :
    β€’ ST-segment elevation (example ECG tracing)
    β€’ Note: "ST-elevation in β‰₯2 contiguous leads on standard 12-lead ECG (or ST-elevation on posterior lead ECG)"
  ## Biomarker Change (cardiac troponin) :
    β€’ Positive (+)
    β€’ Note: "Might be – if short time from symptom onset"

# Layout :
  β€’ Two-column comparison: NSTEMI (blue background, left), STEMI (yellow background, right)
  β€’ Each column subdivided into three horizontal sections: Angiographic Findings, Electrocardiographic Changes, Biomarker Change

# Analysis :
  β€’ NSTEMI is characterized by partial thrombus occlusion, ST-segment depression or T-wave inversion (or nonspecific ECG changes), and positive cardiac troponin.
  β€’ STEMI is defined by complete thrombus occlusion, ST-segment elevation on ECG, and positive cardiac troponin (may be negative early after symptom onset).
  β€’ The figure visually distinguishes the pathophysiology, ECG findings, and biomarker profiles of NSTEMI and STEMI, aiding in clinical differentiation.

Summary : This figure presents the types and classification of Acute Coronary Syndromes, contrasting NSTEMI (Non-ST-Elevation Myocardial Infarction) and STEMI (ST-Elevation Myocardial Infarction) based on angiographic findings, electrocardiographic changes, and cardiac biomarker changes. flowchart: # Main Categories : β€’ Acute Coronary Syndromes (central node) – Branches into: NSTEMI (left), STEMI (right) # NSTEMI : ## Angiographic Findings : β€’ Illustration of a coronary artery with a partially occlusive thrombus. β€’ Label: "Partially occlusive thrombus" ## Electrocardiographic Changes : β€’ ST-segment depression (example ECG tracing) β€’ T-wave inversion (example ECG tracing) β€’ Note: "Nonspecific or no electrocardiographic changes may instead be seen" ## Biomarker Change (cardiac troponin) : β€’ Unstable angina: negative (–) β€’ NSTEMI: positive (+) # STEMI : ## Angiographic Findings : β€’ Illustration of a coronary artery with a completely occlusive thrombus. β€’ Label: "Completely occlusive thrombus" ## Electrocardiographic Changes : β€’ ST-segment elevation (example ECG tracing) β€’ Note: "ST-elevation in β‰₯2 contiguous leads on standard 12-lead ECG (or ST-elevation on posterior lead ECG)" ## Biomarker Change (cardiac troponin) : β€’ Positive (+) β€’ Note: "Might be – if short time from symptom onset" # Layout : β€’ Two-column comparison: NSTEMI (blue background, left), STEMI (yellow background, right) β€’ Each column subdivided into three horizontal sections: Angiographic Findings, Electrocardiographic Changes, Biomarker Change # Analysis : β€’ NSTEMI is characterized by partial thrombus occlusion, ST-segment depression or T-wave inversion (or nonspecific ECG changes), and positive cardiac troponin. β€’ STEMI is defined by complete thrombus occlusion, ST-segment elevation on ECG, and positive cardiac troponin (may be negative early after symptom onset). β€’ The figure visually distinguishes the pathophysiology, ECG findings, and biomarker profiles of NSTEMI and STEMI, aiding in clinical differentiation.

Summary : This figure illustrates the spectrum of Acute Coronary Syndromes (ACS), detailing the progression from mild or asymptomatic presentations to severe outcomes such as cardiac arrest. It organizes ACS into clinical presentation, ECG findings, working diagnosis, high-sensitivity cardiac troponin (hs-cTn) levels, and final diagnosis, showing how these elements interrelate across the ACS continuum.

flowchart:
# ACS Spectrum Overview :
  β€’ Title: "The ACS spectrum"
  β€’ Horizontal colour gradient bar from purple (mild) to red (severe) representing increasing severity.

# Clinical Presentation :
  β€’ Oligo/asymptomatic (stick figure standing)
  β€’ Increasing chest pain/symptoms (stick figure hunched over)
  β€’ Persistent chest pain/symptoms (stick figure clutching chest)
  β€’ Cardiogenic shock/acute heart failure (heart with downward arrow)
  β€’ Cardiac arrest (stick figure collapsed)

# ECG Findings :
  β€’ Normal (standard ECG trace)
  β€’ ST segment depression (ECG trace with depressed ST segment)
  β€’ ST segment elevation (ECG trace with elevated ST segment)
  β€’ Malignant arrhythmia (irregular ECG trace)

# Working Diagnosis :
  β€’ NSTE-ACS (Non-ST Elevation Acute Coronary Syndrome)
  β€’ STEMI (ST-Elevation Myocardial Infarction)

# hs-cTn Levels :
  β€’ Non-elevated (flat bar graph icon)
  β€’ Rise and fall (bar graph with varying heights)

# Final Diagnosis :
  β€’ Unstable angina
  β€’ NSTEMI (Non-ST Elevation Myocardial Infarction)
  β€’ STEMI (ST-Elevation Myocardial Infarction)

# Layout :
  β€’ Five horizontal sections, each with corresponding icons and text, aligned vertically.
  β€’ Progression from left (mild) to right (severe) across all sections.
  β€’ ESC logo at bottom right.

# Analysis :
  β€’ The figure visually organizes ACS as a continuum, showing that clinical severity, ECG changes, troponin levels, and diagnosis all progress together.
  β€’ NSTE-ACS includes unstable angina and NSTEMI, distinguished by troponin levels.
  β€’ STEMI is associated with ST elevation and rise/fall in troponin.
  β€’ The most severe presentations (cardiac arrest, malignant arrhythmia) are at the far right, corresponding to the most critical diagnoses.

Summary : This figure illustrates the spectrum of Acute Coronary Syndromes (ACS), detailing the progression from mild or asymptomatic presentations to severe outcomes such as cardiac arrest. It organizes ACS into clinical presentation, ECG findings, working diagnosis, high-sensitivity cardiac troponin (hs-cTn) levels, and final diagnosis, showing how these elements interrelate across the ACS continuum. flowchart: # ACS Spectrum Overview : β€’ Title: "The ACS spectrum" β€’ Horizontal colour gradient bar from purple (mild) to red (severe) representing increasing severity. # Clinical Presentation : β€’ Oligo/asymptomatic (stick figure standing) β€’ Increasing chest pain/symptoms (stick figure hunched over) β€’ Persistent chest pain/symptoms (stick figure clutching chest) β€’ Cardiogenic shock/acute heart failure (heart with downward arrow) β€’ Cardiac arrest (stick figure collapsed) # ECG Findings : β€’ Normal (standard ECG trace) β€’ ST segment depression (ECG trace with depressed ST segment) β€’ ST segment elevation (ECG trace with elevated ST segment) β€’ Malignant arrhythmia (irregular ECG trace) # Working Diagnosis : β€’ NSTE-ACS (Non-ST Elevation Acute Coronary Syndrome) β€’ STEMI (ST-Elevation Myocardial Infarction) # hs-cTn Levels : β€’ Non-elevated (flat bar graph icon) β€’ Rise and fall (bar graph with varying heights) # Final Diagnosis : β€’ Unstable angina β€’ NSTEMI (Non-ST Elevation Myocardial Infarction) β€’ STEMI (ST-Elevation Myocardial Infarction) # Layout : β€’ Five horizontal sections, each with corresponding icons and text, aligned vertically. β€’ Progression from left (mild) to right (severe) across all sections. β€’ ESC logo at bottom right. # Analysis : β€’ The figure visually organizes ACS as a continuum, showing that clinical severity, ECG changes, troponin levels, and diagnosis all progress together. β€’ NSTE-ACS includes unstable angina and NSTEMI, distinguished by troponin levels. β€’ STEMI is associated with ST elevation and rise/fall in troponin. β€’ The most severe presentations (cardiac arrest, malignant arrhythmia) are at the far right, corresponding to the most critical diagnoses.

Reading File
Loading Image
Reading File
Finding Sources
Reading File
Searching Images

coronary artery territory LAD RCA LCX myocardial infarction ECG leads correlation

A comparison of 12-lead electrocardiograms (ECG) and invasive coronary angiograms demonstrating an acute myocardial infarction before and after primary percutaneous coronary intervention (pPCI). Row (a) displays a pre-procedural ECG showing significant ST-segment elevation in the inferior leads (II, III, aVF) diagnostic of an inferior wall STEMI. Adjacent angiograms reveal a total occlusion of the proximal right coronary artery (RCA) and a significant lesion in the left anterior descending artery (LAD) after the first septal branch (S1), highlighted by a yellow outline. Row (b) presents the post-procedural results, where the ECG shows successful ST-segment resolution and return to baseline. Corresponding angiograms demonstrate restored TIMI 3 flow and luminal patency in both the RCA and LAD following stent deployment. This clinical image illustrates the management of multi-vessel coronary artery disease in the setting of cardiogenic shock and acute myocardial injury, highlighting the correlation between electrical findings on ECG and anatomical revascularization via pPCI.

A comparison of 12-lead electrocardiograms (ECG) and invasive coronary angiograms demonstrating an acute myocardial infarction before and after primary percutaneous coronary intervention (pPCI). Row (a) displays a pre-procedural ECG showing significant ST-segment elevation in the inferior leads (II, III, aVF) diagnostic of an inferior wall STEMI. Adjacent angiograms reveal a total occlusion of the proximal right coronary artery (RCA) and a significant lesion in the left anterior descending artery (LAD) after the first septal branch (S1), highlighted by a yellow outline. Row (b) presents the post-procedural results, where the ECG shows successful ST-segment resolution and return to baseline. Corresponding angiograms demonstrate restored TIMI 3 flow and luminal patency in both the RCA and LAD following stent deployment. This clinical image illustrates the management of multi-vessel coronary artery disease in the setting of cardiogenic shock and acute myocardial injury, highlighting the correlation between electrical findings on ECG and anatomical revascularization via pPCI.

This diagnostic image is a 12-lead electrocardiogram (ECG) demonstrating acute ST-segment elevation myocardial infarction (STEMI). The tracing reveals a sinus rhythm with significant ST-segment elevation in the inferior leads (II, III, and aVF) and the anterior precordial leads (V1 through V4), highlighted by red arrows. Notably, there is reciprocal ST-segment depression in the high lateral leads (I and aVL). The anterolateral leads (V5 and V6) show T-wave inversions. These findings indicate widespread myocardial ischemia or injury involving multiple vascular territories, specifically the inferior and anterior walls. The clinical significance of this ECG suggests acute occlusion of major coronary arteries, such as the right coronary artery (RCA) and left anterior descending (LAD) artery, requiring urgent intervention. This visual is an educational example of multi-territory STEMI and the identification of reciprocal changes in a clinical cardiology context.

This diagnostic image is a 12-lead electrocardiogram (ECG) demonstrating acute ST-segment elevation myocardial infarction (STEMI). The tracing reveals a sinus rhythm with significant ST-segment elevation in the inferior leads (II, III, and aVF) and the anterior precordial leads (V1 through V4), highlighted by red arrows. Notably, there is reciprocal ST-segment depression in the high lateral leads (I and aVL). The anterolateral leads (V5 and V6) show T-wave inversions. These findings indicate widespread myocardial ischemia or injury involving multiple vascular territories, specifically the inferior and anterior walls. The clinical significance of this ECG suggests acute occlusion of major coronary arteries, such as the right coronary artery (RCA) and left anterior descending (LAD) artery, requiring urgent intervention. This visual is an educational example of multi-territory STEMI and the identification of reciprocal changes in a clinical cardiology context.

Reading File
Excellent - all the essential content is loaded. Here are your complete Day 13 notes!

πŸ“˜ WEEK 3 - DAY 13 (Phase 2 begins - Paper I)

Coronary Artery Disease: Mechanism, Angina, ACS, MI, Complications & Management

Sources: Robbins & Kumar Basic Pathology | Guyton & Hall Medical Physiology | Goldman-Cecil Medicine | Bailey & Love's Surgery

1. OVERVIEW - ISCHAEMIC HEART DISEASE (IHD)

Ischaemic Heart Disease (IHD) = A group of syndromes caused by an imbalance between myocardial oxygen demand and supply, most commonly from coronary atherosclerosis.
  • Leading cause of death worldwide - 7.5 million deaths/year
  • In >90% of cases, caused by obstructive atherosclerotic coronary artery disease (CAD)
  • Hence: IHD β‰ˆ CAD in clinical usage

The Four Clinical Syndromes of IHD:

                IHD (Imbalance: Oβ‚‚ supply < Oβ‚‚ demand)
                            ↓
    β”Œβ”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”¬β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”¬β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”
    β”‚               β”‚                  β”‚                β”‚
ANGINA          MYOCARDIAL         CHRONIC IHD      SUDDEN
PECTORIS        INFARCTION         (Ischaemic       CARDIAC
(ischaemia,     (cardiomyocyte     cardiomyopathy)  DEATH
no necrosis)    DEATH)             (pump failure)   (VF)

2. RISK FACTORS FOR CAD

Non-Modifiable:

FactorDetail
AgeRisk rises sharply; MI frequency ↑ 5x between ages 40-60
Male sexMen more susceptible; women protected pre-menopausally by oestrogen; post-menopause risk equals/exceeds men
Family history / GeneticsStrongest independent RF; familial hypercholesterolaemia

Modifiable:

FactorMechanism
Hypercholesterolaemia (LDL↑)Plaque formation; foam cells; plaque rupture
HypertensionEndothelial injury; accelerates atherosclerosis
Cigarette smokingOxidative endothelial damage; ↑ LDL oxidation; ↑ platelet aggregation
Diabetes mellitusAccelerated atherosclerosis; AGE-mediated endothelial damage
Obesity↑ LDL, BP, insulin resistance
Physical inactivity↓ HDL; ↑ LDL, BP
Exam high-yield: Hyperlipidaemia + Hypertension + Smoking together multiply CAD risk by 7-fold!

3. PATHOGENESIS OF CAD

The Core Concept:

Atherosclerosis (Weeks 1-2 revision!)
        ↓
Fatty streak β†’ Fibrous plaque β†’ Advanced plaque
        ↓
CORONARY ARTERY STENOSIS
        ↓
        β”œβ”€β”€ STABLE PLAQUE (thick cap, small core)
        β”‚   β†’ Gradual narrowing β†’ Oβ‚‚ supply ↓ on exertion
        β”‚   β†’ STABLE ANGINA
        β”‚
        └── VULNERABLE PLAQUE (thin cap, large lipid core)
            β†’ PLAQUE RUPTURE / EROSION
            β†’ Platelet aggregation + thrombus
            β†’ Partial occlusion β†’ NSTEMI / Unstable angina
            β†’ Complete occlusion β†’ STEMI

Two Mechanisms Causing IHD:

1. Fixed "Chronic" Vascular Occlusion:
  • <70% stenosis β†’ asymptomatic (even with exertion)
  • >70% stenosis = Critical Stenosis β†’ symptoms on exertion β†’ Stable Angina
  • >90% stenosis β†’ symptoms at rest β†’ Unstable Angina
2. Acute Plaque Change:
  • Plaque rupture/erosion β†’ exposes collagen + tissue factor β†’ thrombus formation
  • Partial thrombus β†’ Unstable Angina or NSTEMI
  • Complete occlusion β†’ STEMI
  • Can also get vasoconstriction triggered by: adrenergic agonists, platelet products, imbalance between NO (vasodilator) and endothelin (vasoconstrictor)

4. ANGINA PECTORIS - Types and Mechanisms

Angina pectoris = Chest pain from myocardial ischaemia that is reversible - ischaemia without infarction (no cell death yet).

Types of Angina:

TypeTriggerMechanismECGRelief
Stable AnginaExertion, emotion, coldFixed stenosis >70% β†’ demand exceeds supplyST depression during episodeRest + GTN (nitrates) within 5 min
Unstable AnginaRest or minimal exertion; NEW or worseningPlaque rupture β†’ partial thrombus; NO myocyte necrosis (troponin NEGATIVE)ST depression, T-wave inversion, or normalDoes NOT fully resolve with rest; medical emergency
Prinzmetal's (Variant) AnginaOften at rest, cyclical (early morning)Coronary artery vasospasm (not fixed stenosis)ST elevation (transient, resolves)GTN + CCBs
Microvascular Angina (Syndrome X)ExertionSmall vessel disease (no epicardial stenosis)ST depression; normal coronary angiogramOften difficult to treat

Oxygen Supply vs. Demand in Angina:

MYOCARDIAL Oβ‚‚ DEMAND determined by:
- Heart rate (HR) ← most important
- Contractility
- Wall tension (= Preload + Afterload)

MYOCARDIAL Oβ‚‚ SUPPLY determined by:
- Coronary blood flow
- Arterial Oβ‚‚ content (haemoglobin Γ— SaOβ‚‚)

ANGINA occurs when DEMAND > SUPPLY

Anti-Anginal Drug Mechanisms:

Drug ClassExampleEffect on Demand/SupplyMechanism
NitratesGTN, Isosorbide mononitrate↓ Preload + ↓ Afterload = ↓ Wall tension = ↓ DemandConverted to NO β†’ venodilation (primarily) + coronary vasodilation
Beta-blockersMetoprolol, Bisoprolol↓ HR + ↓ Contractility = ↓ DemandBlock β₁ receptors β†’ ↓ chronotropy + inotropy
Calcium channel blockers (CCBs)Amlodipine, Diltiazem↓ HR (non-DHP) + ↓ Afterload = ↓ Demand + ↑ SupplyBlock L-type Ca²⁺ channels β†’ vasodilation + (non-DHP) ↓ HR
RanolazineRanolazine↓ DemandBlocks late INa β†’ ↓ diastolic Ca²⁺ overload
IvabradineIvabradine↓ HR = ↓ DemandBlocks If (funny current) in SA node

5. ACUTE CORONARY SYNDROMES (ACS) - The Full Picture

ACS classification diagram showing NSTEMI (partial thrombus, ST depression/T-wave inversion, troponin positive) versus STEMI (complete thrombus, ST elevation, troponin positive), with Unstable Angina distinguished by negative troponin

ACS Classification:

ACUTE CORONARY SYNDROME (ACS)
= Unstable Angina + NSTEMI + STEMI

Trigger in ALL cases: PLAQUE RUPTURE β†’ THROMBUS

β”œβ”€β”€ UNSTABLE ANGINA
β”‚   Partial thrombus, NO myocyte death
β”‚   Troponin: NEGATIVE
β”‚   ECG: ST depression / T inversion / Normal
β”‚   Treatment: Medical (anticoagulation + antiplatelet)
β”‚
β”œβ”€β”€ NSTEMI (Non-ST Elevation MI)
β”‚   Partial thrombus, subendocardial myocyte death
β”‚   Troponin: POSITIVE
β”‚   ECG: ST depression / T inversion (NO ST elevation)
β”‚   Treatment: Medical + consider PCI within 72 hours
β”‚
└── STEMI (ST Elevation MI)
    Complete thrombus, TRANSMURAL myocyte death
    Troponin: POSITIVE (may be negative in first 1-2h)
    ECG: ST elevation in β‰₯2 contiguous leads
    Treatment: EMERGENCY reperfusion (pPCI within 90 min / Thrombolysis)

6. MYOCARDIAL INFARCTION (MI) - IN DEPTH

The Sequence of Coronary Occlusion:

Step 1: Atheromatous plaque RUPTURES or ERODES
        ↓
Step 2: Exposes subendothelial collagen + tissue factor + plaque lipid core
        ↓
Step 3: Platelet ADHESION β†’ ACTIVATION β†’ AGGREGATION
        Release: TXAβ‚‚, ADP, Serotonin β†’ further platelet aggregation + vasospasm
        ↓
Step 4: COAGULATION CASCADE activated by tissue factor
        ↓
Step 5: THROMBUS ENLARGES β†’ Complete luminal occlusion within minutes
        ↓
Step 6: MYOCARDIAL ISCHAEMIA β†’ INFARCTION (if not reperfused)

Subendocardial vs. Transmural Infarction:

FeatureSubendocardial InfarctionTransmural Infarction
Zone involvedInner 1/3 of myocardium (endocardium)Full thickness (endo + mid + epicardium)
CauseOften partial occlusion / global hypoperfusionComplete coronary occlusion
ECGST depression, T-wave changesST elevation β†’ Q waves
Old nameNSTEMISTEMI
Risk zoneSubendocardium is most ischaemia-prone (farthest from coronary supply, highest wall stress)

Morphological Evolution of MI (Table 9.2 from Robbins):

TimeGross AppearanceHistologyKey Feature
0-30 minNormalNormalReversible injury; ATP depletion
30 min - 4 hrsNormalΒ± Waviness of fibres at borderPoint of no return at ~30 min
4-12 hrsOccasionally dark mottlingCoagulation necrosis begins; oedema; haemorrhage
12-24 hrsDark mottlingCoagulation necrosis + pyknosis of nuclei + early neutrophil infiltrateHypereosinophilic myocytes
1-3 daysYellow-tan centre + mottlingCoagulation necrosis + ↑↑ NeutrophilsMax neutrophil infiltrate
3-7 daysHyperaemic border + yellow-tan softeningNeutrophils dying; macrophage phagocytosis beginsHIGHEST RUPTURE RISK - soft friable wall!
7-10 daysYellow-tan + soft + depressed red marginsWell-developed phagocytosis + granulation tissue formingNeovascularisation starts
10-14 daysRed-grey depressed bordersEstablished granulation tissue + collagen deposition
2-8 weeksGrey-white scar formingIncreasing collagen (fibrosis) replacing granulation tissue
>2 monthsWhite, firm SCARDense collagenous scarHealed infarct
Exam critical: Rupture risk is HIGHEST at 3-7 days - the myocardium is soft, friable granulation tissue at maximal lysis!

7. CARDIAC BIOMARKERS - Timing

BIOMARKER RISE TIMELINE AFTER MI:
(Time from symptom onset)

Troponin I/T:
  Rise:  2-4 hours
  Peak:  48 hours (12 hours for high-sensitivity troponin)
  Return to normal: 7-10 days
  ← GOLD STANDARD for MI diagnosis

CK-MB (Creatine Kinase-MB):
  Rise:  2-4 hours
  Peak:  24-48 hours
  Return to normal: ~72 hours (3 days)
  ← Useful to detect REINFARCTION (shorter window)

Myoglobin:
  Rise:  1-3 hours (EARLIEST marker)
  Return to normal: 24 hours
  NOT cardiac specific (also rises in skeletal muscle injury)
  ← Useful for early rule-out in first 2-3 hours

LDH:
  Rise:  24-48 hours
  Peak:  3-6 days
  Return to normal: 8-14 days
  ← Historical marker; LDH-1 > LDH-2 = "flipped LDH" pattern in MI
Cardiac tech exam point: Troponin is the gold standard. With reperfusion (thrombolysis/PCI), both troponin AND CK-MB peak earlier due to washout from necrotic tissue.

8. ECG CHANGES IN MI - Coronary Territory Correlation

ECG Lead-to-Territory Correlation (Draw This!):

ECG LEADS        WALL AFFECTED          CORONARY ARTERY
──────────────────────────────────────────────────────────
V1-V4            Anterior/Septal         LAD (Left Anterior Descending)
V5-V6 + I + aVL  Lateral                 LCX (Left Circumflex)
II, III, aVF     Inferior                RCA (Right Coronary Artery) - 80%
                                          or LCX (20%)
V1-V4 + II,III,aVF  Anteroinferior       LAD (wrapping) / Dominant RCA
R in V1, ST↓ V1-V3  Posterior            RCA or LCX posterior branches

Sequence of ECG Changes in STEMI:

Minutes:    Peaked (hyperacute) T-waves
Hours:      ST ELEVATION (convex upward "tombstone" pattern)
Hours-Days: Q wave formation (>1 small square wide, >1/4 R height)
            T-wave inversion
Days-Weeks: ST returns to baseline
Permanent:  Q waves remain (marker of old infarction)
High-yield: Q waves = transmural, irreversible myocardial damage. A "new" Q wave = acute STEMI or old scar.

Reciprocal Changes:

  • ST elevation in leads facing the infarct = primary changes
  • ST depression in leads on the opposite side = reciprocal changes (supports diagnosis)
  • e.g., Inferior STEMI: ST↑ in II, III, aVF + ST↓ in I, aVL

9. COMPLICATIONS OF MI - Master Table

COMPLICATIONS OF MI - Timeline

IMMEDIATE (0-24 hrs):
β”œβ”€β”€ Arrhythmias (90% of patients!) ← Most common complication overall
β”‚   VF is most common cause of DEATH in first hour
β”‚   Heart block (especially with inferior MI / RCA occlusion)
β”‚   VT, AF, bradycardia
└── Cardiogenic shock (pump failure; ~10% of transmural MIs)

EARLY (Days 1-7):
β”œβ”€β”€ Myocardial RUPTURE (1-5% of MIs) - peak risk 3-7 days
β”‚   β”œβ”€β”€ Free wall rupture β†’ haemopericardium β†’ CARDIAC TAMPONADE
β”‚   β”œβ”€β”€ Ventricular septal rupture β†’ VSD β†’ new harsh pansystolic murmur
β”‚   └── Papillary muscle rupture β†’ acute MITRAL REGURGITATION
β”‚       β†’ new pansystolic murmur at apex
└── Pericarditis (fibrinous, 2-3 days post-MI)
    β†’ Friction rub + pleuritic chest pain

LATE (Weeks-Months):
β”œβ”€β”€ Ventricular ANEURYSM
β”‚   β†’ Thin-walled scar bulges; persistent ST elevation on ECG
β”‚   β†’ Complications: mural thrombus, arrhythmia, heart failure
β”‚   Does NOT rupture (scar tissue)
β”œβ”€β”€ Mural THROMBUS β†’ systemic embolism (stroke, limb ischaemia)
β”œβ”€β”€ DRESSLER SYNDROME (weeks later)
β”‚   Autoimmune pericarditis/pleuritis - antibodies against injured myocardium
β”‚   β†’ Fever, pericardial friction rub, elevated ESR
β”‚   β†’ Treatment: NSAIDs / steroids
└── Chronic IHD / HEART FAILURE
    Progressive pump failure from cumulative ischaemic damage

10. MANAGEMENT OF ACS - FULL TREATMENT LADDER

Immediate Management - "MONABCH" Mnemonic:

M - Morphine (IV): pain relief, ↓ sympathetic activation
O - Oxygen: only if SaOβ‚‚ <94% (avoid hyperoxia)
N - Nitrates (GTN sublingual/IV): vasodilation, ↓ preload
A - Aspirin 300mg STAT (then 75mg/day): COX-1 inhibition β†’ ↓ TXAβ‚‚
B - Beta-blocker (IV Metoprolol then oral): ↓ HR, ↓ Oβ‚‚ demand, anti-arrhythmic
C - Clopidogrel (or Ticagrelor/Prasugrel) 300-600mg loading dose
H - Heparin (LMWH or UFH): anticoagulation to prevent thrombus extension

STEMI - Reperfusion (The Priority):

STEMI β†’ TIME IS MYOCARDIUM!
        ↓
Primary PCI (pPCI) ← PREFERRED if available within 120 min
β€’ Balloon angioplasty + drug-eluting stent (DES)
β€’ Target: "door-to-balloon" time <90 minutes
β€’ Better outcomes than thrombolysis
        ↓
If pPCI not available within 120 min:
THROMBOLYSIS (fibrinolysis)
β€’ Alteplase (tPA), Tenecteplase (TNK-tPA), Streptokinase
β€’ Must be given within 12 hours of symptom onset
β€’ Contraindicated: recent surgery, stroke, active bleeding
        ↓
After thrombolysis: Transfer for angiography within 3-24 hrs

NSTEMI / Unstable Angina:

Antiplatelet: Aspirin + Ticagrelor (DAPT)
Anticoagulation: LMWH (Enoxaparin) or Fondaparinux
Beta-blocker + ACE inhibitor + Statin
Coronary angiography Β± PCI within 72 hours (not emergency like STEMI)

Long-Term Secondary Prevention Post-MI:

DrugMechanismBenefit
Aspirin 75mg/day↓ TXAβ‚‚ β†’ ↓ platelet aggregation↓ Recurrent MI/stroke
P2Y12 inhibitor (Clopidogrel/Ticagrelor)↓ ADP-mediated platelet activationDAPT for 12 months post-ACS/stent
ACE inhibitor (Ramipril)↓ Afterload, ↓ ventricular remodelling↓ Mortality post-MI (especially if EF reduced)
Beta-blocker (Bisoprolol)↓ HR, ↑ diastolic filling time, anti-arrhythmic↓ Mortality post-MI
Statin (Atorvastatin 40-80mg)↓ LDL, plaque stabilisation↓ Recurrent events
Eplerenone / SpironolactoneAldosterone antagonist↓ Mortality post-MI with LV dysfunction

11. COMPLETE FLOWCHART - CAD TO ACS (Draw This!)

RISK FACTORS (LDL↑, HTN, DM, Smoking)
        ↓
ATHEROSCLEROSIS (Coronary arteries)
        ↓
         β”Œβ”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”
         ↓                                  ↓
  STABLE PLAQUE                    VULNERABLE PLAQUE
  (thick cap, small core)          (thin cap, large lipid core)
         ↓                                  ↓
  Fixed stenosis >70%           PLAQUE RUPTURE / EROSION
         ↓                                  ↓
  STABLE ANGINA              Platelet aggregation + Thrombus
  (exertional chest pain,           ↓                ↓
  relieved by rest/GTN)      PARTIAL OCCLUSION   COMPLETE OCCLUSION
                                    ↓                    ↓
                           β”Œβ”€β”€β”€β”€β”€β”€β”€β”€β”΄β”€β”€β”€β”€β”€β”€β”€β”      STEMI (transmural)
                           ↓                ↓      ST elevation
                    Unstable Angina       NSTEMI   Q waves
                    (Troponin -)       (Troponin+) Reperfuse URGENTLY
                    ST depression       ST dep/
                    No necrosis         T inversion
                                        Subendocardial necrosis

12. KEY FACTS FOR MCQs

QuestionAnswer
Most common cause of IHD?Atherosclerosis (>90%)
Critical coronary stenosis threshold?>70% lumen occluded
Stable angina β†’ stenosis threshold?>70% (symptoms on exertion)
Unstable angina β†’ no troponin rise?Correct - troponin negative; no myocyte necrosis
NSTEMI vs STEMI - key ECG difference?NSTEMI = ST depression/T inversion; STEMI = ST elevation
STEMI = which type of occlusion?Complete/total coronary occlusion
NSTEMI = which type of occlusion?Partial/subtotal occlusion
First biomarker to rise in MI?Myoglobin (~1-3 hrs)
Gold standard biomarker for MI?Troponin I or T
How long does troponin stay elevated?7-10 days
Best marker for detecting reinfarction?CK-MB (returns to normal in 72h)
"Door-to-balloon" target time for STEMI?<90 minutes
When is rupture risk highest after MI?3-7 days (soft granulation tissue phase)
Dressler syndrome occurs when?Weeks after MI; autoimmune pericarditis
Most common cause of death in first hour of MI?Ventricular fibrillation (arrhythmia)
VSD post-MI: what do you hear?New harsh pansystolic murmur at left sternal edge
Papillary muscle rupture post-MI: what happens?Acute severe mitral regurgitation
Ventricular aneurysm: ECG finding?Persistent ST elevation (even weeks after MI)
Prinzmetal angina: mechanism?Coronary vasospasm; ST elevation during episode
Aspirin mechanism in ACS?Irreversibly blocks COX-1 β†’ ↓ TXAβ‚‚ β†’ ↓ platelet aggregation
DAPT means?Dual Antiplatelet Therapy = Aspirin + Clopidogrel/Ticagrelor

13. SELF-TEST (Do Before Day 14)

  1. Draw the full ACS flowchart from plaque rupture to STEMI/NSTEMI/Unstable Angina with ECG and troponin changes
  2. A patient presents with central chest pain at rest. ECG shows ST elevation in leads II, III, aVF. Which artery is likely occluded? What is the immediate management?
  3. Explain why the same patient also has ST depression in leads I and aVL
  4. A patient has an MI on Day 5. Suddenly develops a new pansystolic murmur and cardiogenic shock. What is the diagnosis?
  5. Draw the biomarker timeline graph for Myoglobin, Troponin, and CK-MB from hour 0 to day 14
  6. Explain why Dressler syndrome occurs and how it differs from early post-MI pericarditis

Day 13 complete! Welcome to Phase 2 / Paper I. Tomorrow is Day 14 - Valvular Heart Disease: aortic stenosis, aortic regurgitation, mitral stenosis, mitral regurgitation - causes, pathophysiology, murmurs, and management. Just say "Day 14" when ready! πŸ«€

Day 12

Your credits are exhausted. You can purchase a top-up or subscribe to a plan to continue using Orris. If you're already subscribed, your daily credits will reset tomorrow.
This is a shared conversation. Sign in to Orris to start your own chat.